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Abstract 
Insulin and its receptor (IR) play an integral role in metabolism through the 
regulation of blood glucose levels. Abnormal functioning or expression of the IR has 
been found to lead to illnesses and diseases such as diabetes and cancer. Despite the 
increased knowledge and understanding of insulin and the IR in the past few decades, 
the exact mechanism by which insulin binds to and activates its receptor is not 
completely clear. Recent crystallography studies have not only successfully resolved 
the structure of the extracellular domains of the receptor, but also a set of insulin-bound 
IR fragments. This project aimed to use available crystal structure data and 
computational methods to further understand the insulin binding process. This was 
first achieved by examining and comparing existing crystal structures with IR 
molecular models investigated in our group. This resulted in the identification of four 
potentially key residues which were then further investigated using IR models 
containing mutations of these four residues. 
 
Molecular dynamics simulations were performed for each model before 
analysing them using principal components analysis (PCA) and full correlation 
analysis (FCA). These analysis methods separate a given simulation into a subset of 
individual correlated motions and identify the major conformational changes that 
occurred. The analysis found a common conformational change across the investigated 
IR models and was proposed to play a part in the ligand binding process. This proposal 
was tested experimentally by generating IR mutant proteins containing the same 
mutations investigated above. The IR protein structures were designed to contain the 
extracellular domains of the IR (previously shown to only bind insulin with low 
affinity) fused to a leucine zipper which facilitates binding to insulin in its high affinity 
binding state. The Strep-tag II was also engineered onto the C-terminal end of the 
protein and was intended to be used for purification purposes as well as in later 
functional experiments. The designed proteins were expressed in Spodoptera 
frugiperda (Sf9) cells and purified using the engineered Strep-tag II. Western blot and 
silver stain analyses confirmed the successful expression and purification of the 
wild-type (wt-IR) and the four IR mutant proteins. Surface plasmon resonance was 
then used to assess the effects of the four mutations on the receptor’s ability to bind 
insulin compared to the wt-IR control. The functional assays showed the four 
mutations caused an overall detrimental effect on the affinity of the receptor for insulin 
while select mutants displayed altered binding properties (such as association and 
dissociation rates) compared to the wt-IR. These results were then discussed in detail 
and were compared against the simulation data generated earlier. In summary, the use 
of both computational and experimental work in this project has contributed to the 
further understanding of the steps involved in insulin binding and the initial responses 
to that binding. Increased knowledge of the IR binding mechanism will aid future 
research into how illnesses and diseases involving the IR may come about and could 
potentially lead to the development of new therapeutic avenues to combat these 
health-related issues.  
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Chapter 1: Background and Literature 
Review 
1.1 INTRODUCTION 
The insulin receptor (IR) is a tyrosine kinase receptor that plays a critical role in 
metabolism (Kitamura, Kahn, & Accili, 2003). It is a member of the IR family 
subgroup of receptors that also contain the insulin-like growth factor I receptor 
(IGF1R) (Ullrich et al, 1986) and the insulin receptor related receptor (IRR) (Shier & 
Watt, 1989). Extensive research focus in the past few decades has increased our 
knowledge and understanding of the structures as well as the functions these receptors 
play in our body. However, despite many years of research into understanding the IR, 
the exact mechanism by which insulin binds to and activates the IR remains elusive. 
 
1.2 INSULIN AND ITS RECEPTOR 
 INSULIN 
The insulin hormone was first isolated in 1921 by Banting and Best (Banting et 
al, 1922) and has since been the focus of intense research into its biological structure 
and function. Insulin plays a vital role in maintaining metabolic homeostasis through 
the stimulation of its cognate receptor, the IR, resulting in the uptake of glucose into 
cells (Cuatrecasas, 1969). The three dimensional structure of insulin was not clearly 
understood until its successful X-ray crystallisation in 1969 by Dorothy Hodgkin et al 
(PDB ID 1INS) (Adams et al, 1969). Human insulin consists of two chains, a 21 
residue A-chain and a 30 residue B-chain, that are connected via two inter-chain 
disulphide bonds (Adams et al, 1969). Residue numbering on insulin is defined by the 
chain letter followed by the residue number within the chain, thus A1 is the first residue 
on the A-chain while B2 is the first residue in the B-chain. Insulin has been crystallised 
in two different conformational states, the “tight” (T) and “relaxed” (R) states shown 
in Figure 1.1. In the insulin T-state, the A-chain comprises an N- and C-terminal helix 
connected by a short loop and the B chain contains a central helix flanked by N- and 
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C-terminal strands (Baker et al, 1988). The R-state is almost identical to the T-state 
except the B chain central helix extends to the N-terminus (Bentley et al, 1976).  
 
Figure 1.1: Crystal structures of insulin captured in the T and R states. A, the T-state of insulin 
observed in the 4INS structure (Baker et al, 1988). B, the R-state of insulin observed in the 1ZNI 
structure (Bentley et al, 1976). The insulin A-chain is shown in grey and the B-chain is shown in orange. 
The N- and C- terminus of each chain are indicated with the letters N and C respectively. 
 
Extensive investigations have identified residues on insulin that come into 
contact with the IR upon insulin binding (Glendorf et al, 2008; Ludvigsen, Olsen, & 
Kaarsholm, 1998; Nakagawa & Tager, 1992; Pullen et al, 1976; Schaffer, 1994). These 
studies initially identified the following residues that form the receptor-binding region: 
A1, A5, A8, A19, A21, B12, B16, B22, B23, B24, B25 and B26 (Pullen et al, 1976). 
These residues were later extended to include residues A2 and A3 and formed what 
was termed the ‘classical’ binding surface (Nakagawa & Tager, 1992). A subsequent 
study using high-affinity insulin analogues proposed a second binding surface on 
insulin (Schaffer, 1994) and this was later confirmed in mutagenesis experiments 
which identified residues A12, A13, A17, B10, B13 and B17 (Glendorf et al, 2008). 
A sequence alignment of insulin and two other insulin-like peptides are shown in 
Figure 1.2 and residues belonging to the two binding surfaces are highlighted. Other 
studies of insulin mutants showed that movement of the B chain C-terminus was 
critically important in exposing residues belonging to the classical binding surface: 
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A1, A2 and A3 (Ludvigsen et al, 1998). The current model of ligand binding describes 
each receptor as comprising two binding pockets, each including residues from both 
receptor monomers. Insulin contacts two different binding regions within a binding 
pocket (known as site 1 and site 2).  
 
 
Figure 1.2: Sequence alignment of insulin and two insulin-like peptides.  Sequence alignment of 
insulin and insulin-like growth factors (IGF) I and II show differences in their sequences despite high 
structural homology (discussed in section 1.3). The residues forming the “classical binding surface” of 
insulin are highlighted in red while those involved in the second binding surface are highlighted in 
purple.  
 
 INSULIN RECEPTOR (IR) 
The IR exists as a disulphide linked dimer with each monomer consisting of 
several structural domains across two polypeptides (termed the α- and β-chain) 
produced by cleavage of a single-chain precursor. From the N-terminus, each 
monomer comprises a leucine-rich repeat domain (L1), cysteine-rich repeat domain 
(CR), a second leucine-rich repeat domain (L2) and three fibronectin type-III (FnIII) 
domains (termed FnIII-1 and FnIII-2 and FnIII-3), constituting what is termed the 
extracellular portion of the receptor (also referred to as the receptor ectodomain). 
Following these domains are the transmembrane helix, juxtamembrane region, a 
tyrosine kinase domain and a C-terminal tail, the latter three regions primarily 
constituting the intracellular portion (McKern et al, 2006). Within FnIII-2 lies an 
approximately 120 residue long insert domain (ID) that includes the α/β cleavage site, 
a classic signal sequence for a furin endoprotease that separates the extracellular 
INS    -----------------------MALWMRLLPLLALLALWGPDPAAAFVNQH 29 
IGF-I  MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGPET 52 
IGF-II ---------------------MGIPMGKSMLVLLTFLAFASCCIAAYRPSET 31 
 
INS    LCGSHLVEALYLVCGERGFFYT-PKTRRE----AEDLQVGQVELGGGPGAGS 76 
IGF-I  LCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRR 104 
IGF-II LCGGELVDTLQFVCGDRGFYFSRPASRVS----RRSRGIVEECCFRSCDLAL 79 
 
INS    LQPLAL--EGSLQKRGIVEQCCTS--------ICSLYQLENYCN-------- 110 
IGF-I  LEMYCAPLKPAKSARSVRAQRHTDMP------KTQKYQPPSTNKNTKSQRRK 150 
IGF-II LETYCA--TPAKSERDVSTPPTVLPDNFPRYPVGKFFQYDTWKQSTQRLRRG 128 
 
INS    --------------------------------------------------- 
IGF-I  GWPKTHPGGEQKEGTEASLQIRGKKKEQRREIGSRNAECRGKKGK------ 195 
IGF-II LPALLRARRGHVLAKELEAFREAKRHRPLIALPTQDPAHGGAPPEMASNRK 180 
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domain into the α- and β-chains (Kara et al, 2015). Importantly, the C-terminal (CT) 
sequence of the α-chain (known as the CT peptide) has been identified to play a critical 
part in ligand binding as IR constructs lacking this region do not display any detectable 
binding to insulin (Kristensen et al, 2002; Kristensen, Wiberg, Schaffer, & Andersen, 
1998; Menting, Ward, Margetts, & Lawrence, 2009). The CT peptide contains an 
α-helical portion (Glu697-Val715) as well as an unstructured region, referred to from 
hereon as the CT-tail (Pro716-Ser719). There are two splice variants of the IR, termed 
IR-A and IR-B, where the difference resides in the absence or presence, respectively, 
of 12 amino acids located in the ID, encoded by exon 11 of the IR gene (Moller, 
Yokota, Caro, & Flier, 1989; Mosthaf et al, 1990; Seino & Bell, 1989). A study has 
demonstrated that the IR-A isoform binds to insulin with a 1.5-fold higher affinity 
compared to IR-B isoform (Knudsen, De Meyts, & Kiselyov, 2011). The long isoform 
of IR (IR-B) is out of the scope of this project and we will be focussing on the variant 
that binds insulin with a higher affinity, IR-A. A visual representation of the domain 
structure and arrangements in the IR dimer is shown in Figure 1.3. 
 
 5 
Chapter 1: Background and Literature Review 5 
 
Figure 1.3: Illustration of the extracellular domains of the insulin receptor dimer. Secondary 
structure of one monomer is shown in the foreground while the surface representation of the other 
monomer is displayed in the background. Domains are coloured as follows: L1, blue; CR, red; L2, 
yellow; FnIII-1, green; FnIII-2, cyan; FnIII-3, purple; and CT peptide, orange. Structure was generated 
by using the BIOMT information from IR crystal structure 3LOH (Smith et al, 2010). The ID was not 
resolved in this crystal structure. 
 
Each IR monomer is proposed to contain two binding sites that contact the two 
binding surfaces of insulin. Initial alanine scanning mutagenesis studies suggested that 
residues on the central β-sheet of the L1 domain formed binding site 1 of the IR 
(Williams, Mynarcik, Yu, & Whittaker, 1995). However, more recent crystallography 
data showed that a majority of those residues are instead in contact with the CT peptide 
which was interpreted to lie across the beta sheets of the L1 domain (Smith et al, 2010). 
The CT peptide has been strongly argued to contribute to site 1 of the IR through a 
number of mutagenesis and cross-linking experiments. Several cross-linking studies, 
particularly those that used photoactive insulin derivatives, demonstrated that the CT 
peptide of the IR was in direct contact with insulin (Huang et al, 2007; Kurose et al, 
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1994; Xu et al, 2004). It was speculated from these studies that the CT peptide plays a 
possible role in exposing the ‘classical’ binding surface of insulin through facilitated 
displacement of the insulin B-chain’s C-terminus (see T and R conformations shown 
in Figure 1.1) (Ward & Lawrence, 2009). The CT peptide was further shown to be 
essential for ligand binding by experiments using IR fragments consisting of the first 
three domains of the IR (L1, CR and L2). These IR fragments did not display any 
detectable insulin binding while the same fragments fused to the CT peptide bound 
insulin with an affinity similar to the entire soluble ectodomain (Kristensen et al, 
1998). The recent resolution of insulin-bound IR fragment confirmed the importance 
of the CT peptide as insulin was found to be primarily bound to this region of the 
receptor (Menting et al, 2013; Menting et al, 2014). These insulin-bound crystal 
structures of the IR however did not include the entire extracellular domains of the 
receptor and thus were not able to capture insulin bound to site 2, and provided no clue 
about the conformational change of the receptor triggered by insulin binding. Based 
on available crystallography data, it was thought that the possible location of site 2 of 
the IR was located on the loops between the FnIII-1 and FnIII-2 domains (Ward & 
Lawrence, 2009). Additionally, a bioinformatics study on receptors in the IR family 
covering mammals, birds, amphibians and fish, detected a set of highly conserved 
residues in this junction which were speculated to be the location of binding site 2 
(Renteria et al, 2008). However, relatively little information is available regarding the 
second binding site of the IR as most research is currently directed towards 
characterising binding site 1. 
 
The first crystal structure of an extracellular portion of the IR consisted of the 
first three domains (Figure 1.4) (L1, CR and L2 domains; PDB ID 2HR7, 2.32 Å 
resolution) (Lou et al, 2006). A subsequent structure of the entire IR extracellular 
domain was able to successfully visualise the structural alignment of the domains but 
did not detect the CT peptide (PDB ID 2DTG, 3.8 Å resolution) (McKern et al, 2006). 
Following this, re-refinement of the same crystal structure was able to resolve a part 
of the CT peptide (Figure 1.5) (PDB ID 3LOH, 3.8 Å resolution) (Smith et al, 2010). 
A later study successfully captured low resolution crystal structures of insulin bound 
to fragments of the IR and were able to visualise receptor-ligand interactions (Figure 
1.6) (PDB ID 3W11-3W14, 3.9 Å-4.4 Å resolution) (Menting et al, 2013). Several 
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constructs were used in this study to determine the ligand-receptor interaction. The 
3W11 structure details a construct consisting of the L1 and CR domains in complex 
with the CT peptide and insulin. Similarly, structures 3W12 and 3W13 consist of the 
same IR fragments in complex with a high affinity insulin analogue. The last structure, 
3W14, used a construct including the L1, CR, L2 and FnIII-1 domains in complex with 
the CT peptide and insulin. However, some key interactions were not able to be 
observed due to failure to resolve residues B23-B30 of the insulin B-chain tail. These 
interactions were later visualised in a newer structure that successfully resolved 
missing components from the 3W11-3W14 structures (residues B23-B27 in insulin 
and 716-719 in the CT peptide) (Figure 1.7) (PDB ID 4OGA, 3.5 Å resolution) 
(Menting et al, 2014).  
 
 
Figure 1.4: Crystal structure of the first three extracellular domains of the IR. Visualisation of the 
first crystal structure of the IR obtained from PDB ID 2HR7 (Lou et al, 2006). Domains are coloured 
as follows: L1, blue; CR, red and L2, yellow. Resolution of 2.32 Å. This was the first available crystal 
structure of the IR and was able to visualise the arrangements of the first three extracellular domains of 
the IR. The CT peptide was not resolved in this structure. 
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Figure 1.5: Visualisation of the re-refined extracellular domains of the IR. Re-refinement of the 
2DTG crystal structure was able to successfully resolve the CT peptide (PDB ID 3LOH) (Smith et al, 
2010). Domains are coloured as follows: L1, blue; CR, red; L2, yellow; FnIII-1, green; FnIII-2, cyan; 
FnIII-3, purple and CT peptide, orange. Resolution of 3.8 Å. This structure was able to visualise the 
position of the CT peptide in relation to the rest of the receptor. The insert domain remains unresolved. 
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Figure 1.6: First crystal structure of an insulin-bound IR fragment. The crystal structure of an 
insulin-bound IR fragment was able to determine the exact binding site on the IR for insulin (PDB ID 
3W11) (Menting et al, 2013). The structures are coloured as follows: L1 and CR domain, blue; CT 
peptide, red; insulin A-chain, grey and insulin B-chain, orange. Resolution of 3.9 Å. This structure was 
able to visualise the interactions that are formed between the ligand and receptor during insulin binding. 
The CT-tail and insulin B-chain tail were unresolved in this structure. 
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Figure 1.7: Crystal structure of and insulin-bound IR fragment with previously missing regions 
resolved. The latest structure of the insulin-bound IR fragment successfully resolved regions of the 
insulin B-chain tail and the CT-tail (PDB ID 4OGA) (Menting et al, 2014). The structures are coloured 
identical to those shown in Figure 1.6. Resolution of 3.5 Å. This structure improved upon the structure 
in 3W11 and was able to visualise more interactions between ligand and the receptor. 
 
 MODELS OF INSULIN BINDING TO ITS RECEPTOR 
Throughout the years, many different models have been proposed to describe 
how insulin binds to and activates its receptor. These models range from describing 
how the receptor responds upon ligand binding to the changes in the receptor that occur 
during activation. Early experiments found the dissociation rate of tracer insulin was 
accelerated by the binding of unlabelled insulin to the IR resulting in curvilinear 
Scatchard plots. This behaviour (termed negatively cooperative binding) indicated the 
IR bound insulin asymmetrically and could only bind one insulin molecule with high 
affinity and led to the proposal of a two-site model describing how insulin binds to the 
IR (De Meyts et al, 1973).  
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Another study investigating the binding of insulin to membrane-bound receptors 
found insulin dissociated from the IR at two different rates, leading the authors to 
propose a two-state model for insulin binding (Equation 1.1) (Corin & Donner, 1982). 
This model described the initial formation of the ligand-bound receptor complex 
before insulin dissociates from the IR at a rapid rate, constituting the low-affinity state 
of the receptor. However, some of the receptors were found to transition into a high 
affinity binding state in which insulin dissociated at a slower, time-dependent manner 
(Corin & Donner, 1982).  
Equation 1.1 Insulin + IR
𝑘a1
→ 
𝑘d1
←  
IRlow
𝑘a2
→ 
𝑘d2
←  
IRhigh 
 
This model was later updated with a newer model describing the existence of 
two different binding sites on each receptor monomer (Schaffer, 1994). Through the 
use of insulin analogues with different binding properties, a model of insulin binding 
was proposed where insulin initially binds to the low affinity binding site 1 of one 
receptor monomer before transitioning to the high affinity binding state via 
crosslinking to site 2’ on the second receptor monomer (Schaffer, 1994). A second 
insulin monomer is able to bind to site 1’ on the second receptor monomer before 
subsequent binding to the remaining site 2 results in the accelerated dissociation of the 
first bound insulin, driving the negative cooperativity described above. Interestingly, 
studies using soluble IR constructs, truncated N-terminal to the transmembrane 
domain, displayed only the low-affinity state of the receptor (Markussen, Halstrom, 
Wiberg, & Schaffer, 1991) while fusion of the β-chain C-terminus to dimer inducing 
structures such as an immunoglobulin Fc domain (Bass, Kurose, Pashmforoush, & 
Steiner, 1996) or leucine zipper (Hoyne et al, 2000) was able to restore the 
high-affinity state of the IR, implying that the structural composition of the IR is 
critically important for correct receptor function.  
 
Multiple studies have proposed the receptor undergoes conformational changes 
upon ligand binding (Baron, Kaliman, Gautier, & Van Obberghen, 1992; Donner & 
Yonkers, 1983; Florke et al, 2001; Lee, Pilch, Shoelson, & Scarlata, 1997; Pilch & 
Czech, 1980). Some studies proposed the receptor undergoes a single conformational 
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change upon the binding of insulin which then triggers activation of the receptor 
(Donner & Yonkers, 1983; Florke et al, 2001; Pilch & Czech, 1980). Another study 
proposed the existence of more than one conformational change, where the initial 
binding of insulin causes the first response. A subsequent change then occurs where 
the receptor transitions into a pre-activated conformation before another change 
triggers autophosphorylation of the receptor resulting in activation (Baron et al, 1992). 
A similar model involves an initial conformational change triggered by the binding of 
insulin with a subsequent conformational change transmitted through the receptor 
resulting in autophosphorylation and receptor activation (Lee et al, 1997). 
 
Early cryogenic-electron microscopy (cryo-EM) studies were able to visualise 
low resolution images of the overall IR structures (Figure 1.8) (Christiansen, Tranum-
Jensen, Carlsen, & Vinten, 1991; Tranum-Jensen et al, 1994; Woldin et al, 1999). The 
experimental data from these studies led to the proposal of a “T” shaped receptor 
(Christiansen et al, 1991) or a “Y” shaped receptor (Woldin et al, 1999). Both receptor 
models placed the α-region in the “arms” of the letter representations while the β 
domains were speculated to be the “stem”, presumably arranged as a 
closely-associated homodimer. Another cryo-EM study found a population of 
membrane-bound receptors resembled an inverted “V” shape (Tranum-Jensen et al, 
1994) and this structure was later resolved in a crystal structure (McKern et al, 2006) 
with the β domains spaced well apart from each other (Figure 1.3) where the legs were 
formed by the two receptor monomers. Dimerising of the “legs” could then potentially 
form the proposed “T” shape of the receptor. The “Y” shaped receptor on the other 
hand, is likely produced by dissociation of the L1 domain from the other domains, 
resulting in the α-region positioned upwards in the “arms” of the “Y” shape. However, 
despite the availability of multiple crystal structures of the IR (both in the presence 
and absence of insulin), details of the conformational changes of the IR that occur 
following insulin binding have yet to be identified or observed. 
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Figure 1.8: Low resolution images from early cryo-EM studies visualising the IR structure. These 
cryo-EM images were able to provide early clues regarding the structure of the membrane-bound IR. A, 
the IR in the study conducted by Christiansen et al was found to resemble a “T” shaped receptor where 
the “stem” represents the β domains while the “arms” were speculated to be the α-region (Christiansen 
et al, 1991). B, Woldin et al visualised the IR resembling a “Y” shaped receptor where the two open 
“arms” represent the α-region (Woldin et al, 1999). The structure of the open conformation of the 
receptor is presumably a result of dissociation of the L1 domain from the other domains, resulting in 
the α-region positioned upwards in the “arms” of the “Y” shape. C, the IR was captured in experiments 
performed by Tranum-Jensen et al in an inverted “V” shape(Tranum-Jensen et al, 1994), highly similar 
to the first crystal structure of the receptor extracellular domains (McKern et al, 2006).  
 
1.3 OTHER MEMBERS OF THE IR FAMILY  
The IR family of receptors also include the insulin-like growth factor I receptor 
(IGF1R) (Ullrich et al, 1986) and the insulin receptor related receptor (IRR) (Shier & 
Watt, 1989). Although these receptors are not in the scope of study in this project, they 
share high structural and sequence homology and the knowledge surrounding how 
these receptors activate may help in further understanding the IR. 
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 INSULIN-LIKE GROWTH FACTOR (IGF-I) AND ITS RECEPTOR (IGF1R) 
The insulin-like growth factor I (IGF-I) shares high sequence homology 
(approximately 50%) with other members of the insulin-like peptides (insulin and 
IGF-II) and is largely associated with growth and development (Adams, Epa, Garrett, 
& Ward, 2000). Several studies using NMR and crystallography techniques have 
contributed to determining the molecular structure of IGF-I (Brzozowski et al, 2002; 
Cooke, Harvey, & Campbell, 1991; Sato et al, 1992; Vajdos et al, 2001) and have 
shown that the secondary structure of IGF-I closely resembles insulin (Figure 1.9) 
(PDB ID 1PMX) (Schaffer et al, 2003). IGF-I comprises three helices located on the 
A and B domain that are organised into a similar arrangement to insulin (Brzozowski 
et al, 2002). Unlike insulin however, IGF-I also contains a C domain located between 
the A and B domains which is similar to the C-peptide that is cleaved from proinsulin 
(Vajdos et al, 2001). Additionally, an eight residue long D domain extends from the 
C-terminus of the peptide (Brzozowski et al, 2002) and has been demonstrated to 
contain a substrate site for transglutaminases (Sivaramakrishnan et al, 2013). The 
domains are held together by three intramolecular disulphide bonds, analogous to the 
disulphide bonds in insulin. 
 
The D domain of IGF-I is not essential for high affinity binding to the IGF1R as 
a previous mutagenesis study showed deletion of this region of the ligand did not affect 
binding affinity (Bayne et al, 1989). Several studies have shown that the C domain of 
IGF-I is critical for functional binding (Bayne et al, 1989; Gill et al, 1996) with 
deletion of this domain causing extensive loss of structural integrity that is speculated 
to be associated with loss of binding affinity (De Wolf et al, 1996). Mutagenesis 
studies using peptides with residue substitutions at B8, B12, B23, B24, C31, C36, C37, 
A59, A60 and A62 all demonstrated a range of loss in affinity towards the IGF1R 
(Bayne et al, 1989; Cascieri et al, 1988; Jansson, Uhlen, & Nilsson, 1997). The C 
domain has also been proposed to initiate a conformational change of the ligand in 
order to expose the residues of the A domain buried underneath, a manner very similar 
to that seen in insulin (Gill et al, 1996).  
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Figure 1.9: The structural similarities between insulin and IGF-I. Comparison of the structures of 
insulin and IGF-I show they share very high similarity. A, the structure of insulin (PDB ID 4INS) (Baker 
et al, 1988). Colours of the chains are identical to that shown in Figure 1.1. B, the structure of IGF-I 
shows two domains that are analogous to the two chains in insulin with the differences in the extra 
domains C and D (PDB ID 1PMX) (Schaffer et al, 2003). The colours of the A and B domain are the 
same as their equivalent in insulin (orange and grey, respectively). The C domain is shown in green 
while the D domain is shown in yellow. The intramolecular disulphide bonds in each structure are 
visualised in stick representation. The N- and C- terminus of each chain are indicated with the letters N 
and C respectively. 
 
The gene structures of the IGF1R and the IR differ by the absence of the variably 
spliced exon 11 from the former receptor (Abbott et al, 1992). Other than this, the 
genes encode for receptor sequences that share over 50% sequence identity and their 
tertiary structures are highly similar (Rechler & Nissley, 1985). Crystal structures of 
the first three domains of the IGF1R show the same arrangement of domains as that 
determined for the IR (Figure 1.10) (PDB ID 1IGR) (Garrett et al, 1998). Notably 
different to the IR is the existence of specific acidic residues on the cysteine-rich repeat 
domain of the IGF1R that are thought to be important for ligand binding (Whittaker et 
al, 2001) and have been proposed to partly contribute to binding site 1 by interacting 
with the IGF-I C domain (Ward & Lawrence, 2009).  
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The IGF1R has a similar binding site to IR as they are both able to bind insulin 
and IGF-I, albeit at a lower affinity for their non-cognate ligands (De Meyts et al, 
2004). Studies using IGF-I containing regions substituted with their equivalent 
residues from insulin bound to the IGF1R with high affinity, demonstrating that both 
receptors use essentially the same binding site (Gauguin et al, 2008; Kristensen et al, 
1995). A study investigating the IGF1R using alanine scanning mutagenesis showed 
mutation of certain residues resulted in a larger reduction in affinity for IGF-I 
compared to the mutation of other residues (Whittaker et al, 2001). In particular, 
substitution of Phe701 to alanine on the C-terminus of the IGF1R α-chain renders the 
mutant receptor unable to bind IGF-I, thereby demonstrating the importance of this 
receptor segment (Whittaker et al, 2001). Other residue substitutions that resulted in 
impaired or low affinity ligand binding were shown to reside on the L1 and the 
C-terminus of the α-chain which in the insulin/IR model were proposed to contribute 
to binding site 1 (Whittaker et al, 2001). Notably, however, the IGF1R displays 
distinctly different dissociation behaviour compared to the IR (Christoffersen et al, 
1994).  
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Figure 1.10: The structural similarities between the IR and IGF1R. Comparison of the first three 
domains of the IR and IGF1R show the structures and arrangements are highly similar. A, the structure 
of the IGF1R (PDB ID 1IGR) (Garrett et al, 1998). The domains are coloured the same as their 
equivalent domains in IR and are identical to that shown in Figure 1.4. B, the structure of the IR (PDB 
ID 2HR7) (Lou et al, 2006).  
 
 INSULIN-LIKE GROWTH FACTOR 2 (IGF-II) 
The solution structure of insulin-like growth factor 2 (IGF-II) shows it shares the 
same domain structure and arrangement as IGF-I (Figure 1.11) (PDB ID 1IGL) 
(Torres et al, 1995). IGF-II has been demonstrated in mouse knockout models to be an 
important factor during foetal growth (Baker, Liu, Robertson, & Efstratiadis, 1993; 
DeChiara, Efstratiadis, & Robertson, 1990). In humans, IGF-II has been shown to play 
post-natal roles such as the promotion of cell growth and differentiation (Chao & 
D'Amore, 2008). These effects are mainly brought about via signalling through the 
IGF1R but the peptide has also been shown to bind and signal through one of the splice 
variants of the IR, IR-A (LeRoith & Roberts, 2003; Louvi, Accili, & Efstratiadis, 1997; 
Tognon & Sorensen, 2012).  
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Figure 1.11: Solution structure of IGF-II. The structure of the IGF-II is highly similar to the structure 
of IGF-I (Figure 1.9B) (PDB ID 1IGL) (Torres et al, 1995). The domains of the peptide are coloured 
the same as their equivalent domains in IGF-I shown in Figure 1.9. The N- and C- terminus of each 
chain are indicated with the letters N and C respectively. 
 
 EPIDERMAL GROWTH FACTOR (EGF) RECEPTOR (EGFR) 
The EGFR family is a class of receptors distantly related to the IR family and is 
one of the most heavily investigated cell-surface receptors (Citri & Yarden, 2006). 
Although not part of the IR family of receptors and sharing less than 20% sequence 
homology with the IR and IGF1R, the first three extracellular domains of the EGFR 
show a remarkably close structural homology to these receptors (Figure 1.12), 
whereas the remaining domains are very different with three FnIII domains in the IR 
in contrast to a second CR domain in the EGFR (Adams et al, 2000). Despite the 
differences in the C-terminal region of the extracellular domain of these receptors, the 
EGFR is believed to share sufficient similarities with the IR family to provide insights 
into how the latter family of receptors may function (Ward et al, 2007). Extensive 
crystallography studies of the EGFR have successfully resolved different 
conformational states of the receptor in the inactive (PDB ID 1NLQ) (Ferguson et al, 
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2003) and ligand-bound (PDB ID 1IVO) (Ogiso et al, 2002) states, demonstrating a 
large rearrangement of the first three domains upon receptor activation (Figure 1.13). 
 
Figure 1.12: Similarity of the domain structure and arrangement between the EGFR and the IR. 
Comparison of the structures of the EGFR (A) (PDB ID 1NLQ) (Ferguson et al, 2003) and IR (B) show 
similarity in their first three domains. This high similarity is believed to be able to provide insights into 
how the IR may function. Domains are coloured the same as their equivalent in the IR.  
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Figure 1.13: Structural difference between the inactive and active states of the EGFR. The two 
different conformational states of the EGFR demonstrate a large rearrangement of the first three 
domains. A, conformation of the inactive EGFR (PDB ID 1NLQ) (Ferguson et al, 2003). B, the 
conformation of the activated EGFR bound to its ligand, EGF (EGF shown as orange representation) 
(PDB ID 1IVO) (Ogiso et al, 2002). Equivalent regions of the inactive and active structures are shown 
in red and yellow to show the movement of the L2 domain. 
 
 RELAXIN PEPTIDE SUBFAMILY 
The relaxin peptide subfamily shares high structural homology with the insulin 
family of peptides (including insulin, IGF-I and IGF-II) (Bani, 1997; Schwabe, 
Gowan, & Reinig, 1982). Like the peptides within the insulin family, the structure of 
relaxin also contains two chains (chains A and B) that are connected by intermolecular 
disulphide bridges (Eigenbrot et al, 1991; Schwabe & McDonald, 1977). Furthermore, 
the mode by which relaxin peptides bind to their native receptors (leucine-rich repeat-
containing G protein-coupled receptor (LGR7 and LGR8)) shares common features 
observed for the insulin peptide family (Bullesbach & Schwabe, 2005; Scott et al, 
2007; Ward & Lawrence, 2009). Despite these similarities however, the relaxin 
peptides do not display cross reactivity with any of the receptors in the insulin receptor 
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family (Rawitch, Moore, & Frieden, 1980; Sherwood & O'Byrne, 1974) and 
investigations of this peptide’s binding mechanism may not be entirely suitable to 
investigate the interactions between insulin and the IR. 
 
1.4 RECEPTOR SPECIFICITY 
The IR and IGF1R have shown the ability to interchangeably bind both insulin 
and IGF-I indicating the high structural similarities they share, although binding 
affinity of ligands to non-cognate receptors are lower, suggesting receptor-ligand 
specific interactions (Andersen et al, 1992; Schumacher et al, 1991; Ullrich et al, 
1986). It is speculated that the C-domain of IGF-I is responsible for ligand specificity 
as residues on the CR domain of IGF1R interact directly with this region, possibly also 
explaining the low affinity of IGF1R for insulin as the equivalent region is excised 
during peptide production. Interestingly, an IGF-I analogue containing a substitution 
of four amino acids from insulin (Histidine 4, tyrosine 15, threonine 49 and isoleucine 
51) was able to bind to the IR with an affinity equal to that of insulin  indicating the 
IR is able to accommodate the steric bulk of the additional C-domain on IGF-I 
(Gauguin et al, 2008). Furthermore, a hybrid receptor comprising one monomer from 
the IR and one from the IGF1R was able to bind both ligands but with a higher affinity 
for IGF-I (Slaaby et al, 2006). Additional studies using chimeric receptors constructed 
by exchanging domains of the two receptors have shown that different domains are 
responsible for ligand specificity. It is known that the CR domain of IGF1R is 
important for IGF-I binding, but substitution of the equivalent domain in the IR results 
in a chimeric receptor that binds IGF-I with high affinity, suggesting that other regions 
of IGF1R do not contribute largely to ligand specificity (Schumacher et al, 1991). 
Other studies have shown that the residues responsible for insulin-specific binding 
were located within the 68 N-terminal amino acids and when substituted into the same 
region on the IGF1R, yielded a receptor that had a 200-fold higher affinity for insulin 
(Andersen et al, 1992).  
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1.5 APPROACHES TO UNDERSTANDING LIGAND BINDING  
 EXPERIMENTALLY BASED APPROACHES 
Since the discovery of insulin, researchers have used many different methods to 
better understand ligand binding to the IR and IGF1R. Common methods include the 
use of chimeric receptors, mutagenesis studies and insulin analogues. 
 
Chimera studies 
Studies using receptor chimeras have been discussed in Section 1.4. These 
studies involved the substitution of receptor regions with the equivalent regions from 
other receptors in the family and were able to identify regions responsible for ligand 
specificity (Andersen et al, 1992; Kjeldsen et al, 1991; Kristensen, Wiberg, & 
Andersen, 1999; Schumacher et al, 1991; Zhang & Roth, 1991). Table 1.1 summarises 
past chimeric receptor studies which demonstrated different regions of the receptor 
were responsible for ligand binding or specificity. However, the question of how the 
functions of these chimeric receptors were affected has yet to be answered. 
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Table 1.1: Summary of past chimeric receptor studies. The results from these studies were able to identify regions of the receptor that may be important for ligand specificity. 
Receptor Region removed Substituting region Effect on binding Reference 
IR Residues 1-137 Equivalent residues from IGF1R Loss of affinity for both insulin and IGF-I (Schumacher et al, 1991) 
IR CR domain CR domain from IGF1R Bound both insulin and IGF-I with high affinity (Schumacher et al, 1991) 
IGF1R Residues 1-68 Equivalent residues from IR 
200-fold increased affinity for insulin, 5-fold 
decreased affinity for IGF-I 
(Kjeldsen et al, 1991) 
IGF1R Residues 1-27 Equivalent residues from IR Increased affinity for insulin (Andersen et al, 1992) 
IGF1R Residues 28-68  
Equivalent residues 28-68 from 
IR 
Increased affinity for insulin (Andersen et al, 1992) 
IR CT peptide CT peptide from IGF1R 
Decreased affinity for insulin, increased 
affinity for IGF-I 
(Kristensen et al, 1999) 
IR CT peptide  CT peptide from IRR No detectable binding for insulin or IGF-I (Kristensen et al, 1999) 
IGF1R CT peptide CT peptide from IR 
Minimal change to binding affinity for insulin 
and IGF-I 
(Kristensen et al, 1999) 
IGF1R CT peptide CT peptide from IRR No detectable binding for insulin or IGF-I (Kristensen et al, 1999) 
IR Residues 191-297 Equivalent residues from IGF1R Bound IGF-I with high affinity (Zhang & Roth, 1991) 
IR Residues 191-297 Equivalent residues from IRR Bound insulin with similar affinity to wt-IR (Zhang & Roth, 1991) 
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Truncated receptor studies 
Truncated receptor constructs have been used to find the receptor domains that 
may contain the binding sites for their respective ligands. Studies implementing this 
approach were able to identify regions of the receptor that were essential for receptor 
functions such as ligand binding and exhibiting negative co-cooperativity (Bass et al, 
1996; Brandt, Andersen, & Kristensen, 2001; Hoyne et al, 2000; Kristensen et al, 
2002; Kristensen et al, 1998; Surinya et al, 2002). Importantly, studies have 
demonstrated the importance of the CT peptide by showing that while truncated 
versions of the IR consisting of the L1, CR and L2 domains were unable to bind 
insulin, the same constructs fused to the CT peptide or mixed with an excess of soluble 
CT peptide bound insulin with an affinity equivalent to the whole soluble ectodomain 
(Kristensen et al, 2002; Kristensen et al, 1998; Menting et al, 2009).  
 
Mutagenesis studies 
Extensive mutagenesis studies have identified residues on the IR that may play 
important roles during insulin binding. These studies chose regions of the receptor that 
were within close proximity to the speculated binding sites for insulin and mapped out 
regions of the receptor that, when mutated, resulted in a range of reductions in the 
affinity of the receptor for insulin (Mynarcik, Yu, & Whittaker, 1996; Nakae, Morioka, 
Ohtsuka, & Fujieda, 1995; Whittaker, Sorensen, Gadsboll, & Hinrichsen, 2002; 
Williams et al, 1995). The mutations that were determined to significantly affect the 
binding affinity of the IR are summarised in Table 1.2. Detailed information about IR 
and IGF1R mutants (both naturally occurring and mutagenesis generated) can be found 
in the Receptors for Insulin-Like Molecules (RILM) database (Garza-Garcia, Patel, 
Gems, & Driscoll, 2007). However, although this ‘shot-gun’-like approach was able 
to identify residues that affected the receptor’s affinity for insulin, it does not provide 
information as to how these reductions in affinity come about. Do they directly affect 
ligand-receptor interactions? Or do they affect other aspects of the receptor such as 
preventing important conformational changes?  
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Table 1.2: Summary of mutations that significantly affected IR binding affinity. 
IR residue Mutation Effect on receptor Reference 
Asp12 D12A ~10-fold decrease in affinity (Whittaker et al, 2002) 
Arg14 R14A Insulin binding too low to be determined accurately (Whittaker et al, 2002) 
Asn15 N15A Insulin binding too low to be determined accurately (Whittaker et al, 2002) 
Gln34 Q34A ~15-fold decrease in affinity (Whittaker et al, 2002) 
Leu36 L36A ~5-fold decrease in affinity (Whittaker et al, 2002) 
Leu37 L37A ~20-fold decrease in affinity (Whittaker et al, 2002) 
Phe64 F64A Insulin binding too low to be determined accurately (Whittaker et al, 2002) 
Arg86 R86P Loss of insulin binding (Gronskov et al, 1993) 
Leu87 L87I 4-fold increase in affinity (Nakae et al, 1995) 
Leu87 L87A 13-fold decrease in affinity (Nakae et al, 1995) 
Thr704 T704A Insulin binding too low to be determined accurately (Mynarcik et al, 1996) 
Phe705 F705A Insulin binding too low to be determined accurately (Mynarcik et al, 1996) 
Glu706 E706A Insulin binding too low to be determined accurately (Mynarcik et al, 1996) 
Tyr708 Y708A ~180-fold decrease in affinity (Mynarcik et al, 1996) 
Leu709 L709A ~150-fold decrease in affinity (Mynarcik et al, 1996) 
His710 H710A Insulin binding too low to be determined accurately (Mynarcik et al, 1996) 
Asn711 N711A ~70-fold decrease in affinity (Mynarcik et al, 1996) 
Val713 V713A Insulin binding too low to be determined accurately (Mynarcik et al, 1996) 
Phe714 F714A ~150-fold decrease in affinity (Mynarcik et al, 1996) 
Val715 V715A ~10-fold decrease in affinity (Mynarcik et al, 1996) 
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Insulin analogues 
Studies have attempted to better understand the insulin binding process using 
insulin analogues containing mutations at selected sites. Glendorf et al (2011) 
investigated the binding of insulin analogues containing mutations at B25 and B27 to 
the two IR isoforms and found that these two sites are responsible for IR isoform 
selectivity (Glendorf et al, 2011). Another study modified residues B10 and B26-B30 
and found these insulin analogues did not significantly affect binding to the IR but 
instead caused a greater reduction in affinity for IGF1R (Slieker et al, 1997). A 
different study generated an inactive insulin analogue by linking the A- and B-chains 
together with a peptide bond (Derewenda et al, 1991). Later studies showed that 
movement of the B-chain C-terminus, particularly residues B16 and B24, was 
important for exposing residues belonging to the classical binding surface of insulin 
and proposed the presence of a functional switch (Hua, Shoelson, Kochoyan, & Weiss, 
1991; Ludvigsen et al, 1998). A more recent study performed mutations at position 
B26 and identified a conformation that was different from native insulin and was 
proposed to represent the active form of insulin when it is in complex with the IR 
(Zakova et al, 2014). 
 
Photo-active insulin analogues have also been used to elucidate residues on the 
receptor that directly contact insulin during ligand binding (Huang et al, 2007; Kurose 
et al, 1994; Wan et al, 2004; Wan et al, 2005; Xu et al, 2004; Yip et al, 1988). These 
insulin analogues crosslinked to residues on both the L1 domain and the CT peptide 
after replacing residues ValA3 (Huang et al, 2007), PheB24 (Xu et al, 2004) and 
PheB25 (Kurose et al, 1994; Xu et al, 2004) with photo-active molecules 
demonstrating insulin comes into close proximity to these regions of the receptor upon 
ligand binding.  
 
 COMPUTATIONALLY BASED APPROACHES 
Bioinformatics 
An extensive bioinformatics study of the IR family in vertebrates found highly 
conserved residues within the IR throughout evolution (Table 1.3), which were 
hypothesised to form the two suspected binding sites for insulin (Renteria et al, 2008). 
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The residues agreed with data from previous mutagenesis studies (summarised in 
Table 1.2) that reported mutation of these residues and their effects on the receptor’s 
affinity for insulin.  
 
Table 1.3: List of conserved residues identified in a bioinformatics study of IR. Residues were 
identified via multiple sequence alignment of IR sequences from vertebrates (Renteria et al, 2008). 
Conserved 
residue 
Location on 
receptor 
Significance 
Gln34 L1 Likely involved in ligand binding 
Leu36 L1 Likely involved in ligand binding 
Leu37 L1 Likely involved in ligand binding 
Phe39 L1 Likely involved in ligand binding 
Asp59 L1 Likely involved in ligand binding 
Tyr60 L1 Likely involved in ligand binding 
Leu62 L1 Likely involved in ligand binding 
Phe64 L1 Likely involved in ligand binding 
Arg65 L1 Likely involved in ligand binding 
Tyr67 L1 Likely involved in ligand binding 
Leu87 L1 Likely involved in ligand binding 
Phe88 L1 Likely involved in ligand binding 
Phe89 L1 Likely involved in ligand binding 
Asn90 L1 Likely involved in ligand binding 
Tyr91 L1 Likely involved in ligand binding 
Val94 L1 Likely involved in ligand binding 
Phe96 L1 Likely involved in ligand binding 
Glu97 L1 Likely involved in ligand binding 
Arg114 L1 Likely involved in ligand binding 
Arg118 L1 Likely involved in ligand binding 
Glu120 L1 Likely involved in ligand binding 
Lys121 L1 Likely involved in ligand binding 
Tyr507 FnIII-1 Potentially receptor binding site 2 
Asn527 FnIII-1 Potentially receptor binding site 2 
Trp529 FnIII-1 Potentially receptor binding site 2 
Lys557 FnIII-1 Potentially receptor binding site 2 
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Pro558 FnIII-1 Potentially receptor binding site 2 
Trp559 FnIII-1 Potentially receptor binding site 2 
Ser596 FnIII-2 Potentially receptor binding site 2 
Val597 FnIII-2 Potentially receptor binding site 2 
Pro598 FnIII-2 Potentially receptor binding site 2 
Leu599 FnIII-2 Potentially receptor binding site 2 
Asp600 FnIII-2 Potentially receptor binding site 2 
Pro601 FnIII-2 Potentially receptor binding site 2 
Lys614 FnIII-2 Strictly conserved-possibly important for function 
Trp615 FnIII-2 Strictly conserved-possibly important for function 
Lys616 FnIII-2 Strictly conserved-possibly important for function 
Pro617 FnIII-2 Strictly conserved-possibly important for function 
Pro618 FnIII-2 Strictly conserved-possibly important for function 
Pro621 FnIII-2 Strictly conserved-possibly important for function 
 
Molecular docking and dynamics simulations 
Molecular docking and simulation techniques have been extensively used in 
recent years to study the molecular structures and predict possible conformations of 
proteins. The conformational transitions of insulin between its T and R states were 
illustrated using targeted molecular dynamics (TMD) (discussed in Section 1.8.1) 
providing insights into the secondary structure pathways that insulin may undertake 
during transition between these two states (Schlitter et al, 1993). Another study applied 
multiple molecular dynamics simulations to the B chain of insulin and from their 
results, speculated that GlyB8 was a potentially key residue involved in the structural 
changes of insulin between its known conformational states (Legge, Budi, Treutlein, 
& Yarovsky, 2006).  
 
Studies have used molecular docking and molecular dynamics (MD) simulations 
in an attempt to investigate the IR and its mechanism of ligand binding. An earlier 
study reporting the crystal structure of the first three domains of the IR (L1, CR and 
L2) also attempted to understand the mode of insulin binding by docking insulin (R 
state) to the L1 domain of the receptor (Lou et al, 2006). More recently, a study using 
molecular dynamics simulations demonstrated that the IR ectodomain in the absence 
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of insulin maintained a stable structure across a 70 ns simulation, and displayed only 
small conformational fluctuations between domains or subunits (Vashisth & Abrams, 
2010). The same authors also docked insulin (both T and R states) into an exposed 
pocket and showed that the ligand-bound structure remained stable during the 30 ns of 
simulation that followed (Vashisth & Abrams, 2010). Problematically, due to the 
absence of the CT peptide in the crystal structure, the simulations and docking 
experiments were done with this essential peptide omitted, indicating their results are 
inaccurate. The authors also acknowledged the possibility that insulin may not 
necessarily be in the T or R state upon ligand binding as movement of the C-terminus 
of the B chain is required to expose the buried residues of the A-chain that are required 
for ligand-receptor interaction (Vashisth & Abrams, 2010). Furthermore, the 
availability of the insulin-bound crystal structures show that the results presented by 
Vashisth and Abrams (2010) are incorrect. Following the availability of the CT peptide 
coordinates, a new docking study was performed by ashisth and Abrams (2010) that 
docked insulin to an IR construct containing the CT peptide. However, the results 
presented do not accurately represent insulin binding as the positions and contacts 
between insulin and IR do not match those reported in the insulin-bound IR crystal 
structures (PDB ID 3W11-3W14 and 4OGA) (Menting et al, 2013).  
 
1.6 NATURALLY OCCURRING MUTATIONS IN IR AND IGF1R 
The IR and its family of receptors play pivotal roles in the normal bodily 
functions of humans, including homeostasis, development and growth (Lee & Pilch, 
1994; Siddle, 2011). Non-functional or abnormal expression of these receptors and 
their ligands lead to a range of diseases and disorders such as diabetes and cancer.  
 
Defects in the IR can result in impaired or abolished ligand binding, aberrant or 
absent receptor activation, receptor processing and receptor transportation (Elsas et al, 
1985; Olefsky, 1976; Rabson & Mendenhall, 1956). These functional and receptor 
processing deficiencies can lead to a range of expressed phenotypes, such as insulin 
resistance (Olefsky, 1976), Rabson-Mendenhall syndrome (Rabson & Mendenhall, 
1956) and Leprechaunism (Elsas et al, 1985). One particular naturally-occurring point 
mutation on the L1 domain of the IR, R86P, is of particular interest, since it both 
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abolishes insulin binding and causes constitutive activation of the receptor (Longo, 
Langley, Griffin, & Elsas, 1993). The fact that this mutation is located in very close 
proximity to both the CT peptide and the proposed binding site 1 indicates that Arg86 
could potentially play a major role in governing receptor activation. Whilst studies 
have demonstrated that mutation of this residue to either proline or alanine abolishes 
binding to insulin (Gronskov et al, 1993; Williams et al, 1995), they do not explain 
how this mutation causes such intriguing effects on the receptor (Longo et al, 1993). 
Important information may be gained by identifying the conformations the receptor 
adopts during constitutive receptor activation as these same conformations may also 
be present during binding of insulin to the wild-type IR. 
 
1.7 DRUGS AND MIMETICS 
Due to the high degree of structural similarity between the IR and the IGF1R, 
designing inhibitors and peptide mimetics that are specific to one receptor has proven 
difficult. Phage display techniques found a cohort of peptides that were able to 
competitively bind to the IR and displayed affinities in the nanomolar to micromolar 
range (Pillutla et al, 2002). Although the peptides showed no sequence homology with 
insulin, they were still able to bind the IR and caused insulin-induced effects (Pillutla 
et al, 2002). Later studies with these peptides, however, showed that they did not bind 
to the IR in the same negatively cooperative manner as insulin nor did they activate 
the same downstream signalling pathways and thus could not be used to mimic the 
effects of insulin binding (Jensen et al, 2007).  
 
Other studies have attempted to bypass the receptor-binding step and targeted 
the tyrosine kinase domain or downstream signalling pathways in order to induce 
similar cellular responses in the absence of insulin. Compounds derived from 
arylalkylamine vanadium salts were shown to potently activate downstream effects 
and induce insulin signalling in diabetic animal models (Garcia-Vicente et al, 2007).  
 
Researchers have also targeted the extracellular domains of the IR family of 
receptors due to the high specificity they have for their cognate ligands. A study using 
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an allosteric monoclonal antibody found it was able to activate the tyrosine kinase 
domain of the receptor in the absence of insulin (Bhaskar et al, 2012). However, when 
compared with normal insulin binding, this antibody did not completely activate the 
receptor or the subsequent signalling pathways suggesting it was only a partial agonist 
(Bhaskar et al, 2012). The IGF1R is highly regarded as a potential therapeutic target 
for cancer due to its growth and proliferation promoting functions. Antibodies such as 
Figitumumab have been developed to specifically block IGF1R’s ability to bind its 
associated ligands (Tognon & Sorensen, 2012). This particular antibody was being 
tested in human patients with non-small cell lung cancer but was permanently 
suspended due to lack of improvement to patients and the development of serious 
adverse effects such as dehydration, hyperglycemia, and hemoptysis (Jassem et al, 
2010). Another monoclonal antibody, developed to target IGF1R and hybrid receptors 
(insulin/IGF1 receptor) was shown to inhibit IGF-I binding to both IGF1R and hybrid 
receptors without affecting the IR (Pandini et al, 2007). Phase II/III trials of this 
antibody were terminated due to the treatment worsening progression-free and overall 
survival (Watkins et al, 2011). These aforementioned studies demonstrate that without 
a complete understanding of the underlying mechanisms of ligand binding, designing 
highly specific and efficient inhibitors, antibodies or mimetics has proven to be a 
difficult task. 
 
1.8 EXPERIMENTAL TECHNIQUES FOR STUDYING LIGAND-RECEPTOR 
BINDING 
 MOLECULAR DYNAMICS (MD) SIMULATIONS 
All-atom MD simulations 
All-atom molecular dynamics simulations have been commonly used to study 
proteins and biomolecules in a computational environment (Baker & Best, 2014; Doss, 
Chakraborty, Chen, & Zhu, 2014; Jo, Jiang, & Roux, 2015; Klepeis, Lindorff-Larsen, 
Dror, & Shaw, 2009). This approach to study proteins in silico was first reported by 
McCammon et al (1977) where an MD simulation was used to investigate protein 
dynamics (McCammon, Gelin, & Karplus, 1977). MD simulations involve 
computationally complex algorithms that calculate the relative positions and energy 
potentials of atoms over a simulated period of time, repeatedly solving Newton’s laws 
of motion for each atom (Karplus & Petsko, 1990). The forces on each atom are 
32 
32 Chapter 1: Background and Literature Review 
derived from formulas and parameters termed “force fields” that describe the energy 
of the protein (Guvench & MacKerell, 2008). These force fields treat the proteins as a 
group of atoms that are connected to each other via springs, where spring constants 
define the bond lengths, bond angles and dihedrals (Mackerell, 2004). Other 
non-bonded parameters such as individual atom charges and van der Waals forces are 
also described in force fields (Boas & Harbury, 2008). With the continuous 
advancements in computing technology and their availability, the use of MD 
simulations for research purposes has gained increased traction. This has resulted in 
increased research and development into both the improvement of simulation software 
as well as the underlying force fields that are equally important (Hess, Kutzner, van 
der Spoel, & Lindahl, 2008; Kalé et al, 1999; Klauda et al, 2010; Schmid et al, 2011; 
Wang et al, 2004). 
 
While there are studies that have reported MD simulations reaching millisecond 
timescales (Freddolino, Liu, Gruebele, & Schulten, 2008; Klepeis et al, 2009), a 
majority of the MD simulations of proteins are only able to reach the nanosecond to 
microsecond timescale due to limitations in computational resources. Problematically, 
protein folding and conformational changes occur in the millisecond and higher 
timescales (Henzler-Wildman & Kern, 2007; Shastry & Roder, 1998). This essentially 
means that current MD simulation methods are not able to fully gauge the dynamics 
and kinetics of proteins. Thus, MD simulations cannot reliably determine how proteins 
of interest may function and it is necessary to experimentally validate any speculations 
that may arise from the computational work. 
 
Coarse-grained modelling and dynamics simulations 
Researchers have used coarse-grained dynamics simulations in order to reach 
simulation timescales that more closely matches the timescales of protein movements 
and changes in biological events (Bond et al, 2007; Heath, Kavraki, & Clementi, 2007; 
Tozzini, 2005). Coarse-grained models reduce the size of the simulation system by 
treating groups of atoms as a single entity or particle and allow longer timescale 
simulations to be achieved compared to all-atom MD simulations (Tozzini, 2005). 
Studies have used coarse-grained models to investigate protein folding (Zhou & 
 33 
Chapter 1: Background and Literature Review 33 
Karplus, 1999), peptide aggregation (Derreumaux & Mousseau, 2007) and the 
conformational states of membrane-bound peptides (Durrieu et al, 2009). However, 
while coarse-grained dynamics simulations are able to reach biologically relevant 
timescales, accuracy is sacrificed in order to achieve this (Bond et al, 2007; Tozzini, 
2005). While this method is proposed to be suitable to study overall changes in proteins 
or peptides, the sacrifice in accuracy renders it difficult to use coarse-grained models 
to study the more detailed interactions at the molecular level. 
 
Targeted molecular dynamics (TMD) simulations 
A particular type of MD simulation, known as targeted molecular dynamics 
(TMD), is used to investigate the intermediate conformations of proteins from known 
conformations (Schlitter, Engels, & Krüger, 1994). Steering forces are applied to a 
protein structure to induce a conformational change to a known target structure 
(Schlitter et al, 1994). By doing so, the structural changes that occur between different 
conformations can be investigated in more detail. This method has previously been 
used to investigate the two different conformational states of insulin (the R-state and 
T-state) and was able to identify structural changes that may show the potential 
structural transitions insulin undertakes during the binding process (Schlitter et al, 
1993).  
 
Principal components analysis (PCA) and full correlation analysis (FCA) 
Principal components analysis (PCA) is one of the most common approaches to 
analyse large, complex data sets. This method is a type of statistical analysis that takes 
a given data set and reduces its complexity to a more manageable set of variables 
(Dunteman, 1989). In MD simulations, the simulated protein or molecule not only 
samples many different conformations, but also experiences natural vibrations as the 
bonds between atoms stretch and shrink. The conformational changes that the 
simulation target undergoes is often masked by these natural vibrations. In these 
situations, PCA can be used to analyse the dynamics of the system by identifying or 
extracting sets of conformational changes that are not linked to other motions of the 
model (such as natural vibrations) (Stein, Loccisano, Firestine, & Evanseck, 2006). 
Principal components analysis has been extensively used to simplify and analyse 
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protein folding, molecular docking and MD simulation data (Bonvin, 2006; Haider, 
Parkinson, & Neidle, 2008; Smith, Sternberg, & Bates, 2005; Stein et al, 2006). More 
recently, a new method called full correlation analysis (FCA) was developed and 
studies show that this method was able to refine the output from PCA, showing an 
improved separation of conformational states while still maintaining the benefits of 
PCA (Lange & Grubmuller, 2008).  
 
Both PCA and FCA produce their analysis in the form of eigenvectors and 
eigenvalues. These two terms are generated via diagonalising the covariance matrix of 
the given MD simulation (Lange & Grubmuller, 2008). In the context of PCA of MD 
simulations, an eigenvector describes the shift of a set of atoms over the simulation 
period (represents the conformational change of the simulated protein or molecule) 
while the eigenvalues represent the variance of the eigenvector it is associated with 
(the proportion of the overall movements in the system occupied by the corresponding 
conformational change). During analysis, individual eigenvectors can also be 
projected onto the simulated trajectory to track the movement of the associated 
conformational change throughout the simulation. The sum of all the eigenvalues in a 
simulation trajectory describes the total variance in the system. 
 
 PROTEIN EXPRESSION 
Protein expression has been extensively used in a wide range of applications to 
study proteins and their properties. Mammalian (Bandaranayake & Almo, 2014), 
insect (van Oers, Pijlman, & Vlak, 2015), yeast (Gasser et al, 2013) and bacterial 
(Peck, Bowden, Shiell, & Michalski, 2014) cells have all been used to express the 
proteins of interest. Mammalian and insect cell expression systems are more 
commonly used to express proteins from mammalian origin as they are able to more 
correctly fold and perform post translational modifications of these proteins than 
simple eukaryote (yeast) and prokaryote systems (Kost, Condreay, & Jarvis, 2005).  
 
Advancements in mammalian cell expression systems have improved upon their 
properties such as the development of cell lines that can be induced to express 
recombinant protein (Reeves, Kim, & Khorana, 2002) and also cell lines that can be 
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cultured at higher densities and at much larger scales (Jäger, Büssow, & Schirrmann, 
2015; Wurm, 2004). The most commonly used mammalian expression systems are 
Chinese hamster ovary (CHO), human embryonic kidney (HEK) and baby hamster 
kidney (BHK) cells (Wurm & Bernard, 1999). The IR has successfully been produced 
using mammalian expression systems in multiple studies investigating insulin binding 
activity and receptor activation (Andersen et al, 1992; Bass et al, 1996; Kjeldsen et al, 
1991; Kristensen et al, 1998; Myers, Backer, Siddle, & White, 1991). However, while 
mammalian cells are ideal for protein expression, one drawback of using them is their 
slow growth and lower yields compared to other cell types such as insect cells (Yin, 
Li, Ren, & Herrler, 2007). 
 
Comparison of proteins expressed from mammalian and insect cell types have 
found different glycosylation patterns between them (Kost & Condreay, 1999). Insect 
cells are unable to perform N-linked glycosylation with complex glycan chains as they 
process glycoproteins differently compared to mammalian cells (Kost et al, 2005). 
Importantly, the IR is a heavily glycosylated protein and studies have shown the 
critical role glycosylation plays in folding into the correct tertiary and quaternary 
structures (Adams et al, 2000; Olson, Bamberger, & Lane, 1988). Whilst studies have 
mapped out many of the glycosylation sites on the extracellular domain (Sparrow et 
al, 2008), other studies have shown that the removal of all but a few individual glycans 
does not adversely affect receptor function, indicating the receptor has some level of 
tolerance for variations in glycosylation states (Elleman et al, 2000). The IR has been 
successfully expressed in both insect and mammalian cell types and receptors 
produced in both cell types have been demonstrated to bind insulin with similar 
affinities (Ellis, Levitan, Cobb, & Ramos, 1988; Sissom & Ellis, 1989). While both 
insect and mammalian expression systems have been reported to successfully produce 
functional IR, the insect cell expression system has been well established within our 
research group and was thus used in this study to generate IR receptors for 
investigation.  
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 SURFACE PLASMON RESONANCE (SPR) 
One method commonly used to analyse biomolecular interactions is surface 
plasmon resonance (SPR) technology. This technology generally involves the 
immobilisation of one biomolecule (ligand) and applying a second molecule (analyte) 
in a fluid phase and measuring the interactions that occur between them during this 
time. This happens by measuring the change in the refractive index during the binding 
interactions between the analyte and ligand before determining the binding constants 
using established kinetic models (Liedberg, Nylander, & Lundstrom, 1995; Szabo, 
Stolz, & Granzow, 1995). An advantage to using SPR compared to other methods that 
analyse biomolecular interactions is the ability to measure binding interactions in 
real-time and performing this without the need for labelled biomolecules (Hoa, Kirk, 
& Tabrizian, 2007). Another feature of SPR is the option to tailor biosensor surfaces 
with different dextran matrices allowing the covalent immobilisation and investigation 
of a wide variety of biomolecules (Jönsson, 1992). 
 
The first biosensor-based technology developed for widespread use was the 
BIAcore (Jonsson et al, 1991). The BIAcore quickly gained traction and became a 
commonly used approach to study biomolecular interactions (Fivash, Towler, & 
Fisher, 1998). Since then, surface plasmon resonance (SPR) technology has been used 
in a multitude of applications ranging from the analysis of binding interactions 
between biomolecules to screening of potential drug compounds (Rich & Myszka, 
2000).  
 
SPR technology has previously been applied to investigate the binding kinetics 
between the IR or IGF1R and their respective ligands (Forbes et al, 2002; Subramanian 
et al, 2013). These studies immobilised the receptor of interest on a biosensor surface 
and successfully measured ligand binding and determined the rate constants of the 
protein-protein interactions (Forbes et al, 2002; Subramanian et al, 2013). Thus, SPR 
technology was chosen as the approach for use in this study to investigate the binding 
interactions between insulin and different receptor constructs. 
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1.9 SIGNIFICANCE 
While many structures of the IR have been successfully resolved including the 
extracellular domains and insulin-bound IR fragments, the mechanisms by which the 
receptor binds to insulin and its subsequent responses that lead to activation have yet 
to be elucidated. The IR plays an integral role in metabolism and non-functioning or 
abnormal expression of this receptor has been reported to cause diseases such as 
diabetes and cancer. Therefore, a better understanding of how the receptor binds 
insulin and the subsequent changes that occur will contribute to furthering research 
into aiding IR related illnesses. 
 
1.10 HYPOTHESIS AND AIMS 
The following hypothesis was tested during the course of this research project: 
Long term simulation and molecular dynamics analyses of receptor structures 
can be used to identify significant residues that are key to receptor-ligand 
interactions. 
 
The hypothesis above was tested in the following aims: 
Aim 1: Further understand the insulin binding process and the role of the CT peptide. 
Crystal structure data and simulation data of the IR were compared to identify 
potentially important interactions and conformations of the receptor. 
 
Aim 2: Perform in silico investigations of mutant IR constructs. Potentially key 
residues were identified and mutated before performing molecular dynamics 
simulations and subsequent analyses. Predictions regarding ligand binding and 
receptor function were formed from the analyses for experimental validation. 
 
Aim 3: Generate mutant IR protein constructs and experimentally assess the functions 
of wild-type and mutant IR. The mutant IR constructs investigated in Aim 2 were 
recombinantly engineered, expressed, purified and verified. Experimental 
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investigations were then performed to complement the predictions drawn from the 
computational work and analyses in Aim 2.  
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2.1 COMPUTATIONAL 
 MOLECULAR MODELLING 
A summary of all the currently available crystal structures of the IR and IGF1R 
and their uses in this study is provided in Appendix A. The Visual Molecular 
Dynamics (VMD) 1.9 software program (Humphrey, Dalke, & Schulten, 1996) was 
used for the molecular modelling work on the IR. PDB files were obtained from the 
Protein Data Bank (accessed at www.rcsb.org) (Berman et al, 2000). Once obtained, 
PDB files were checked for any errors before being used for the molecular modelling 
work. 
 
The molecular modelling files, a protein structure file (PSF) and a PDB file, were 
generated using the VMD plug-in autopsf. This plug-in takes the supplied PDB file 
and, using the provided topology file, generates a new structure of the protein that 
includes user-selected modifications such as identifying the separate chains of the 
protein, the type of termini at each end as well as a complete description of all bonds 
present. The models used in this study were all generated using the default topology 
file available in VMD. The N-termini remained at the default NTER option while the 
C-termini were acetylated using the CT2 option. Following this, the disulphide bonds 
were identified and added at the end of this process.  
 
 MOLECULAR DYNAMICS (MD) SIMULATIONS 
The molecular modelling files generated in Section 2.1.1 were then prepared for 
MD simulations. Firstly, a solvent box containing water molecules with a padding of 
10 Å on all sides of the protein was generated using the Add Solvation Box plug-in 
before neutralising the whole system with NaCl to a concentration of 0.15 M using the 
Add Ions plug-in. The generated files were then used as input files for MD simulation, 
performed in the NAnoscale Molecular Dynamics (NAMD) 2.9 software (Phillips et 
al, 2005).  
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All simulations were performed with hydrogen atoms included using the 
Chemistry at HARvard Macromolecular Mechanics force field (CHARMM27) 
(Brooks et al, 2009). Simulations were performed in the absence of carbohydrates as 
simulation of these structures were unsupported at the time of study. All new structures 
had steric clashes removed by running 20,000 steps of energy minimisation. Structures 
were equilibrated with movement of all C-α atoms constrained for 1 ns while all 
restraints (movement and bond restraints) were released during simulations. MD 
simulations were performed at a timestep of 2 fs/step under physiological conditions 
with a constant temperature of 310 K and one atmosphere pressure. The cut-off 
distance for calculating local interaction forces was set to 12 Å, potential switching 
was applied where the switch distance was set to 10 Å and the pair-list distance was 
set to 13.5 Å. Periodic boundary conditions were applied using the Particle Mesh 
Ewald (PME) full electrostatic method and a maximum grid spacing of 1.5. Langevin 
dynamics was used to control temperature and pressure parameters during the 
simulation. 
 
 SIMULATIONS OF WT-IR AND IR-R86P 
The wt-IR model was generated by using the 3LOH crystal structure as the 
template. The coordinates of the first three domains (L1, CR and L2 domains; residues 
1-468) and the resolved portion of the CT peptide (residues 697-710) were extracted 
into a separate file. The remaining unresolved region of the CT peptide was added 
using VMD’s molefacture plug-in (Humphrey et al, 1996). The IR-R86P model was 
generated using the wt-IR model as the template and Arg86 mutated to proline using 
the mutate residue function in VMD. Any steric clashes in the generated structures 
were resolved via short equilibration simulations in the interactive molecular dynamics 
(IMD) function. 
 
 SETTING UP MUTANT RECEPTOR SIMULATIONS 
Equilibrated IR[1-468, CT] models were used as the template and mutations were 
performed using the ‘mutate residue’ function in VMD (Humphrey et al, 1996) which 
replaces the selected residue with the desired mutation (e.g. Arg to Ala). Mutated IR 
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structures were then re-built using the AutoPSF function and prepared for simulations 
using the procedures outlined in Sections 2.1.1 and 2.1.2. 
 
 TARGETED MOLECULAR DYNAMICS (TMD) 
A target pdb structure was generated by setting the coordinates of the residues 
to be moved on the starting structure to those of the destination structure as per the 
user guide at http://www.ks.uiuc.edu/Research/namd/2.10b1/ug/node47.html. This 
generated file was then used as the TMD target towards which the residues in the 
starting structure would migrate. Structures were first minimised for 10000 steps 
before applying TMD with a spring constant of 1675 kJ mol-1 Å-2 (evenly distributed 
amongst all atoms subject to TMD) to the selected residues. TMD simulations were 
run for 20 ns, in which the target root mean square deviation (RMSD) from the target 
structure was gradually reduced from its starting value to zero. 
 
 PRINCIPAL COMPONENTS ANALYSIS (PCA) 
Output files generated from NAMD (Phillips et al, 2005) simulations (DCD 
format) were incompatible with the GROMACS (GROningen MAchine for Chemical 
Simulations) (Hess et al, 2008) software package (used for analysis of the simulations). 
It was therefore necessary to convert the trajectory files from DCD format to the 
GROMACS readable TRR format using the VMD plug-in, CatDCD 4.0.  
 
The converted TRR file treated each frame of the trajectory as 10 ps rather than 
1 ps present in the DCD file and required a second round of conversion using the 
GROMACS 3.3.4 (Hess et al, 2008) trjconv command. 
 
The principal components of each simulated trajectory were then extracted using 
the g_covar function which first constructs a covariant matrix of coordinates before 
diagonalising the output, resulting in separated components or modes. These modes 
were listed out in the form of eigenvectors and eigenvalues. The eigenvectors represent 
the separated modes or collective motions of the structure while the eigenvalue 
describes the extent of the motion that is associated with its respective eigenvector. 
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 FULL CORRELATION ANALYSIS (FCA) 
Full correlation analysis (FCA) (Lange & Grubmuller, 2008) was developed as 
an extension tool to GROMACS (Hess et al, 2008) and was used to extract and analyse 
the collective motions of protein from the PCA modes.  
The output files from PCA were used as the input files for FCA, invoked using 
the g_fca function. This refined the output from PCA and extracted correlated motions 
with improved separation. 
 
Finally, by using the g_anaeig tool and the output file from g_fca, individual 
motions were projected onto the original pdb file or mapped onto an XMGrace graph 
(http://plasma-gate.weizmann.ac.il/Grace/). 
 
 CONFORMATION CLUSTER ANALYSIS 
To identify distinct clusters of conformations in the simulation, an extension to 
VMD developed by Weill Medical College of Cornell University’s Luis Gracia called 
‘Clustering’ was used (Gracia, 2014). The conformational changes in the simulations 
were clustered into groups with root mean square deviation (RMSD) of backbone 
atoms <2 Å. The different groups were visualised in distinct colours and the 
conformations in each cluster were examined further. 
 
2.2 CT PEPTIDE EXPERIMENTS 
 CYCLIC-CT (CYC-CT) PEPTIDE DESIGN 
It was hypothesised that a cyclic-CT (cyc-CT) peptide, designed specifically to 
mimic the compact conformation observed in preliminary work performed by my 
supervisor, Dr Tristan Croll, would facilitate in constraining the IR[1-468, CT] model in 
the closed configuration. The initial approach to designing the cyc-CT was to observe 
the molecular structure of the peptide and identify any residues in close proximity that 
could potentially be used as the cyclisation point of the peptide. Observation of the 
peptide structure found Val715 and Lys703 to be in close proximity to each other and 
it was proposed that the cyc-CT peptide could be generated by mutating Val715 to a 
glutamic acid residue and forming a peptide bond with Lys703, thus cyclising the 
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peptide. The proposed cyc-CT design was sent to GL Biochem Ltd for synthesis of the 
peptide. However, after repeated attempts, the peptide analogue could not be 
synthesised and a new design was needed. 
 
A previous paper described an efficient method for synthesis of cyclised peptides 
using thio-ether chemistry (Roberts et al., 1998). Based on their findings, mutation of 
Val715 to a homo-cysteine residue and terminating the synthesis at Glu697 with a 
bromo or iodoacetate would allow a thioether cyclisation of the peptide (Roberts, et al., 
1998). This peptide design was submitted to Mimotopes Pty Ltd and was successfully 
synthesised. 
 
 MOLECULAR MODELLING AND DYNAMICS SIMULATIONS OF IR CYC-CT 
Cyclising of the CT peptide was performed in VMD (Humphrey et al, 1996) 
following the peptide design described above. Firstly, Val715 was modified to 
homo-Cys715 which allowed cyclisation of the new residue with the acetylated 
N-terminus via a thioether bond.  
 
Using the psfgen command and creating the thioether bond between 
homo-Cys715 and the acetylated N-terminus using our own defined patch (See 
Appendix B) based upon the topology of a model thioether compound generated on 
the ParamChem server using the CGenFF forcefield (Vanommeslaeghe et al, 2010). 
Details of the patch can be found in Appendix B. 
 
 BUFFER EXCHANGE OF THE IR[1-468] PROTEIN  
IR[1-468] protein was provided by Michael Lawrence and John Menting from the 
Walter and Eliza Hall Institute (VIC, Australia). This construct was not the full length 
receptor and contained only residues 1 to 468 of the IR (CT peptide is absent). The 
construct was received in TBSA buffer (24.8 mM Tris-HCl, 137 mM NaCl, 2.7 mM 
KCl, pH 8.0) containing 0.2% sodium azide at a concentration of 25.3 mg/mL 
(439 µM) based on molecular weight of 54 kDa, calculated from its amino acid 
sequence.  
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From the IR[1-468] solution, 10 µL was pipetted into a Nanosep 3K centrifugal 
device with Omega membrane (Pall Corporation, New York, USA) before adding 
250 µL HEPES buffer (10 mM HEPES, 140 mM NaCl, 5 mM KCl, pH 8.0) and 
centrifuging for 15 mins at 14,000 x g. This process was repeated twice, discarding the 
flow through between each spin. 
 
IR[1-468] protein was finally resuspended in 250 µL of HEPES buffer (final 
concentration estimated using dilution factors and assuming no loss of protein) and 
stored at -80°C for later use.  
 
 BIOTINYLATION OF IR[1-468] AND INSULIN 
Biotinylation was performed by first allowing the reagents (IR[1-468], insulin and 
EZ-Link® Sulfo-NHS-LC-LC-Biotin (Pierce, IL, U.S.A.)) to equilibrate to room 
temperature for 15 mins. For biotinylation of the IR, a stock biotin solution (10 mM) 
was prepared by dissolving 0.5 mg of biotin in 75 µL of milliQ H2O. A biotin working 
solution of 100 µM was prepared before adding 5.3 µL of this solution to 20 µL of 
IR[1-468] to produce a molar ratio of 1.5:1 (biotin: IR[1-468]). The reaction was undertaken 
for 2 hrs at room temperature. 
 
For biotinylation of insulin, a stock insulin solution (1 mg/mL) was prepared by 
dissolving 1.2 mg of insulin in 1.2 mL of HEPES buffer (pH 8.0) to make a 0.17 mM 
insulin solution. From the stock biotin solution, 2.58 µL was added to 100 µL of the 
stock insulin solution to produce a ratio of 1.5:1 (biotin:insulin). The reaction was 
undertaken for 2 hrs at room temperature before adding 0.1% 
ethylenediaminetetraacetic acid (EDTA) w/v to remove zinc from insulin in order to 
match conditions used in a previous study (Menting et al, 2009). 
N-Hydroxysuccinimide (NHS) Biotin reacts with the primary amino groups of amino 
acids such as the N-terminus of peptides or the side chain of lysine. Therefore, the 
NHS-Biotin was expected to mostly react with the only lysine residue on insulin 
(LysB29) and the N-terminal residues. The biotin-IR and biotin-insulin solutions were 
then dialysed overnight against 2 L of HEPES buffer at 4°C and stored as single 
aliquots at -80°C for later use. 
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 BIOTIN QUANTITATION 
Biotin was quantified using the Fluorescence Biotin Quantitation Kit (Thermo 
Fisher Scientific, MA, USA). Following manufacturer’s guidelines, seven biocytin 
standards between 5 and 100 pmoles were prepared in 100 µL phosphate buffered 
saline (PBS). DyLight Reporter Working Reagent (DWR) was prepared by mixing 
PBS and DyLight Reporter at a ratio of 14:1. Biotinylated IR was diluted 1:4, 1:10 and 
1:20 in PBS.  
 
From each sample, 10 µL was taken, diluted with DWR and incubated for 5 mins 
at room temperature in a Nunc Microwell 96-well Microplate (Thermo Fisher 
Scientific, MA, USA). Fluorescence was then measured using excitation/emission 
settings of 494/520 nm on a Polarstar Optima microplate reader (BMG Labtech, 
Ortenberg, Germany). 
 
The control standards were then used to plot a standard curve in Microsoft Excel 
and a linear regression equation was generated. The fluorescence value of biotinylated 
IR was then used to determine biotinylation efficiency. 
 
 BIACORE EXPERIMENT – BIOTINYLATED IR 
All standard procedures for operating the Biacore X100 machine (GE 
Healthcare, NSW, Australia) were followed as per manufacturer’s instructions. A 
Biotin CAPture Kit (GE Healthcare, NSW, Australia) was used. The running buffer 
used contained 0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v 
surfactant p20 (HBS-EP) (GE Healthcare, NSW, Australia). 
After docking and priming the supplied Biotin CAP sensor chip, Biotin CAPture 
Reagent was flowed through both flow cells of the machine (Fc1 and Fc2) at a flow 
rate of 5 µL/min for 5 mins. Running buffer containing 0.5 µM of biotinylated IR was 
then flowed over the chip through Fc2 at the same flow rate.  
 
A 1 µM cyclic-CT or linear CT peptide solution containing 500 nM insulin was 
then flowed over both flow cells and binding activity was recorded. Fc1 values were 
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subtracted from those of Fc2 before processing to obtain the binding activity. Binding 
curves were fitted to a 1:1 binding model using the BIAevaluation software v2.0.1 (GE 
Healthcare, NSW, Australia). 
 
 BIACORE EXPERIMENT – BIOTINYLATED INSULIN 
Following no detectable response from immobilised IR[1-468], it was suggested 
that insulin could be immobilised instead and IR[1-468] used as the analyte. Following a 
similar protocol to that described above, after docking and priming the supplied Biotin 
CAP sensor chip, Biotin CAPture Reagent was flowed through both flow cells of the 
machine (Fc1 and Fc2) at a flow rate of 5 µL/min for 5 mins. Running buffer 
containing 400 nM biotinylated insulin was then flowed over the chip via Fc2 at 
5 µL/min for 5 mins.  
 
Solutions containing between 62.5 nM – 1 µM of IR[1-468] and either 10 µM 
cyclic-CT or linear CT peptide were then flowed over both flow cells and binding 
activity was recorded. Fc1 values were subtracted from those of Fc2 before processing 
to obtain the binding activity. Binding curves were fitted to a 1:1 binding model using 
the BIAevaluation software v2.0.1. 
 
2.3 DNA CLONING 
 AMPLIFICATION OF IR-A GENE AND CLONING INTO PIB/V5-HIS VECTOR 
Initially, a plasmid containing the human IR gene sequence was obtained from 
Addgene (Addgene plasmid 24049). The plasmid was described by Jacob et al (2002) 
to contain the gene sequence coding for the long isoform (IR-B) of the IR whereas the 
simulation work performed in Chapters 3 and 4 focussed on the short isoform (IR-A) 
of the IR. The difference between the two isoforms of the receptor is the presence of 
an extra 12 amino acids in IR-B, a result of alternate splicing (Ward & Lawrence, 
2009). The amino acid sequence of IR-A is provided in Appendix C and the 
corresponding gene sequence is provided in Appendix D. Therefore, the extra 12 
amino acids belonging to the long isoform needed to be removed from this vector. 
Removal was attempted following the concepts introduced by Wallace et al (1981), 
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using primers designed to anneal to either side of the sequence and applying 
site-directed mutagenesis to remove the extra nucleotide bases via polymerase chain 
reaction (PCR). The primers used are listed in Appendix E. After repeated failed 
attempts at producing the desired product (determined via visualisation of PCR 
products), it was suspected that the template may be the underlying cause of the issues. 
This was further investigated by restriction enzyme digestion of the plasmid template 
with HindIII (New England Biolabs, MA, U.S.A) and SalI (New England Biolabs, 
MA, U.S.A). The products were then separated on a 1% agarose gel running at 100 V 
for 60 mins. The separated samples were then visualised on a ChemiDoc™ XRS+ 
System (Bio-Rad, CA, U.S.A) using SYBR Safe DNA gel stain (Life Technologies, 
VIC, Australia). Results demonstrated that the plasmid did not match the size reported 
by Addgene and work with this plasmid was discontinued.  
 
An alternative plasmid containing the human IR-A gene sequence was sourced 
from GeneCopoeia (GeneCopoeia, MD, U.S.A). This plasmid contained a proprietary 
Gateway pDONR 221 vector with the short isoform of the human IR gene as the insert 
(GC-Y4304-CF). Primers were used to amplify the extracellular domains of the IR and 
also incorporated HindIII and XbaI sites at the 5’ and 3’ ends respectively using PCR. 
The primers were designed in NetPrimer (Premier Biosoft International, CA, USA) 
and ordered from Sigma Aldrich’s custom oligo DNA synthesis service 
(Sigma-Aldrich, MO, USA). The primer sequences are provided in Table 2.1. 
Following PCR, the amplified product was visualised on an agarose gel before 
extracting the band corresponding to the expected product size. The extracted product 
was then cloned into a pIB/V5-His vector (Life Technologies, VIC, Australia) using 
HindIII and XbaI (New England Biolabs, MA, U.S.A) restriction enzymes to create 
the IR-pIB/V5-His vector. A leucine zipper fragment (containing the leucine zipper, a 
(Gly6-Ser-Ala) linker sequence and the Strep-tag II followed by a double stop codon 
and ordered through Sigma Aldrich’s custom oligo DNA synthesis service 
(Sigma-Aldrich, MO, USA)), flanked by XbaI and AgeI sites at the 5’ and 3’ ends 
respectively was then cloned into the IR-pIB/V5-His vector, linearised using XbaI and 
AgeI (leucine zipper sequence provided in Appendix F). This resulted in the leucine 
zipper fragment being positioned at the 3’ end of the IR coding sequence. Figure 2.1 
shows a flow diagram summarising the steps taken to clone the IR-A and leucine 
48 
48 Chapter 2: Methods 
zipper coding sequences into the pIB/V5-His vector. Ligations were performed using 
T4 ligase (Section 2.3.8) (New England Biolabs, MA, U.S.A) before transforming into 
JM109 chemically competent E. coli cells (Promega, NSW, Australia) for 
amplification. Successful transformations were isolated by culture on Ampicillin 
(Roche, QLD, Australia) agar. Plasmids were extracted from the transformed cells 
using a Mini-prep kit (Qiagen, VIC, Australia). At each step of the modification 
process, cloned products were verified for the desired change via sequencing analysis 
(performed by Queensland University of Technology, Molecular Genetics Research 
Facility; QUT-MGRF).  
 
Table 2.1: Primers designed for amplification of the IR-A gene and the leucine zipper fragment. 
Primers were designed in NetPrimer (Premier Biosoft International, CA, USA) and ordered from Sigma 
Aldrich’s custom oligo DNA synthesis service (Sigma-Aldrich, MO, USA). 
Intended modification Sense Primer Anti-sense primer 
Amplification of IR 
extracellular domains 
5’-GGTGGTAAGCTTG 
CAATGCTTTTTTATAA 
TGCC-3’ 
5’-TGGTGGTCTAGATGC 
AATATTTGACGGGA 
CG-3’ 
Amplification of leucine 
zipper fragment 
5’-CGGGCTCTAGAGG 
GTGGTAGGATG-3’ 
5’-GCCCGGACCGGTTC 
ATCACTTCTC-3’ 
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Figure 2.1: Schematic of the procedures taken in the cloning of the wild-type IR and leucine zipper 
fragment coding sequences into the pIB/V5-His vector. Both the wild-type IR and leucine zipper 
fragment coding sequences were cloned into the vector using restriction enzymes following the 
procedures outlined in Section 2.3.1. Briefly, the IR extracellular sequence was amplified from the 
pDONR vector (A) and cloned into the pIB/V5-His vector, linearised using HindIII and XbaI (B), 
resulting in the IR-pIB/V5-HIS vector. Following this, the leucine zipper fragment, synthetically made 
through Sigma Aldrich’s custom oligo DNA synthesis service, was amplified (C) and cloned into the 
IR-pIB/V5-His vector that was linearised using XbaI and AgeI (D). 
 
 MUTAGENESIS OF IR 
The IR-pIB/V5-His vector generated in Section 2.3.1 was then used as the 
template to generate mutant IR constructs. Constructs were generated using an adapted 
method of inverse PCR (Erster & Liscovitch, 2010; Hemsley et al, 1989) shown in 
Figure 2.2. This method involved the design of two primers for each mutation where 
one primer carries the mismatch sequence while the second primer amplifies the 
complimentary sequence (Figure 2.2A). This produces a linear PCR product (Figure 
2.2B) containing the vector sequence flanked by the two halves of the IR gene 
sequence. The linearised PCR product was then re-circularised by ligating the two ends 
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of the product together following the procedures outlined in Section 2.3.8. The primer 
sequences used to generate the mutations are shown in Table 2.2. 
 
Figure 2.2: Inverse PCR method used to generate IR mutants. Using the IR-pIB/V5-His vector as 
the template, mutant IR constructs were generated using inverse PCR. A, one primer is responsible for 
the mutation and another primer used to amplify the complimentary sequence. B, the linearised PCR 
product generated by inverse PCR containing the vector sequence flanked by two halves of the IR gene 
sequence. C, the linearised PCR product is re-circularised by ligating the two ends of the product 
together. 
 
Table 2.2: Primers designed to generate the desired mutations. Underlined bases indicate the bases 
responsible for the mutations. Primers with a ‘p’ indicate phosphorylated primers. 
Intended modification Sense Primer Anti-sense primer 
IR-R114A mutation 
5’-ATCACCGCTGGTTC 
TGTCC-3’ 
5’-p-GTTCATCAGGTTG 
TAGAGGC-3’ 
IR-E329A mutation 
5’-GCCCAGGCTTCCGA 
GGATG-3’ 
5’-p-AGACGTCACCGA 
GTCGATGG-3’ 
IR-A351D mutation 
5’-CAGATTGTTGCCTC 
CTCG-3’ 
5’-p-GATGCTGAGCTA 
GAAGCCAA-3’ 
IR-E438A mutation 
5’-TGTCAGCAATCCAC 
AAGATG-3’ 
5’-p-AGCAGAGTTTGG 
GGTTATAGT-3’ 
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 TRANSFERRING AGAR COLONIES TO LB MEDIA 
Luria-Bertani media (LB) was made by dissolving 10 g tryptone, 5 g yeast 
extract and 10 g NaCl in 950 ml deionized water. The pH of the solution was adjusted 
to 7.0 with NaOH before bringing the volume up to 1 L. The solution was then 
autoclaved on a liquid cycle for 20 minutes before cooling to 60°C. The solution was 
then stored at room temperature. 
 
Sterile 15 mL tubes were prepared with 5 mL LB media and 100 µg/mL 
Ampicillin. A single colony was selected from the agar plate using a pipette tip before 
ejecting the tip into the tube. The tubes were then shaken at 200 rpm in a 37°C 
incubator overnight. 
 
 GLYCEROL STOCKS 
Glycerol was diluted from 100% to 40% with MilliQ H2O and autoclaved. 
Working next to a flame, 400 µL of 40% glycerol was added into screw cap tubes 
before adding 600 µL of bacterial culture media. Glycerol stocks were stored at -80°C 
for later use. 
 
 VISUALISATION OF DNA USING AGAROSE GELS 
A 1% agarose gel was prepared by heating 0.5 g of agarose powder in 50 mL of 
TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA) in a glass bottle. The gel 
was cooled by running tap water around the bottle before adding 3 µL of SYBR Safe 
DNA gel stain, supplied as 10,000X concentrate in dimethyl sulfoxide (DMSO) (Life 
Technologies, VIC, Australia). Samples were prepared by adding tracking dye to them 
before loading onto the gel. Samples were run at 110 V for 60 mins. 
 
 GENERAL POLYMERASE CHAIN REACTION (PCR) PROTOCOL 
Many different PCR kits were trialled to optimise production of the desired 
product. The following tables summarise the contents of the samples that were 
prepared for the different PCR kits. All reactions were performed in 0.5 mL 
microcentrifuge tubes. 
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Table 2.3: Preparation of PCR samples for Phusion-HF (New England Biolabs, MA, USA). 
Reagent Volume in 50 µL reaction (µL) 
5X Phusion HF buffer 10 
dNTP (10 mM each nucleotide) 1 
Forward Primer (10 µM) 2.5 
Reverser Primer (10 µM) 2.5 
Template DNA (<250 ng) variable 
DMSO 1.5 
Phusion polymerase (2,000 units/mL) 1 unit 
H2O to 50 µL variable 
 
Table 2.4: Preparation of PCR samples for Thermopol Taq (New England Biolabs, MA, USA). 
Reagent Volume in 50 µL reaction (µL) 
10X Thermopol buffer 5 
dNTP (10 mM each nucleotide) 1 
Forward Primer (10 µM) 2.5 
Reverser Primer (10 µM) 2.5 
Template DNA (<250 ng) variable 
Taq polymerase (5,000 units/mL) 1.25 units 
H2O to 50 µL variable 
 
Table 2.5: Preparation of PCR samples for Platinum Taq (Life Technologies, VIC, Australia). 
Reagent Volume in 50 µL reaction (µL) 
10X Platinum Taq buffer, Minus Mg 5 
dNTP (10 mM each nucleotide) 1 
50 mM MgCl2 1.5 
Forward Primer (10 µM) 2.5 
Reverser Primer (10 µM) 2.5 
Template DNA (<250 ng) variable 
Platinum Taq DNA Polymerase (5,000 units/mL) 1 unit 
H2O to 50 µL variable 
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Table 2.6: Cycling conditions used for PCR. 
Step 
Phusion-HF Thermopol Taq Platinum Taq 
Temp 
(°C) 
Time 
(sec) 
Temp 
(°C) 
Time 
(sec) 
Temp 
(°C) 
Time 
(sec) 
Initial Denaturation 98 30 95 30 94 30 
30 
cycles 
Denature 98 10 95 30 94 30 
Anneal 
Primer 
dependent 
60 
Primer 
dependent 
60 
Primer 
dependent 
30 
Extension 72 30/kb 68 60/kb 72 60/kb 
Final Extension 72 300 68 300 72 300 
Hold 11 
As 
needed 
11 
As 
needed 
11 
As 
needed 
 
 GEL EXTRACTION – QIAQUICK GEL EXTRACTION KIT 
DNA fragments were extracted from agarose gel pieces using the QIAquick Gel 
Extraction Kit (Qiagen, VIC, Australia) and following the provided user manual. 
Extracted samples were stored at 4°C for later use. 
 
 DNA LIGATION 
Ligation of DNA fragments were performed following the protocol outlined on 
the New England Biolabs website (www.neb.com). Reactions were prepared 
differently depending on whether one (inverse PCR product) or two fragments 
(ligating vector + insert) were being ligated. Reactions were performed at room 
temperature for 2 hrs. 
 
Inverse PCR products were re-circularised via the following ligation reaction: 
Table 2.7: Ligation reaction used to re-circularise inverse PCR products.  
Reagent Volume in 40 µL reaction (µL) 
10X T4 DNA Ligase Buffer 4 
Inverse PCR product (100 ng) variable 
T4 DNA Ligase 2 
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H2O to 40 µL variable 
Ligation reactions were also performed to insert either the IR gene fragment or 
the leucine zipper into the target vector. The leucine zipper was a much smaller insert 
compared to the vector and was thus mixed with the vector at a 3:1 ratio. The IR gene 
on the other hand was similar in size to the vector (3.2 kb and 3.5 kb respectively) and 
was thus mixed with the vector at a 1:1 ratio. The following reactions were prepared 
to insert the different DNA fragments into the vector: 
 
Table 2.8: Ligation reactions used to insert the different DNA fragments into the target vector.  
Reagent IR gene fragment Leucine zipper fragment 
10X T4 DNA Ligase Buffer 2 2 
Vector DNA 150 ng 150 ng 
Insert DNA 150 ng 450 ng 
T4 DNA Ligase 1 1 
H2O to 40 µL variable variable 
 
 PLASMID EXTRACTION – QIAPREP SPIN MINIPREP KIT 
Plasmid extraction was performed using the QIAprep spin miniprep kit (Qiagen, 
VIC, Australia) and following the provided user manual. Plasmids were stored at 4°C 
for later use. 
 
 RESTRICTION ENZYME DIGEST 
All restriction enzymes were sourced from New England Biolabs (New England 
Biolabs, MA, U.S.A) and restriction enzyme digestion of DNA fragments were 
undertaken following guidelines provided by the manufacturer. Digests were prepared 
according the following table and the reactions were undertaken overnight at room 
temperature: 
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Table 2.9: Restriction enzyme digest of vector or PCR products.  
Restriction enzyme digest of DNA (20 µL) 
Reagent Amount  
10X CutSmart buffer 2 µL (1X concentration) 
DNA (200 ng) Variable 
Restriction enzyme 2 µL 
H2O to 20 µL Variable 
 
 BACTERIAL CELL TRANSFORMATION 
Sterile 1.5 mL tubes were chilled on ice before transformation. Frozen 
chemically competent E.coli JM109 Cells (cell density not supplied by manufacturer) 
(Promega, NSW, Australia) were removed from -80°C storage and thawed on ice. 
Immediately after thawing, 50 µL of cells were transferred into the pre-chilled tubes. 
DNA was added to the cells (1-50 ng), moving the tip through the cells while 
dispensing before returning the tubes to ice for 10 mins. Cells were then heat shocked 
at 42°C for 45 sec and immediately placed on ice for 2 mins. To each transformation, 
450 µL of LB media was added before shaking (210 rpm) at 42°C for 1 hr. Following 
this, 100 µL of cells were then spread on LB agar plates with Ampicillin pre-warmed 
to 37°C and incubated overnight at 37°C. 
 
2.4 PROTEIN EXPRESSION AND PURIFICATION 
 SF9 TRANSFECTION 
After successful generation of the desired expression vectors was confirmed via 
sequencing analysis (QUT MGRF), they were transfected into Spodoptera frugiperda 
(Sf9) cells following instructions provided by the suppliers of the pIB/V5-His vector 
(Life Technologies, VIC, Australia). Briefly, 1x106 cells were seeded onto the surfaces 
of each well in a 6-well plate (Thermo Fisher Scientific, MA, USA) and incubated for 
15 mins to allow the cells to attach to the bottom. Transfection mixtures containing 
1 mL fresh SF900-II media (Life Technologies, VIC, Australia), 10 µL of expression 
vector solution and 6 µL of Cellfectin® Reagent (Invitrogen, CA, U.S.A) were added 
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drop wise into each well so as to not disturb the cell monolayer. Cellfectin® only and 
vector only transfections were performed as the negative and positive controls 
respectively. Excess media in the wells were aspirated before adding the transfection 
mixture to each well. The plate was incubated at room temperature for 4 hrs with 
rocking every 30 mins. After incubation, 2 mL of fresh SF900-II SFM was added to 
each transfection and incubated at 28°C for 48 hrs before transferring the cells into 
T-25 flasks (Thermo Fisher Scientific, MA, USA). Cells were selected for successful 
transfection of the expression vectors with 50 µg/mL Blasticidin S (InvivoGen, San 
Diego, California) and continued until the cells in the negative control transfections 
had completely died. Transfected cells were then allowed to grow to confluency before 
subculturing into T-75 flasks (Thermo Fisher Scientific, MA, USA) at a maintenance 
concentration of 10 µg/mL. Protein expression was then performed as per procedures 
outlined in Section 2.4.2. 
 
 SF9 CELL CULTURE 
Untransfected frozen Sf9 cell stocks (Life Technologies, VIC, Australia) were 
cultured on adherent surfaces (T-75 flasks) following guidelines set out by the 
suppliers. Confluent cells were subcultured by displacing the monolayer with a sterile 
cell scraper and mixing the lifted cells with the media. Two millilitres of the cell 
mixture was then diluted at a ratio of 1:5 to a volume of 10 mL with fresh SF900-II 
media pre-warmed to 37°C. Cells were transfected and selected according to the 
procedures outlined in Section 2.4.1. Selected cells were then allowed to grow to ~80% 
confluency before splitting cells into four separate adherent culture flasks (T-75 
flasks), each at 10 mL culture volume at a reduced Blasticidin S concentration of 
10 µg/mL. Once the four separate cultures reached ~80% confluency (determined 
under a light microscope), the cells were lifted from the flask surfaces and the 
cell-media mixtures (40 mL total) were transferred into a 250 mL Erlenmeyer flask 
(Sigma-Aldrich, MO, USA) containing an additional 60 mL of media pre-warmed to 
37°C (100 mL total volume). From here onwards, the cells were cultured as suspension 
cultures and were allowed to reach a density of 5x106 cells/mL before transferring the 
cells into 2 L Erlenmeyer flasks (Sigma-Aldrich, MO, USA) containing 400 mL of 
media (500 mL culture volume). An additional 500 mL of fresh media was added to 
the suspension cultures once cell densities reached 5x106 cells/mL, effectively scaling 
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up the suspension cultures to 1,000 mL. The cultured media was monitored daily and 
collected when cell densities reached 5x106 cells/mL. Transfected Sf9 cells were 
frozen at a density of 1x107 cells/mL in media containing 7.5% DMSO (Life 
Technologies, VIC, Australia), 50% conditioned media and 42.5% fresh SF900-II 
media in 1 mL aliquots in Cryovials (Sarstedt, Nümbrecht, Germany) using a 
cryovessel (Thermo Fisher Scientific, MA, USA) with a controlled temperature 
decrease rate of 1°C/hr for 24 hrs in a -80°C freezer. The frozen cells were then 
transferred to liquid nitrogen for long term storage. 
 
 CELL COUNTING 
Cells were counted using a haemocytometer following protocols outlined on the 
ABCAM website (ABCAM, 2014). Cells were first diluted with Trypan blue at a ratio 
of 1:1. A coverslip was placed onto the counting surface and 10 μL of the cell mixture 
was gently pipetted into each of the two chambers. The haemocytometer was then 
viewed under a light microscope at 100X magnification and viable cells in the outer 
four and middle squares were counted. The total cell count was then divided by the 
number of squares counted and multiplied by two to account for the dilution of the 
cells with Trypan blue. The resulting number was then multiplied by 10,000 to 
determine the number of cells per mL of the suspension culture. 
 
 CONDITIONED MEDIA COLLECTION AND PROTEIN PRECIPITATION 
Suspension cultures were centrifuged at 200 x g at room temperature before 
collecting conditioned media (supernatant phase). Collected media were treated with 
polyethylene glycol 6,000 (PEG 6,000) (Thermo Fisher Scientific, MA, USA) to a 
final concentration of 30% (w/v). The mixtures were shaken at 4°C for ~16 hrs before 
centrifugation at 2,400 x g to separate the precipitated protein from supernatant. The 
precipitated protein was then resuspended in buffer containing 100 mM Tris-HCl, 
150 mM NaCl, 1 mM EDTA, pH 8.0 (buffer W) in a volume 1/20th the starting 
volume. 
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 PROTEIN PURIFICATION 
Resuspended protein was then purified following procedures described by 
Schmidt et al (2007). Briefly, purifications were performed using SigmaPrep™ spin 
columns (Sigma-Aldrich, MO, USA) attached to a peristaltic pump with a flow rate of 
0.5 mL/min. Columns were loaded with 100 µL of Strep-Tactin Superflow matrix 
(IBA, Goettingen, Germany) and equilibrated with buffer W before sample loading 
and capturing the expressed IR constructs containing the Strep-tag II. Captured 
proteins were washed with 0.5 mL of buffer W before eluting with 6 mL of buffer W 
containing 2.5 mM D-desthiobiotin (buffer E) (Sigma-Aldrich, MO, USA) collecting 
fractions every 2 mL. D-desthiobiotin was displaced from the Strep-Tactin with 
1.5 mL of buffer W containing 1 mM 2-(4-hydroxyphenylazo)benzoic acid (HABA) 
(Sigma-Aldrich, MO, USA) with red staining indicating successful removal of the 
D-desthiobiotin. The matrix was then regenerated with 1 mL of buffer W to prepare 
the Strep-Tactin for re-use. 
 
 SDS-PAGE 
Purified protein samples were run on 4-12% NuPAGE® Bis-Tris gels under 
reducing conditions. Loading samples were prepared by mixing 300 ng of purified 
protein with 10 μL 4X NuPAGE® LDS sample buffer, 4 μL 10X NuPAGE® 
Reducing Agent and deionised water to a total volume of 40 µL and heated to 70°C 
for 10 mins. Gels were then electrophoresed in NuPAGE® MES Running Buffer for 
35 mins at a constant 200 V. Precision Plus Protein™ Dual Colour Standards 
(Bio-Rad, CA, U.S.A) was used as the molecular weight marker. 
 
 PROTEIN DETECTION VIA SILVER STAIN 
Resolved gels were stained using a Silver Stain kit following the protocols 
outlined by the manufacturer (Pierce-Thermo Fisher Scientific, MA, USA). Stained 
gels were imaged using a Canon CanoScan 8600F scanner. 
 
 PROTEIN DETECTION VIA WESTERN BLOT 
Purified samples were electrophoresed on gels as per procedures outlined in 
Section 2.4.7. Separated proteins were transferred onto Nitrocellulose membranes in 
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25 mM Tris, 192 mM glycine, 20% methanol at 4°C for 1 hr with a constant 120 V. 
Membranes were then blocked with 5% skim milk powder in Tris buffered saline 
(TBS) containing 0.1% Tween 20 (TBST) overnight at 4°C. Horse radish peroxidase 
(HRP)-conjugated Strep-Tactin was then added at 1:100,000 dilution in TBST and 
incubated for 1 hr. Membranes were then washed with TBST two times for 1 min each, 
TBS two times for 1 min each before activating the chemiluminescence reaction with 
an ECL-Plus Western blotting detection kit (GE Healthcare). The membrane was then 
exposed to x-ray film between 30 seconds to 5 mins and developed using an AGFA 
film developer CP-1000 machine (Mortsel, Belgium). 
 
The HRP-conjugated Strep-Tactin probe was then stripped from the membrane 
with 10 mL of the d-desthiobiotin elution buffer used in the protein purification (buffer 
E). A subsequent x-ray film was then exposed to the stripped membrane to ensure no 
residual signal was present. 
 
After removal of the initial probe, a polyclonal IR antibody raised against 
residues His28-Lys944 of the IR (R&D Systems, MN, U.S.A) was used as the second 
probe to detect the presence of IR fragments. The antibody was added to the membrane 
at a 1:10,000 dilution in TBST containing 5% skim milk powder and incubated for 
1 hr. The membrane was washed three times for 5 mins before incubating with an 
anti-goat HRP secondary antibody (R&D Systems, MN, U.S.A) (in 5% skim milk 
powder and TBST) for 30 mins. The membrane was washed three times with TBST 
for 5 mins before activating the chemiluminescence reaction, exposing and developing 
the Western blot as per the first probe. 
 
 PROTEIN QUANTIFICATION 
Purified protein elutions were quantified using a Bradford protein quantitation 
assay. Bovine Serum Albumin (BSA) (Thermo Fisher Scientific, MA, USA) was used 
as the protein standard and prepared to cover a range of concentrations between 0 and 
1000 μg/mL. From the standard and protein elution samples, 10 μL of each were added 
to a 96-well plate before the addition of 300 μL of Bradford reagent (Thermo Fisher 
Scientific, MA, USA). Each sample was loaded onto the plate in triplicate. The plate 
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was gently agitated to mix the solutions before incubation in the absence of light for 
15 mins. Following incubation, samples were read on a plate reader at 595 nm 
wavelength and concentrations calculated for optical density values relative to the 
generated standard curve. 
 
2.5 ASSESSING INSULIN BINDING TO PURIFIED RECEPTOR PROTEIN 
 IRREVERSIBLE IMMOBILISATION OF STREPMAB-IMMO™ ONTO BIACORE 
CM5 SENSOR CHIP 
BIAcore CM5 sensor chips (GE Healthcare, NSW, Australia) were activated 
according to supplier recommendations with an injection of 70 µL of 11.5 mg/mL 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC)/ 75 mg/mL 
N-hydroxysuccinimide (NHS) (GE Healthcare, NSW, Australia) for 7 mins at a flow 
rate of 10 µL/min. A volume of 35 µL of StrepMAB-Immo™ was flowed over the 
activated surface at 5 µL/min and immobilised via amine coupling. Active groups on 
the chip matrix that were not linked/reacted with StrepMAB-Immo™ were coupled 
with 70 µL of ethanolamine (Sigma-Aldrich, MO, USA) at a flow rate of 10 µL/min. 
Approximately 11000-13000 response units (RU) would be achieved after 
immobilisation of StrepMAB-Immo™. StrepMAB-Immo™ was immobilised onto 
both flow cells (fc) of the CM5 sensor chip (fc1 and fc2). Running buffer used was 
HBS-EP+ (0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v 
Surfactant P20) (GE Healthcare, NSW, Australia). 
 
 CAPTURING PURIFIED WT-IR AND MUTANT RECEPTOR CONTRUCTS  
Purified wt-IR and IR mutant receptor proteins were captured onto the BIAcore 
CM5 sensor chip via the engineered strep-tag II on the C-terminal ends of the protein. 
A volume of 35 µl of each construct (200 nM in HBS-EP+) was flowed over the 
immobilised StrepMAB-Immo™ at a flow rate of 5 µL/min. Capturing of the protein 
resulted in a response of approximately 1200 RU. Capture cycles that yielded lower 
than 1200 RU required a second capture cycle in order to reach 1200 RU, and this was 
routinely used for such samples to minimise variation between the receptors. The value 
of 1200 RU was suggested by the GE Healthcare consultants in order to optimise 
binding responses that can be evaluated by the BIAevaluation software. Receptor was 
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captured only on fc2 leaving fc1 having only StrepMAB-Immo™ immobilised for use 
as the first reference control. Later analysis of the binding data would be performed 
using the values after subtraction of the first reference control (fc2-1). 
 
 BIACORE ANALYSIS OF BINDING DATA OF WT-IR AND MUTANT RECEPTOR 
CONTRUCTS 
A single cycle kinetics protocol was used to assess the receptor protein’s insulin 
binding capacity. Five concentrations of insulin (Sigma-Aldrich, MO, USA) ranging 
from 1-25 nM (1, 2.5, 5, 10 and 25), dissolved in running buffer, were flowed over the 
immobilised receptor protein at a flow rate of 20 µL/min. Each insulin concentration 
was allowed 270 s to associate with the immobilised IR and 900 s was allowed for 
dissociation to end the cycle. These time-frames were established based on the 
methods of a related study that assessed the binding of IGF1R to IGF-I analogues 
(Forbes et al, 2002). Experiments were performed at 25°C. Blanks containing only 
running buffer were run in two separate cycles as the second reference control. 
Triplicate experiments were conducted for each receptor protein construct. A summary 
of the BIAcore experimental procedure is shown in Figure 2.3. The resulting fc2-1 
sensorgrams were then analysed using BIAevaluation software v2.0.1 (GE Healthcare, 
NSW, Australia) where the blank responses were subtracted from the cycles containing 
insulin. The results were then fitted to a two-state reaction model, defined in the 
software, from which kinetic constants were calculated. The two-state reaction 
equation used by the BIAevaluation software to determine KD is shown in Equation 
2.1 (GE Healthcare, 2007b): 
 
Equation 2.1 
1
𝐾𝐷
=
𝑘a1
𝑘d1
× (1 +
𝑘a2
𝑘d2
) 
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Figure 2.3: Illustration of BIAcore experimental procedure with typical experimental traces. 
StrepMAB-Immo™ was irreversibly immobilised onto the CM5 sensor chip (upper) before capturing 
IR constructs via the engineered strep-tag II on the C-terminal ends of the protein to a target RU 
differential of 1200 (middle). Different concentrations of insulin ranging from 1-25 nM were then 
flowed over the immobilised receptor protein and binding responses recorded (lower). BIAevaluation 
software was then used to fit the binding curves to a two-state reaction model where the different binding 
parameters were calculated. 
 
 STATISTICAL ANALYSIS OF KINETIC CONSTANTS 
Previous studies have found kinetic rate constants to show log-normal 
distribution properties (Barillot, 2013; Poulsen, Jensen, Haurum, & Andersen, 2011; 
Rate, McLaren, & Swift, 1992). Therefore, the logarithms of the kinetic constants were 
used in a one-way analysis of variance (ANOVA), performed in GraphPad Prism 
version 6.03 (GraphPad Software, CA, U.S.A), to test for variance between all four 
mutant constructs and the wt-IR with a confidence interval of 95%. A subsequent 
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Dunnett’s multiple comparisons test was used to compare each mutant IR protein 
construct to the wt-IR. 
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Chapter 3: Investigating the role of the CT 
peptide in insulin binding 
3.1 INTRODUCTION 
In order to elucidate the binding mechanism of insulin to its cognate receptor, 
the role that the CT peptide plays during the binding and activation phase must first be 
understood. The CT peptide has been shown to be an important part of the receptor 
structure as multiple studies have shown it is integral to insulin binding. Studies using 
truncated IR constructs show that in the absence of the CT peptide, the receptors do 
not exhibit insulin binding activity (Kristensen et al, 2002; Kristensen et al, 1998; 
Molina, Marino-Buslje, Quinn, & Siddle, 2000). The studies then went further and 
added free CT peptide (Kristensen et al, 2002) or fused the CT peptide to the truncated 
domains (Kristensen et al, 1998; Molina et al, 2000) resulting in the reconstitution of 
insulin binding. Furthermore, recent crystal structures of IR fragments in complex with 
insulin show the position of the CT peptide shifts upon ligand binding (Menting et al, 
2013). However, much about how the CT peptide interacts with insulin and what 
subsequent events occur in response to the binding remains unclear. 
 
Two research groups have previously attempted to computationally model the 
IR extracellular domain and investigate where insulin may bind to the receptor using 
molecular docking methods (Lou et al, 2006; Vashisth & Abrams, 2010). Despite 
finding potential binding sites for insulin on the IR and showing the insulin-docked 
models remained stable over a period of simulation time, the crystal structure 
containing the CT peptide was not yet resolved at the time of their investigations and 
thus all their molecular modelling and docking work was performed on an IR structure 
that was void of this fundamentally important peptide. The presented results therefore 
did not accurately reflect receptor-ligand interactions in the presence of the CT 
peptide. Once the CT peptide coordinates were available, a new docking study was 
performed by Vashisth et al (2013) that docked insulin to an IR construct containing 
the CT peptide (Vashisth & Abrams, 2013). However, although the new models in this 
report agreed with many past experimental studies, the positions and contacts between 
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insulin and IR do not match those reported in the latest insulin-bound IR 
crystallographic structure (PDB ID 3W11) (Menting et al, 2013). 
 
The first crystal structure of the entire IR extracellular domain resolved the 
structural alignment of the domains but was not able to detect the CT peptide or insulin 
(PDB ID 2DTG) (McKern et al, 2006). A subsequent re-refinement of the same crystal 
structure resolved a part of the CT peptide (PDB ID 3LOH) (Smith et al, 2010). This 
refined structure was used in most of our investigations in an attempt to further 
understand the CT peptide and its interactions with the IR.  
 
However, despite knowing the position of the CT peptide relative to other 
domains, other potentially important regions were not resolved. Only residues 693-710 
of the CT peptide were successfully crystallised (the entire peptide encompasses 
residues 693-719) leaving the rest unresolved (Figure 3.1). The position of the CT 
peptide showed that it was in contact with many key residues on the L1 domain, 
residues that were speculated in previous alanine mutagenesis studies to be in contact 
with insulin (Mynarcik et al, 1997a; Williams et al, 1995) (Figure 3.2). However, 
residues 711-719 (unresolved at the time of this study) are also important as residues 
within this region have been found to be in close proximity to insulin (Huang et al, 
2007; Kurose et al, 1994; Xu et al, 2004). At the time of this study, it was not known 
what residues the unresolved region interacted with and where it was situated in the 
insulin-bound complex. 
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Figure 3.1: Comparison of IR monomers from two previously available crystal structures of IR, 
2DTG and 3LOH.  A, The first crystal structure of the IR extracellular domain (2DTG) (McKern et al, 
2006). B, Refined structure from 2DTG, CT peptide is represented in red (3LOH) (Smith et al, 2010). 
The availability of the 3LOH structure demonstrated that many residues on the L1 domain previously 
thought to be in contact with insulin were, in fact, in contact with the CT peptide. 
 
 
Figure 3.2: CT peptide with key residues located on the L1 domain. The key residues located 
between the interface of the CT peptide and the β-sheets of the L1 domain are annotated and shown in 
stick representation. These residues were identified to contribute to insulin binding via alanine 
mutagenesis experiments but were initially speculated to be in direct contact with insulin (Mynarcik et 
al, 1997a; Williams et al, 1995). The L1 domains is coloured blue and the CT peptide is coloured red. 
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The rationale for this project stems from simulation and modelling work 
performed by my primary supervisor, Dr Tristan Croll (personal communication). The 
investigation started from a study by Kristensen et al (1998) that described a truncated 
version of the IR containing the first three extracellular domains fused to the C-
terminal 16 residues of the CT peptide (TFEDYLHNVVFVPRPS) (Kristensen et al, 
1998). The IR fusion construct in this study displayed an insulin binding affinity of 
4.4 nM, similar to the whole soluble ectodomain. Problematically, as mentioned 
earlier, later experimental data indicated the CT peptide in the native receptor is 
positioned on the L1 domain while that in the IR fusion construct (Kristensen et al, 
1998) was, according to the crystal structure, structurally distant from the classical 
binding surface of the L1 domain. Dr Croll investigated these conflicting results by 
creating a model of the L2 domain fused to the CT peptide using data from the 
available crystal structures of the IR extracellular domain at the time, 2DTG and 2HR7 
(IR extracellular domain without the CT peptide resolved). Simulations of this 
construct predicted the formation of stable interactions between residues on the CT 
peptide and the L2 domain. These interactions were facilitated by two salt bridges and 
two hydrogen bonds between the L2 domain and CT peptide. The salt bridges were 
formed by residues Arg717-Glu438 and the C-terminal acid-Arg383 while the 
hydrogen bonds were formed between Ser719-Ser380 and Phe705-Ser467 (Figure 
3.3) suggesting a potential binding site on the L2 domain for the CT-tail. 
 
The next reported IR crystal structure (3LOH) (Smith et al, 2010), refined from 
the original 2DTG structure, was able to resolve the CT peptide and confirmed the 
essential contradiction between the structural data and the Kristensen et al (1998) 
result. The fusion point between the L2 domain and CT peptide in the Kristensen et al 
(1998) IR construct was located on Cys468 (L2 domain) and Thr704 (CT peptide). 
Considering the critical need of the CT peptide for insulin binding, it was not clear 
how the IR-CT fusion construct bound insulin when the fusion point, Cys468, is 
located 56 Å away from the Thr704 in the crystal structure. Figure 3.4 demonstrates 
the difference between the IR-CT fusion construct investigated by Kristensen et al 
(1998) and the 3LOH crystal structure. 
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Figure 3.3: The interaction predicted between the CT peptide and L2 domain in MD simulations. 
Preliminary simulation work performed by Dr Tristan Croll found a potential binding site on the L2 
domain for the CT-tail, which was unresolved at the time of this study. The L2 domain is coloured blue 
while the CT peptide is coloured red. Residues Ser380, Arg383, Glu438, Ser467, Phe705, Arg717 and 
Ser719 were predicted to contribute to the potential interaction between the CT peptide and L2 domain 
and are shown in stick representation.  
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Figure 3.4: The major discrepancy between the truncated IR experiments, the 3LOH crystal 
structure and the combined model. A, Structure of the truncated IR (blue) fused to the CT (red) 
overlaid with the position of the CT peptide in the 3LOH crystal structure (green). Thr704 in each 
structure is shown in yellow stick representation. B, Combined IR structure showing compatibility of 
L2-CT interaction with the same domains from the 3LOH crystal structure. 
 
Substantial structural rearrangements of the domains have been observed in the 
distantly related but structurally homologous EGFR which has been successfully 
crystallised in both the inactive (Ferguson et al, 2003) and active (Ogiso et al, 2002) 
states. Receptor activation causes a conformational change where the EGFR 
equivalent of the IR L2 domain rotates around a hinge point involving residues 
309-311 (equivalent to 308-311 in IR). Dr Croll therefore speculated that a similar 
rotation could occur in the IR L2 domain which would place Thr704 in the Kristensen 
et al (1998) IR-CT fusion construct in close proximity to that in the 3LOH crystal 
structure. To test this, a model of the first three domains of IR was generated where a 
rotation of the L2 domain was manually induced and equilibrated (IRrot). 
Simultaneously, the fusion point in the L2-CT construct was cleaved leaving only the 
proposed interaction between the CT-tail and the L2 domain. This new structure was 
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briefly equilibrated and the CT peptide extended to include residues 693-703 from the 
3LOH structure before replacing the L2 domain in IRrot with the equivalent residues 
in the 3LOH structure. Using molecular dynamics flexible fitting (MDFF), the CT 
peptide in this new combined structure was then forced into the position of the 
as-crystallised CT peptide. The resulting structure, referred to from here on as 
IR[1-468, CT], was investigated further where the interaction between the CT-tail and L2 
domain was observed to remain stable throughout the conducted simulations.  
 
The MDFF simulation used to generate the IR[1-468, CT] structure brought the L1 
and L2 domains into close proximity which in turn dramatically compacted the 
structure. This compact configuration of the IR was interesting in light of previous 
experimental work where the IR showed a reduction in the Stokes radius of the 
receptor upon insulin binding (Florke et al, 2001).  
 
The IR[1-468, CT] was observed to compact even more during 118 ns of MD 
simulations where the CT-tail gradually shifted towards the α-helical portion of the CT 
peptide, forming a hairpin structure (as shown in Figure 3.5B). This observed change 
in the CT-tail not only caused the L2 domain to move closer towards the L1 domain, 
it also resulted in the formation of new interactions between the CT-tail and the CT 
α-helical region. Closer examination of this hairpin configuration showed that a series 
of salt bridges and hydrogen bonds (listed in Table 3.1) formed a majority of the 
interactions between the L2 domain and the CT peptide. Phe714 on the CT peptide is 
also deeply buried in a highly conserved hydrophobic pocket formed by multiple 
residues on the L2 domain (Figure 3.6). Furthermore, the closed conformation is 
stabilized by a hydrophobic zipper between Val696, Val715, Lys703 and Val712 
(Figure 3.7). Based upon the idea that the closed configuration of the CT peptide could 
potentially reflect what occurs during ligand binding, the work performed in this 
chapter further investigated the hairpin structure by capturing the closed configuration 
of the CT peptide using simulated and synthesised cyclic-CT peptide analogues. 
72 
72 Chapter 3: Investigating the role of the CT peptide in insulin binding 
 
Figure 3.5: Comparison of the open and closed conformations of the simulated IR[1-468, CT] model 
investigated by Dr Croll. A, The open conformation of the model. B, The closed conformation that 
was speculated to play a part in insulin binding. This compact configuration of the IR was interesting 
in light of previous experimental work where the IR showed a reduction in the Stokes radius of the 
receptor upon insulin binding (Florke et al, 2001) suggesting the receptor experiences compacting-like 
changes upon insulin binding. The L1-CR-L2 fragment is coloured blue and the CT peptide is coloured 
red. 
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Table 3.1: List of potential interactions between L2 domain and CT peptide identified in the 
simulation of the IR[1-468, CT] model.
L2 domain  CT peptide  Type of contact 
Ser380 Val715 Hydrogen bond 
Glu438 Arg717 Salt bridge 
Trp412 backbone Arg717 Hydrogen bond 
His417 Ser719 Hydrogen bond 
Gly359 Ser719 Hydrogen bond 
Arg383 Ser719 Salt bridge 
Ala351 Asn711 Hydrogen bond 
Phe381 Phe714 Hydrophobic pocket 
Leu354 Phe714 Hydrophobic pocket 
Leu376 Phe714 Hydrophobic pocket 
Leu350 Phe714 Hydrophobic pocket 
Val377 Phe714 Hydrophobic pocket 
Total buried surface area between L2 and CT peptide = 484 Å 2 
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Figure 3.6: Phe714 was observed in the IR[1-468, CT] model to be buried in a hydrophobic pocket on the L1 domain. A, Phe714 (shown in stick representation) was observed 
to interact with a hydrophobic region on the L2 domain. B, a close-up stick representation of the identified residues in the interaction. Domains are shown in secondary structure 
representation; CT peptide, red; L2 domain, blue; hydrogen bonds, pink. This interaction was speculated to contribute to the stable interaction between the CT peptide and the 
L2 domain. 
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Figure 3.7: The hydrophobic zipper predicted to form in the compact configuration of the CT 
peptide. The closed conformation is stabilized by a hydrophobic zipper between Val696, Val715, 
Lys703 and Val712. As previously mentioned, the identified conformation could potentially be the same 
decrease in Stokes radius reported by Florke et al (Florke et al, 2001) and may represent what occurs 
during ligand binding. 
 
More recently, an insulin-bound IR crystal structure was resolved and identified 
the contacts between ligand and receptor (Figure 3.8) (PDB ID 3W11-3W14) 
(Menting et al, 2013). Multiple constructs were used in this study to determine the 
ligand-receptor interaction. The 3W11 structure used a construct comprising L1-CR-
CT in complex with insulin while 3W12 and 3W13 consist of the same IR fragments 
in complex with a high affinity insulin analogue. The construct used in the last 
structure, 3W14, included the L1, CR, L2 and FnIII-1 domains in complex with the 
CT peptide and insulin. Two prominent differences were observed in these new crystal 
structures. Firstly, the α-helix of the CT peptide gained an extra turn at the C-terminal 
end which brought residues on the CT-tail closer towards the L1 domain and the bound 
insulin. As a result of the extra turn, Phe714 was found to be buried within a cleft 
between the insulin A- and B-chains. This was particularly important as Phe714 has 
been shown in a previous study to be highly important for ligand binding: mutation of 
Phe714 to alanine reduces the receptor’s affinity for insulin 182-fold (Mynarcik et al, 
1997a). However, despite successfully resolving insulin-bound IR fragments, the L2 
domain was either not included in the constructs or was not in the same position as 
that observed in the IR dimer structure, 3LOH. The C-terminal portion of the CT-tail 
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also still remained unresolved. As such, the L2-CT interaction suggested by the 
simulations in Dr Croll’s work remained unconfirmed. In a newer insulin-bound 
crystal structure of the IR, most of the insulin B-chain tail and the C-terminal portion 
of the CT-tail were resolved revealing many of the interactions that are present 
between the ligand and receptor domains (Figure 3.9) (PDB ID 4OGA) (Menting et 
al, 2014).  
 
 
Figure 3.8: Crystal structure of the insulin-bound IR fragment (PDB ID 3W11) (Menting et al, 
2013). The crystal structure was able to resolve the position of insulin and the interactions it forms with 
the CT peptide of IR. Only residues 705-715 of the CT peptide was successfully resolved in this crystal 
structure. Residues B23-B30 of the insulin B-chain were unresolved. The domains are coloured as 
follows: L1 & CR domains, blue; CT peptide, red; Insulin B-chain, grey; Insulin A-chain, orange. This 
insulin-bound structure showed the α-helix of the CT peptide gained an extra turn at the C terminal end 
which brought residues on the CT-tail closer towards the L1 domain and the bound insulin. 
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Figure 3.9: Crystal structure of the newer insulin-bound IR fragment (PDB ID 4OGA) (Menting 
et al, 2014). In this new crystal structure, residues B23-B27 of the insulin B-chain and 716-719 of the 
CT peptide were successfully resolved and showed newly identified interactions between insulin and 
the IR domains. Due to the late availability of this structure, only preliminary work was able to be 
performed and was thus only used to facilitate analysis of the results produced from the work in this 
chapter. 
 
These new insulin-bound IR structures only became available late into this 
project and because of this, only preliminary modelling and simulation work was 
performed to aid analyses of results from other work performed in this project. The 
previously resolved IR structures (2DTG, 2HR7 and 3LOH) were used for the majority 
of this project (as they were the only ones available at the time) which enabled 
computational models of the IR to be digitally constructed and visualised in order to 
not only investigate how the CT peptide might interact with insulin during ligand 
binding, but also the conformational changes that may occur. 
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3.2 RESULTS AND DISCUSSION 
Although the first insulin-bound IR crystal structure (3W11) was able to define 
the interactions between insulin and parts of the IR (Menting et al, 2013), it only 
included the CT peptide, L1 and CR domains and hence couldn’t provide information 
regarding the conformation of the IR when insulin is bound. Previous work using the 
IR[1-468, CT] model not only suggested a potential interaction between the unresolved 
regions of the IR (L2 domain and CT-tail), but also suggested a conformational change 
that could potentially be part of insulin binding. It was therefore proposed that the 
observed compact conformation could potentially represent either the insulin-bound 
state of the receptor or an intermediate and this was further investigated using a 
cyclic-CT peptide to mimic the native CT peptide in this closed state.  
 
 MD SIMULATIONS OF IR[1-468, CT] SUGGESTED DIFFERENCES COMPARED TO 
THE CRYSTAL STRUCTURE 
The IR[1-468, CT] model (Figure 3.5B, p72) was further simulated for 150 ns in 
order to predict potential conformations that the structure can adopt. The 
configurations taken on by the IR[1-468, CT] model throughout the simulations were then 
compared against available crystal structures to identify the effects these 
conformational changes have on the interactions between residues and domains. All 
analyses in this section used both the 118 ns of simulation performed by Dr Croll and 
the 150 ns performed here. 
 
The angle of the L2 domain relative to L1 was measured using the C-α atoms of 
residues Glu120, Arg14 and Lys425 (each of which is found in a rigid beta sheet) as 
reference points; these same residues were used in later measurements where 
applicable. The conformational change involving the L2 domain resulted in an increase 
of 15° to the angle formed by these residues and also changed the position of the CR 
domain (Figure 3.10A and B). Furthermore, this angle gradually increased over the 
course of the simulation (Figure 3.10C) while identified interactions (described 
below) between the L2 and CR domains remained stable. The root mean square 
deviation (RMSD) of the CT-α-helix and CT-tail were measured against the L1 and 
L2 domains respectively and it can be seen in Figure 3.10D and Figure 3.10E that 
each region of the CT peptide displayed RMSD values <5 Å throughout the simulation 
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suggesting the interactions between these regions were stable despite large changes in 
the inter-domain angle. Importantly, the change in the position of the CR domain 
allowed the formation of new potentially stabilising interactions with the L2 domain 
(listed in Table 3.2). Two main interactions formed in the IR[1-468, CT] structure that 
were not present in the 2HR7 crystal structure (Figure 3.11 and Figure 3.12) and 
suggested links between the L2 and CR domains where movement of one domain 
would induce a reactional movement in the other. 
 
The first identified interaction was a salt bridge between Lys310 on the L2 
domain and Glu287 on the CR domain (Figure 3.12). The residues involved were 
positioned in close proximity to each other at the beginning of the simulation where 
the identified interaction formed 4 ns later. The interaction was broken four times 
during the simulation, each lasting briefly for 1 ns before reforming. Supplementary 
sequence alignment data obtained from the Renteria et al (2008) study showed very 
high conservation of the residues involved in the identified interactions (Renteria et al, 
2008). As seen in Figure 3.13, residues Glu287 and Lys310 are strongly conserved 
across all the analysed species. While Lys310 is 100% conserved, Glu287 had all but 
one analysed species with a difference of an aspartic acid residue instead. The different 
residue however, shares similar properties to glutamic acid and was therefore 
considered to still be strictly conserved. The strict conservation of Glu287 and Lys310 
across species suggested the identified interaction between them could potentially be 
important for receptor functionality.  
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Figure 3.10: The conformational change observed in the IR[1-468, CT] simulation. A, Angle of the L2 
domain relative to the L1 domain in the starting structure. B, The same measured angle in the ending 
structure of the simulation. In both A and B, the L1, CR and L2 domains are coloured blue while the 
CT peptide is coloured red. C, Change in angle between the L1 and L2 domains throughout the 
simulation. D, Change in all-atom RMSD of the CT α-helix relative to the L1 domain. E, Change in 
all-atom RMSD of the CT-tail relative to the L2 domain. The smal RMSD values indicate that the 
interactions between these regions of the receptor remained stable despite large changes in the 
inter-domain angle. The L1-CR-L2 fragment is coloured blue (individual domains are annotated) and 
the CT peptide is coloured red. 
 
Table 3.2: Differences in interactions in the IR[1-468, CT] structure compared to the 2HR7 
crystal structure. 
Interaction on IR [1-468, CT] Difference in 2HR7 
Glu329 on L2 salt bridged to Arg270 on CR Interaction not observed 
Lys310 on L2 salt bridged to Glu287 on CR Interaction not observed 
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Figure 3.11: Comparison of the first two identified interactions between IR[1-468, CT] and 2HR7. A, the salt bridges formed by interactions between Glu329-Arg270 and 
Lys310-Glu287 in the IR[1-468, CT] structure. B, the same identified residues are positioned away from each other in the 2HR7 structure. These interactions could potentially 
stabilise the receptor in the observed conformation as well as link the CR and L2 domains together. 
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Figure 3.12: Close up view of the identified residues that form potentially important interactions between the L2 and CR domains.in IR[1-468, CT] compared to the same 
residues in 2HR7. A, identified residues forming salt bridge interactions on the IR[1-468, CT] model. B, the same identified residues are seen to point away from each other in the 
2HR7 crystal structure. These interactions could potentially create a link between the CR and L2 domains whereby movement experienced by one domain could induce a similar 
change in the other.  
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Figure 3.13: Sequence alignment of identified residues in the first two interactions in IR across species. Glu329, Arg270, Lys310 and Glu287 (Homo Sapien numbering; 
annotated and indicated with red arrows) were identified in the IR[1-468, CT] simulation to form salt bridge interactions and are shown here to exhibit high conservation across 
species analysed in the Renteria et al study (Renteria et al, 2008).  
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The second identified interaction was a salt bridge between Glu329 and 
Arg270 (Figure 3.11). Unlike the first identified interaction, Glu329 and Arg270 did 
not form a salt bridge early in the simulation as they were initially positioned far apart. 
Instead, Arg270 was observed to contact a different residue, Lys319, for ~200 ns of 
the simulation until the conformational change gradually brought Glu329 into close 
proximity over the course of ~10 ns. This rearrangement of the L2 domain allowed the 
salt bridge to form between Arg270 and Glu329, which remained in contact for the 
remaining 50 ns of the simulation. Further analysis found Arg270 is highly conserved 
across species with close to 100% sequence conservation, where two species have 
mutations that result in amino acids with similar properties (Figure 3.13). Similarly, 
Glu329 also has high conservation across most species with the exception of two 
mutations which result in a change from glutamic acid to alanine. Although this change 
does not maintain similar amino acid properties, the high conservation of both Arg270 
and Glu329 suggested the interaction formed by these two residues may also be 
important for receptor functionality. 
 
Analysis of the distance between the residues forming the identified salt bridges 
found the C-α atoms of Glu287 and Lys310 were within 10 Å of each other for 90% 
of the simulation. On the other hand, the distance between the C-α atoms of Glu329 
and Arg270 remained above 10 Å for ~70% of the simulation, coming within that 
distance ~30% of the time. This was not surprising as Glu329 and Arg270 were located 
over 10 Å apart early in the simulation until the conformational change of the receptor 
occurred (at ~200 ns into the simulation) which brought the residues closer together 
and allowed the formation of the identified salt bridge. Thus, the salt bridge between 
Glu329 and Arg270 could potentially be an interaction that stabilises the IR[1-468, CT] 
structure in the observed changed conformation shown in Figure 3.10B. The 
simulation of the receptor was therefore analysed to find the most populated 
conformational states to determine how important the observed conformational change 
could potentially be. 
 
In order to find the most common conformational states taken by the receptor 
during the simulation, the trajectory was clustered into groups with RMSD of 
backbone atoms <2 Å (Gracia, 2014). Approximately 42% of the trajectory clustered 
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into a group with hinge angle of 97±1.5°. The conformations belonging to this cluster 
appeared to be the open conformation of the IR[1-468, CT] structure suggesting this may 
be the most stable state of the construct. The closed conformation of the IR[1-468, CT] 
structure appeared to belong to the next largest cluster, where ~25% of the trajectory 
was grouped with hinge angle of 87±4°. This suggested that while the open 
conformation of the IR[1-468, CT] structure may be the most stable state, the closed 
conformation could represent a different state of the receptor that is also stable. Three 
representative conformations from each of these clusters are shown in Figure 3.14. 
The remaining clusters contained a lower portion of the trajectory and showed 
conformations that appeared to represent the transition between the two states of the 
receptor. Experimental studies have repeatedly shown that the IR experiences a 
conformational change upon the binding of insulin (Donner & Yonkers, 1983; Florke 
et al, 2001; Lee et al, 1997; Pilch & Czech, 1980; Waugh & Pilch, 1989). Furthermore, 
the conformational change results in a more compact receptor compared to its 
as-crystallised form which agrees with a previous study where the insulin-bound 
receptor displayed a smaller Stokes radius (Florke et al, 2001). Thus, the two clusters 
observed in Figure 3.14 could potentially represent the conformational change of the 
receptor upon insulin binding. 
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Figure 3.14: The two most populated clusters of conformations identified in the IR[1-468, CT] 
simulation. Analysis of the IR[1-468, CT] simulation showed two clusters of conformations that 
represented 42% and 25% of the simulation respectively. These two clusters appeared to be the open 
(A) and closed (B) configuration of the receptor observed in Figure 3.5 and were interpreted to be two 
stable states of the receptor.  
 
 MODELLING OF THE INSULIN-BOUND IR CRYSTAL STRUCTURE (3W11) 
SUGGESTED SUBSTANTIAL CONFORMATIONAL CHANGES 
A detailed comparison of the insulin-bound IR crystal structure (PDB ID 
3W11) (Menting et al, 2013) with the 3LOH structure showed differences in the CT 
peptide despite only a fragment being successfully resolved. Firstly, it can be clearly 
seen in Figure 3.15 that the position of the CT peptide in the 3W11 structure (green) 
is different compared to that in 3LOH (red). In the latter structure, the CT peptide lies 
diagonally across the top face of the L1 domain whereas in the 3W11 structure the CT 
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peptide fragment is oriented approximately orthogonal to the L1 domain β-strands. 
Furthermore, it was observed in the 3W11 structure that the α-helix of the CT peptide 
was extended at the C-terminal end. In 3LOH, the CT peptide α-helix terminated at 
residue Asn711 whereas in the 3W11 structure the α-helix has been extended by an 
extra loop ending at Val715. This shifted the entire CT peptide further down along the 
face of the L1 domain, exposing different residues on the underside of the CT peptide 
to those on the L1 domain. For instance, in the 3W11 structure, residues Phe705, 
Leu709 and Val713 were buried inside the hydrophobic pocket formed by Leu36, 
Leu37, Leu62, Phe64, Val94 and Phe96 on the L1 domain (Figure 3.16). In contrast, 
in the 3LOH structure, only residues Phe701 and Phe705 on the CT peptide are buried 
in the pocket formed by the same residues on the L1 domain.  
 
Figure 3.15: Comparison of the CT peptide position between the 3LOH and 3W11 crystal 
structures. The CT peptide in the 3LOH structure (red) is positioned differently compared to that in 
the insulin-bound IR structure (green). Both CT peptides are superimposed onto the L1 domain (blue). 
Residue Asn711 on the 3LOH (yellow) and 3W11 (pink) structures are shown in stick representation. 
The differences between these two structures indicate that the CT peptide undergoes a positional shift 
upon the binding of insulin and that these changes could potentially be important for the subsequent 
conformational change and activation of the receptor. 
88 
88 Chapter 3: Investigating the role of the CT peptide in insulin binding 
 
Figure 3.16: Comparison of the L1-CT interactions between 3LOH and 3W11 crystal structures. Different residues on the CT peptide (red) are exposed to the L1 domain 
(blue) in the 3LOH crystal structure (A) compared to the 3W11 crystal structure (B). The differences between these two structures suggest that the CT peptide substantially 
shifts along the face of the L1 domain and that this positioning may potentially be important for the binding of insulin or the subsequent changes in the receptor in response to 
ligand binding. 
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Comparison of the 3W11 structure with the IR[1-468, CT] model also showed differences 
between the structures. Apart from the difference in the CT peptide mentioned above, Phe714 
was also positioned differently. In the IR[1-468, CT] model, Phe714 was observed to be buried in a 
hydrophobic pocket on the L2 domain (Figure 3.6). However, in the 3W11 crystal structure of 
the insulin-bound IR, Phe714 was found to be buried between the two chains of insulin. While 
the 3W11 structure shows Phe714 in contact with insulin, the potential interaction between 
Phe714 and the hydrophobic pocket on the L2 domain may represent the residue’s position in 
the unbound state of the receptor. 
 
The introduction of the insulin-bound crystal structure and the observed differences 
regarding the CT peptide brought about a new question regarding our IR[1-468, CT] model. The 
position and structure of the CT peptide in the IR[1-468, CT] model was built based on the 3LOH 
crystal structure and the subsequent simulations suggested compatibility with the interactions 
between the L2 domain and CT peptide. We therefore questioned whether the IR[1-468, CT] 
structure was able to accommodate the changes to the CT peptide structure observed in the 
insulin-bound IR crystal (3W11). To test this, a TMD simulation was performed on the 
IR[1-468, CT] structure which induced the α-helix extension into the CT peptide with no artificial 
restraints on the interaction between the L2 domain and the CT-tail or between the L1 domain 
and the CT α-helix (atoms that were subjected to TMD force (Phe705-Val715) are shown in 
Figure 3.17B). The resulting IR[1-468, CT] structure with the induced α-helix extension will hereon 
be referred to as IR[1-468, CTex]. As seen in Figure 3.17A, following the TMD simulation, the 
structure of the CT peptide in IR[1-468, CTex] very closely matched the CT peptide fragment in the 
3W11 crystal structure. Interestingly, the CT peptide in IR[1-468, CTex] was observed to undergo a 
similar change in position to that observed in the 3W11 insulin-bound crystal structure where the 
CT peptide became positioned orthogonally across of the L1 domain. This was intriguing because 
the TMD atoms were only forced relative to each other’s positions while the domains in the rest 
of the receptor did not have any TMD force applied, suggesting formation of the extra turn in the 
CT peptide causes it to rearrange itself on the face of the L1 domain. Furthermore, residues on 
the CT peptide in IR[1-468, CTex] were observed to contact the same residues on the L1 domain as 
that observed in the 3W11 crystal structure. For example, Phe705 was observed to be in contact 
with the hydrophobic pocket formed by Phe88, Phe89, Val94 and Phe96 on the L1 domain while 
Leu709 and Val713 were positioned similarly to that shown in Figure 3.16B. Important to note 
here is that the 3W11 crystal structure had a resolution of >4 Å and a perfect match should not 
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be expected. Furthermore, induction of the α-helix extension into the CT peptide caused the L2 
domain to substantially shift towards the N-terminal end of the L1 domain (Figure 3.18).  
 
 
Figure 3.17: Comparison of the position and structure of the CT peptide after the TMD simulation. A, The 
CT peptide of the IR[1-468, CTex] structure (red) closely matched that in the 3W11 structure (green) after induction of 
the extra turn in the α-helix of the CT peptide. B, the atoms (yellow) that were subjected to the TMD force in the 
TMD simulation. The L1 domain is shown in blue and was included to show the position of the CT peptide from 
the IR[1-468, CTex] structure also matched that observed in 3W11 following the TMD simulation. 
 
This conformational change bears similarity to those seen in the simulation of the 
IR[1-468, CT] model in Section 3.2.1, where opening of the CT peptide resulted in a rearrangement 
of the L2 domain. The change in this simulation however, resulted in a larger movement of the 
L2 domain, increasing the previously defined hinge angle from 104° to 117° (Figure 3.18). This 
substantial rearrangement of the L2 domain brought it into very close proximity to the L1 domain 
resulting in the formation of new interactions between them.  
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Figure 3.18: The conformational change after incorporating the extended α-helix of the CT peptide into the 
IR[1-468, CT] structure. The conformational change in the IR[1-468, CTex] TMD simulation resulted in a shift of 116.5° 
experienced by the L2 domain. The first three domains of the IR (blue) in complex with the new CT peptide position 
and conformation (red).  This conformational change brought the L2 domain into close proximity to the N-terminal 
end of the L1 domain, resulting in the formation of new interactions between them. 
 
The identified interactions included an extensive network of salt bridges involving the L1 
and L2 domains as well as the CT peptide (Figure 3.19). This network involved residues Arg331, 
Glu353, Arg19, Asp12, Arg14, Glu355, the C-terminal acid of Ser719 and Arg383. This cluster 
of salt bridges was not present in the first 1 ns of the simulation where residues on the L1 and L2 
domains were positioned far apart. However, once the conformational change (starting after 1 ns 
into the simulation) brought the L1 and L2 domains into close proximity, the network of salt 
bridges began to form. From the trajectory, it appeared that Glu353 was the residue that initiated 
the link between the two domains before subsequent interactions between the other residues 
formed the remainder of the identified salt bridge network. It is possible that the extended α-helix 
configuration of the CT peptide is formed in response to insulin binding which causes a 
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subsequent rearrangement of the L2 domain as seen in our TMD simulation. The potential salt 
bridge network that was formed could possibly act to stabilise the conformational change and 
result in receptor activation. 
 
 
Figure 3.19: The network of salt bridges formed by residues on the L1, L2 domains and the CT peptide in the 
IR[1-468, CTex] TMD simulation. A collection of eight amino acids were identified in the TMD simulation of the 
IR[1-468, CTex] model to form a network of salt bridges and appeared to help induce the observed conformational 
change. Hydrogen bonds formed between the residues are shown in pink. This salt bridge could also potentially 
stabilise the conformation of the L2 domain relative to the L1 domain. 
 
The residues involved in the salt bridge network were also in contact with local residues 
in the surrounding environment. Although these local residues did not contribute to the salt bridge 
network, they appeared to stabilise the positions of those that did. Arg383 was positioned close 
to the α-helix of the CT peptide and was stabilised by the carbonyl oxygen atoms on residues 
Asn711, Val712 and Val713. Additionally, Asn16 on the L1 domain was positioned where it 
could potentially interact with two different residues in the salt bridge network, Glu353 and 
Arg19. While these two residues were observed to be in contact with each other, Asn16 is located 
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close to Glu353 and Arg19 where interactions could potentially form and expand the salt bridge 
network to include Asn16.  
 
Analysis of the eight identified residues involved in the salt bridge network showed very 
high conservation across species analysed by Renteria et al (Renteria et al, 2008). As shown in 
Figure 3.20, six residues (Arg331, Glu353, Asp12, Arg14, Glu355 and Arg383) were found to 
be strictly conserved while Arg19 and Ser719 were lower but still had a high level of 
conservation. Arg19 in particular had two sequences that replaced the arginine with asparagine 
and glutamine; although these residues would not participate in a salt bridge interaction, they 
would still be able to form the weaker hydrogen bond interactions. Such a high level of 
conservation across a majority of the residues involved in the salt bridge network supports the 
idea that the observed conformational change of the receptor could potentially be important for 
the receptor. Indeed, further evidence could be found in site directed mutagenesis studies that 
showed a reduction in the receptor’s affinity for insulin when residues Asp12 or Arg14 were 
mutated to alanine (Mynarcik et al, 1997a; Williams et al, 1995). Although the mutation D12A 
was well tolerated by the receptor with a reduction in affinity by 5-6.2 fold (Mynarcik et al, 
1997a; Williams et al, 1995), the R14A mutation saw a >500 fold decrease in affinity suggesting 
this residue plays a crucial role in ligand binding (Mynarcik et al, 1997a). Unfortunately, no 
mutagenesis data is available for the other identified residues and future experiments could 
further investigate this salt bridge network by assessing the effects of mutations of these residues 
on the receptor’s ability to bind insulin. 
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Figure 3.20: Sequence alignment depicting conservation of the eight identified residues in IR across species. The indicated residues (Homo Sapien numbering; annotated 
and indicated with red arrows) were identified to form a potentially important network of salt bridges that connected the L1, L2 domains and the CT peptide. The residues are 
shown here to exhibit high conservation across the species that were analysed in the Renteria et al study (Renteria et al, 2008).  
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Furthermore, considering the observed potential conformation change was 
very similar to that seen in the previous simulation of the IR[1-468, CT] model, the 
IR[1-468, CTex] TMD simulation was analysed to determine whether the previously 
identified interactions listed in Table 3.2 could also be found. Closer examination of 
the TMD simulation showed that Glu287 and Lys310 did not form any interactions 
with each other apart from a salt bridge in the starting structure, which then broke apart 
after starting the simulation. Conversely, the second identified interaction, the salt 
bridge between Glu329 and Arg270, was also observed in this simulation. This 
interaction formed when the movement of the L2 domain brought these residues closer 
together (~1 ns into the simulation), allowing the formation of the identified salt 
bridge. However, these two residues did not remain stable for the duration of the 
simulation and instead broke away from each other after ~0.5 ns. This appeared to 
coincide with the formation of the salt bridge network mentioned above suggesting the 
interaction between Glu329 and Arg270 may act as a mediator that brings Glu353 
close enough to Arg19 to initiate the salt bridge network. This interaction between 
Glu329 and Arg270 and its role in the IR was investigated and discussed in more detail 
in Chapter 4. 
 
 MD SIMULATION OF THE IR CYC-CT COMPLEX REVEALS SUBSTANTIAL 
CONFORMATIONAL CHANGES 
The IR cyc-CT model was generated using our own defined patch that cyclised 
the CT peptide as a thioether as described in Section 2.2.1. A TMD simulation to 
induce an extension into the cyc-CT α-helix was then performed to mimic the CT 
peptide structure observed in the insulin-bound IR crystal structure (3W11) (Figure 
3.21). Formation of the extra turn in the cyc-CT α-helix forced the N-terminal loop to 
unravel in order to accommodate the conformational change at the C-terminus.  
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Figure 3.21: Observed conformational change of the cyc-CT during MD simulations. Starting 
conformation of cyc-CT (red) is superimposed onto the observed conformational change (blue). The 
cyc-CT peptides are shown in secondary structure representation while the cyclisation points are 
visualised in stick representation. This simulation was performed to induce the same extension to the 
CT α-helix observed in the insulin-bound IR crystal structure (3W11). 
 
Interestingly, after inducing the extra turn into the cyc-CT α-helix, the L2 
domain experienced an highly similar change to that observed in the IR[1-468, CTex] 
model. Indeed, the angle formed by the same reference points (Arg14, Glu120 and 
Lys425) used in previous measurements was 115° (Figure 3.22), similar to the 117° 
measured in the TMD simulation of the IR[1-468, CT] model. Furthermore, comparison 
of the interactions and the residues involved in the previously discussed IR models 
with those seen in this TMD simulation found contrasting results. Firstly, the identified 
salt bridge network that linked the L1, L2 domains and the CT peptide was partially 
formed in this TMD simulation (Figure 3.23). Of the eight previously identified 
residues, only five were observed to form salt bridge interactions in this simulation 
(Asp12, Arg14, Glu355, Ser719 and Arg383). Moreover, Glu355 (which formed 
interactions with Arg383 and Arg14 in the IR[1-468, CT] simulation) formed a single salt 
bridge with Arg383 as it was positioned too far to interact with Arg14. This resulted 
in a break in the salt bridge network which removed the link between the L1 and L2 
domains seen in the previous simulation. However, approximately 5 ns into the TMD 
simulation, Asn711 moved in between Glu355 and Arg14 allowing the formation of 
two new hydrogen bonds resulting in the formation of a link between the two domains. 
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Figure 3.22: Model of the IR cyc-CT model and the conformational change of the L2 domain in 
its final resting angle relative to the L1 domain. The conformational change in the IR cyc-CT TMD 
simulation resulted in a shift from 89° to 114.8° experienced by the L2 domain. The first three domains 
of the IR (blue) in complex with the cyc-CT (red). This conformational change was highly similar to 
that observed in the TMD simulation of the IR[1-468, CTex] simulation. 
 
 
Figure 3.23: The network of salt bridges formed by residues on the L1, L2 domains and the CT 
peptide in the IR cyc-CT TMD simulation. Six amino acids were identified in the TMD simulation 
of the IR cyc-CT model to form a network of salt bridges that resembled the network seen in the 
IR[1-468, CT] simulation.  
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Residues Glu287 and Lys310 were observed to form an interaction for the entire 
duration of the TMD simulation, linking the L2 and CR domains despite the L2 domain 
making such a large rearrangement. This was in direct contrast to that seen in the 
IR[1-468, CTex] simulation where these residues did not form stable interactions. On the 
other hand, residues Glu329 and Arg270 were observed in both the IR[1-468, CTex] and 
IR cyc-CT simulations to form more stable interactions. Interestingly, with the 
exception of Asn711, the salt bridges shown in Figure 3.23 were observed in the 
IR cyc-CT simulation to form prior to the formation of the interaction between Glu329 
and Arg270. As mentioned previously, Asn711 was observed to bridge the gap 
between Glu355 and Arg14 in this simulation and this did not occur until after the 
formation of the salt bridge between Glu329 and Arg270. This supports the idea that 
the interaction between these two identified residues could play a potentially important 
role in the formation of the salt bridge network which in turn causes the structural 
rearrangements of the L2 and CR domains.  
 
Furthermore, as seen in Figure 3.24, the interaction between the L2 domain and 
the last three residues of the CT-tail predicted in Dr Tristan Croll’s work remained 
intact despite the conformational shift of the L2 domain. This suggests that not only 
was the IR[1-468, CT] model able to accommodate the new position of the CT peptide 
seen in the 3W11 crystal structure, it was also able to adapt to the repositioning of the 
L2 domain whilst maintaining the previously predicted interactions. Interestingly, 
Renteria et al found Arg717 and its equivalent residue in IGF1R, Arg704, to be highly 
conserved throughout evolution (Renteria et al, 2008). Moreover, although not 
included in their results or discussion, after analysing the supplementary data from this 
publication, Glu438 was found to be conserved in all but two of the IR sequences used 
in their alignment study (Figure 3.25). This further supports the possibility that the 
proposed interaction between Arg717 and Glu438 plays an important role in receptor 
function. 
 
Future investigation would involve setting up simulations with cyc-CT having 
varying lengths at the cyclisation point between Cys715 and Glu697. This would 
change the degree of flexibility of the cyc-CT peptide and the effects on the IR 
conformational change could then be observed. The importance of the interaction 
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between Arg717 and Glu438 was further investigated using simulations of mutated IR 
and mutagenesis studies using expressed protein (described in Chapters 4 and 5).  
 
 
Figure 3.24: Salt bridge between Arg717 and Glu438 is maintained during the conformational 
change seen in the IR cyc-CT simulation. A, the interaction between Arg717 and Glu438 at the 
beginning of the TMD simulation. B, the interaction is maintained throughout the simulation despite the 
conformational change. Arg717 and Glu438 are shown in stick representation. This interaction was 
further found to be highly conserved from supplementary data in a bioinformatics study of IR and 
IGF1R across multiple species (Renteria et al, 2008) and was proposed to play a potentially important 
role in receptor function. 
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Figure 3.25: Sequence alignment depicting conservation of Glu438 in IR across species. Glu438 (Homo Sapien numbering; annotated and indicated with a red arrow) was 
observed in Dr Tristan Croll’s work to form a potentially important interaction that linked the L2 domain to the CT-tail. This interaction was observed to remain stable despite 
the conformational changes experienced by the L2 domain in TMD simulations of the IR cyc-CT model.  
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 FULL CORRELATION ANALYSIS (FCA) OF IR CYC-CT MD SIMULATIONS 
SHOW COLLECTIVE MOTIONS EXPERIENCED BY CYC-CT 
It is difficult to visually identify specific motions within a MD simulation as 
local vibrations and collective motions occur simultaneously. In order to separate the 
two different types of movements that are occurring, FCA was used to extract the large, 
collective motions of the system from MD simulations.  
 
Table 3.3 lists the first 10 eigenvectors extracted by FCA and their percentage 
of total variance (PTV) of the system. It can be seen from the table that the listed 
eigenvectors occupy over 70% of the total variance with the first identified eigenvector 
having a PTV of over 30%. The high PTV of eigenvector 1 indicates that the respective 
correlated motion is the predominant movement experienced by the IR cyc-CT 
complex during the MD simulations. Figure 3.26 shows the motion of the IR cyc-CT 
complex in the first eigenvector and suggests that the most important movement is the 
bulk shift in the L2 domain that contributed to the observed conformational change. 
The motion shown in Figure 3.26 does not represent that from beginning to end of the 
MD simulation but rather the most extreme conformations experienced. Further 
examination of this motion shows the L2 domain shifting in position but not to the 
same extent as that seen in Figure 3.22.  
 
Table 3.3: List of the first 10 eigenvectors of the IR cyc-CT complex and their percentage of total 
variance (PTV). 
 Eigenvector Percentage 
1 32.46 
2 12.98 
3 5.95 
4 5.45 
5 3.66 
6 3.06 
7 2.56 
8 1.75 
9 1.27 
10 1.15 
Total 70.29 
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Figure 3.26: Movement of IR cyc-CT along the first eigenvector. A, the change in conformation 
experienced by the IR cyc-CT along the first eigenvector is shown where the L2 domain shifts from the 
beginning (red) to the end (blue) of the extracted motion. B, the difference in CT peptide is also shown 
where the α-helix changes from the beginning (red) to the end (blue) of the same extracted motion. The 
shift of the L2 domain was determined by FCA to contribute over 30% of the total variance of the MD 
simulation suggesting this motion could potentially be important for receptor function. 
 
Projections on the first three eigenvectors are shown in Figure 3.27. It can be 
seen in the first eigenvector that the motion involves the complex changing at 
approximately 30 ns from the starting structure to a different conformation. From the 
change in receptor conformation shown in Figure 3.26, the main motion detected by 
FCA was both a shift in the position of the L2 domain as well as the change 
experienced by the CT peptide when it was forced to mimic the position of that seen 
in the 3W11 crystal structure. However, examination of projection on the second and 
third eigenvectors also showed conformational changes of the L2 domain at 90 and 
50 ns respectively, but these changes happened more gradually compared to the 
sudden change seen in the first eigenvector. Visualisation of the structures described 
by eigenvectors two and three show the L2 domain shifting further compared to 
eigenvector one, similar to that seen in Figure 3.22. This suggests that the observed 
shift in the position of the L2 domain (Figure 3.22) was a combination of motions 
spread across three eigenvectors. The overall conformational change of the IR cyc-CT 
complex was therefore speculated to involve multiple steps. Firstly, the change in the 
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cyc-CT peptide conformation pulled the L2 domain into its position shown in 
eigenvector one (Figure 3.26). After the change in the CT peptide was over, the L2 
domain began sampling a new environment, seen in eigenvector three before settling 
into the new conformation seen in eigenvector two.  
 
 
Figure 3.27: Projection on first three eigenvectors of the IR cyc-CT complex. Analysis of the 
IR cyc-CT complex showed the first eigenvector having a much larger change in conformation 
compared to the next two extracted eigenvectors. The conformational changes in the three eigenvectors 
shown here were speculated to contribute to the overall conformational change of the L2 domain 
observed in the simulation. 
 
Figure 3.28: Visualisation of the conformations of the IR cyc-CT structure described by 
eigenvectors two and three. A, the conformation of the structure in eigenvector two shows the L2 
domain sampling the new environment before transitioning into B, the new conformation described in 
eigenvector three. The overall conformational change of the L2 domain observed in the simulation was 
speculated to involve multiple steps where the change in the CT peptide conformation induced 
subsequent changes in the L2 domain.  
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Analysis of the IR[1-468, CTex] and the IR cyc-CT simulations appear to suggest 
that induction of the extra turn into the CT peptide leads to a new stable state of the 
receptor. Importantly, multiple studies have reported the IR experiences a 
conformational change upon ligand binding (Florke et al, 2001; Kavran et al, 2014; 
Lee et al, 1997; Pilch & Czech, 1980; Waugh & Pilch, 1989), some even suggesting 
the possibility of more than one conformational change (Baron et al, 1992; Lee et al, 
1997). Therefore, the new stable state of the receptor observed here could potentially 
be one of the conformations of the IR referred to by these studies. The compatibility 
of the compact configuration of the IR[1-468, CT] model with the 4OGA crystal structure 
was further analysed and discussed later in this chapter. 
 
 CYC-CT PEPTIDE INDUCES STRONGER BINDING OF IR TO IMMOBILISED 
BIOTINYLATED INSULIN 
The initial approach to assess the effects of a cyclised CT peptide on insulin 
binding was to biotinylate the IR[1-468] protein and immobilise it onto the surface of a 
sensor chip. The IR[1-468] protein used in this study was kindly provided by John 
Menting and Michael Lawrence from the Walter and Eliza Hall Institute and was 
identical to that used in a previous isothermal titration calorimetry (ITC) study to 
determine insulin binding affinity (Menting et al, 2009) and was thus expected to bind 
insulin in the presence of CT peptide. Insulin solutions containing either linear or 
cyc-CT were then flowed over the IR[1-468] protein and the binding response measured. 
However, this approach did not yield a response that was distinguishable from the 
normal drift of the baseline (data not shown) and was thus not pursued any further. 
Discussions with external collaborators (John Menting and Michael Lawrence from 
the Walter and Eliza Hall Institute) resulted in the idea to immobilise insulin instead 
and flow solutions of IR[1-468] protein containing the two different CT peptides. This 
approach was able to successfully detect the binding interactions between insulin and 
the IR[1-468] protein and was the method used for the work described here. 
 
Solutions containing IR[1-468] protein and either linear or cyc-CT were used to 
examine their effects on IR ligand binding. Figure 3.29 shows the binding response of 
these different solutions to immobilised insulin at IR concentrations between 62.5 nM 
and 1 mM receptor. It can be clearly seen that the solution containing IR with 10X 
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cyc-CT bound to the immobilised insulin with a higher and faster response compared 
to the linear CT solution. Interestingly, the same solution also displayed a faster 
dissociation compared to the linear CT solution. Table 3.4 lists the binding parameters 
of the different samples. The binding data clearly shows that the solution containing 
cyc-CT bound to immobilised insulin with much higher association and dissociation 
rates compared to the linear CT. The KD determined for the cyc-CT solution was 
approximately six-fold higher compared to the linear CT. 
 
 
Figure 3.29: Binding response of different IR solutions to immobilised biotinylated insulin. 
BIAcore experiments using the IR+cyc-CT bound insulin at a much faster and stronger response 
compared to the IR+linear CT solution. These binding data indicated that the cyc-CT peptide was able 
to induce a stronger binding of the receptor to insulin suggesting the cyc-CT structure causes a change 
in the receptor that binds insulin more favourably. 
 
Table 3.4: Binding parameters of different samples using BIAcore analysis  
Sample ka (1/Ms) kd (1/s) KD (µM) 
IR + linear CT 1.3x103 7.1x10-3 8.14 
IR + cyc-CT 1.9x104 2.4x10-2 1.28 
IR only No binding 
detected 
No binding 
detected 
No binding 
detected Cyc-CT only No binding 
detected 
No binding 
detected 
No binding 
detected Linear CT only No binding 
detected 
No binding 
detected 
No binding 
detected 
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The IR[1-468] protein was used in a previous isothermal titration calorimetry (ITC) 
study to determine insulin binding affinity (Menting et al, 2009). The authors used a 
ten-fold higher concentration of CT peptide compared to IR to determine insulin 
binding which was applied to the BIAcore experiments performed here. We therefore 
expected the binding affinity from these experiments to be similar to those reported by 
Menting et al (2009). Importantly, the binding affinity between the immobilised 
biotinylated insulin and IR in the presence of linear CT was measured to be 8.14 µM, 
markedly different from the 11 nM reported in the previous study (Menting et al, 
2009). The difference of two orders of magnitude between these two binding affinities 
could be attributed to three potential factors. Firstly, insulin binding involves an 
intricate series of steps which are thought to include movement of the B-chain 
C-terminus that exposes residues belonging to the classical binding surface: A1, A2 
and A3. Biotinylation of insulin may have potentially affected the ligand’s ability to 
expose those critical residues and thus contributing to the observed low affinity 
(Ludvigsen et al, 1998). Secondly, biotinylation of insulin was expected to occur on 
LysB29 which would result in the immobilisation of the ligand onto the chip via this 
residue. Importantly, binding surface 1 of insulin has been determined through 
multiple studies (Nakagawa & Tager, 1992; Pullen et al, 1976) and includes residues 
GlyB23, PheB24, PheB25 and TyrB26, all of which are located in very close proximity 
to the biotintylated residue LysB29. Considering immobilisation of insulin occurred 
via residue LysB29, it is highly likely that the residues identified to bind the IR were 
positioned very close to the sensor chip matrix and may have potentially created a 
steric barrier for stable insulin binding. Thirdly, the use of a soluble CT peptide rather 
than a fused alternative further complicated the binding process as interactions 
between three components were necessary in order for binding to be detectable (as 
evidenced by a lack of binding in the IR only or CT-only controls). Future experiments 
using a similar approach could improve this by using an alternative biotin derivative 
containing long polyethylene glycol (PEG) spacers. The biotinylation of insulin with 
longer spaced biotin may allow it to be more optimally positioned to interact with the 
IR-CT peptide complex.  
 
Two main factors may have contributed to the lower binding affinity to insulin 
observed for IR[1-468] protein. Firstly, the BIAcore experiment involved immobilising 
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insulin and passing the IR-CT peptide solution over. Although not as ideal as flowing 
insulin over an immobilised IR[1-468]+CT peptide complex, this was a necessary 
compromise as immobilising the IR[1-468] protein and flowing insulin-CT peptide 
solution surprisingly yielded no detectable response. Biotinylation of the IR[1-468] 
protein prevented the formation of interactions between the CT peptide and insulin or 
affected conformational changes that are necessary for insulin binding. Secondly, the 
intended constrained nature of the cyc-CT peptide also likely played a role in the fast 
dissociation rate as substitution of the cyclised peptide by the linear counterpart 
resulted in a three-fold lower dissociation rate. The reduction in flexibility of the CT 
peptide via cyclisation may have prevented conformational changes during ligand 
binding that would stabilise the interaction between insulin and its receptor. Indeed, 
simulations of the IR[1-468, CTex] and IR cyc-CT structures saw different interactions 
emerge (analysed and discussed in Sections 3.2.2 and 3.2.3) despite the L2 domain in 
both structures undergoing similar shifts in position and angle. The subtle differences 
between these structures may have potentially resulted in the different dissociation 
rates observed in the BIAcore experiments.  
 
The BIAcore results indicated that the IR cyc-CT solution bound immobilised 
insulin differently compared to the IR linear-CT solution. More specifically, the 
solution containing cyc-CT bound insulin with a 10-fold faster association rate but also 
displayed a dissociation rate that was 3.4-fold higher. It was speculated earlier that the 
compact conformation of the IR[1-468, CT] model may represent an intermediate state of 
the receptor during ligand binding and these results may support this theory. For 
example, if the compact conformation does indeed represent an intermediate binding 
state of the IR, then the IR+cyc-CT complex should bind insulin with a faster 
association as the cyclised peptide was designed to restrain the receptor in that specific 
configuration. This was observed in the BIAcore experiments where solutions 
containing cyc-CT peptide bound insulin with a 10-fold higher association rate 
compared to the linear-CT solutions. However, this does not explain why the same 
solutions (IR cyc-CT) displayed a faster dissociation rate from the immobilised 
insulin. It is possible that while cyclisation of the CT peptide may have constrained 
the IR[1-468] protein into an intermediate state, it may have also restricted the receptor 
from forming a stable ligand-bound conformation. This may explain why solutions 
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containing linear-CT displayed a slower dissociation rate compared to the solutions 
containing cyc-CT. Importantly, the experimental data shows that cyclisation of the 
CT peptide resulted in a higher affinity for insulin compared to the linear-CT. 
Considering the experiments performed here involved three components that were 
required to associate with each in order for insulin binding to be achieved (IR, insulin 
and either cyc-CT or linear CT), two potential reasons may explain this increased 
binding. Firstly, cyclisation of the CT peptide potentially increased its affinity to the 
receptor, resulting in faster formation of the receptor+cyc-CT peptide which in turn 
bound insulin faster. This is possibly why solutions containing cyc-CT bound insulin 
with a higher association rate. Another possibility is that instead of increasing the 
receptor’s affinity for the CT peptide, cyclisation increased the CT peptide’s affinity 
for insulin which would also result in the higher association rate that was observed. 
The affinity of cyc-CT to either the receptor or insulin can be determined in future 
experiments using ITC experiments similar to those performed by Menting et al using 
the same IR[1-468] construct (2009).  
 
Alternatively, the latest insulin-bound IR crystal structure may provide a 
different explanation for the observed binding data. In this new structure (PDB ID 
4OGA), new residues in the insulin B-chain tail and IR CT-tail were successfully 
resolved and showed where they were positioned relative to the residues on other IR 
domains (Menting et al, 2014). The structural data clearly shows the B-chain tail 
positioned between the first β-sheet of the L1 domain and residues 715-718 of the CT 
peptide where residues TyrB26 and ThrB27 are in very close proximity to Arg14 on 
the L1 domain. In the IR[1-468, CT] model, Arg14 was observed to form a salt bridge 
interaction with Glu355  while in the IR cyc-CT model, Arg14 was observed to form 
a salt bridge interaction with Asn711. These interactions could potentially have been 
disrupted when TyrB26 and ThrB27 were brought into close proximity to these 
residues during insulin binding. This disruption to the salt bridge network may have 
been tolerated in the IR[1-468, CT] model due to residues Arg19 and Glu353 still linking 
the L1 and L2 domains together (Figure 3.19), allowing the IR[1-468] construct to 
remain in the compact conformation. However, in the IR cyc-CT model, the L1 and 
L2 domains are only linked via Arg14 and Asn711 (Figure 3.23) and any disruption 
 109 
Chapter 3: Investigating the role of the CT peptide in insulin binding 109 
to that interaction could potentially result in loss of the compact conformation, 
resulting in the IR cyc-CT solution displaying a 3.4-fold higher dissociation rate.  
 
 SIMULATION SHOWS COMPATIBILITY OF OUR MODELS WITH THE 4OGA 
INSULIN-BOUND IR CRYSTAL STRUCTURE  
Very recently, near the end of my studies (September 2014), a new insulin-bound 
IR crystal structure was made available that had successfully resolved residues on the 
B-chain tail of insulin and the previously unresolved residues on the CT-tail (PDB ID 
4OGA) (Menting et al, 2014). Similar to the 3W11 crystal structure, the 4OGA 
structure used a construct that did not include the L2 domain and thus the possibility 
of the conformational changes seen in our simulations of both the IR[1-468, CTex] and 
IR cyc-CT models have not yet been ruled out.  
 
Examination of the IR[1-468, CTex] structure showed that after the conformational 
change of the L2 domain, a small void region was formed between the L1 domain, L2 
domain and the CT peptide and it was speculated that the insulin B-chain tail may be 
able to fit into this area. The conformational change of the L2 domain in our 
simulations was therefore tested for its compatibility with the 4OGA crystal structure. 
In order to do this, an IMD simulation was set up which took the IR[1-468, CTex] structure 
and manually pulled insulin into a similar position to that resolved in 4OGA. 
Furthermore, to more closely match the CT-tail of the 4OGA crystal, Phe714 was 
pulled out of the previously identified potential hydrophobic binding pocket (Figure 
3.6) and buried within the interface between the CT peptide and insulin. Interestingly, 
alignment of the IR[1-468, CTex] structure with the 4OGA crystal structure showed 
PheB25 on the insulin B-chain was positioned in close proximity to the hydrophobic 
binding pocket on the L2 domain. Considering that region was no longer occupied by 
Phe714, PheB25 was ideally positioned to take its place and was thus moved into said 
binding pocket. The resulting structure, from here on referred to as IR[merge] (shown in 
Figure 3.30), showed that the aforementioned void region between the domains was 
able to accommodate the insulin B-chain as seen in the 4OGA crystal structure. The 
IR[merge] structure was then subjected to 219 ns of simulation where little change in the 
overall structure occurred indicating the addition of the insulin B-chain tail did not 
adversely affect the structure. This suggested that the conformational change of the L2 
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domain seen in the simulations of the IR[1-468, CTex] and IR cyc-CT models was 
compatible with the coordinates of insulin in the new crystal structure. 
 
Figure 3.30: The IR[merge] structure consisting of the IR[1-468, CT] structure and the 4OGA crystal 
structure.  The IR[merge] structure showed that the region between the L1 domain, L2 domain and the 
CT peptide was able to accommodate the insulin B-chain from the 4OGA crystal structure. Simulations 
showed little change to the overall structure indicating the conformations compatibility with the 
coordinates of insulin from the 4OGA crystal structure. The domains are coloured as follows: L1-CR-
L2 domains, blue; CT peptide, red; insulin A-chain, grey and insulin B-chain, orange. 
 
The presence of the insulin B-chain between the L1 and L2 domains did not 
significantly alter the conformation of the receptor. The L2 domain remained in a 
similar position compared to that at the beginning of the simulation indicating the 
IR[1-468, CTex] structure was compatible with the 4OGA crystal. Closer examination of 
the simulated IR[merge] structure identified different interactions between insulin and 
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the receptor domains. Many of the intra-domain interactions in the salt bridge network 
previously identified from the IR[1-468, CTex] simulation (Figure 3.19) remained in the 
simulation of the IR[merge] structure whereas the inter-domain interactions were no 
longer present due to the addition of the insulin B-chain located between the domains. 
For example, the salt bridges between Arg14, Asp12 and Arg19 on the L1 domain 
were still present while the interaction between Glu355 and Arg14 no longer formed. 
Likewise, Arg383 on the L2 domain was still observed to form salt bridge interactions 
with Ser719 and Glu355. The main difference observed was the loss of the salt bridge 
interactions between Arg19 and Glu353 and also between Glu353 and Arg331. These 
salt bridge interactions were lost due to Glu353 forming a hydrogen bond with TyrB26 
on the insulin B-chain.  
 
Merging of the IR[1-468, CTex] structure and insulin from the 4OGA crystal 
structure formed a new interface between insulin and the L2 domain. This interface 
has not been observed in any of the crystal structures due to either the absence of 
insulin (when the L2 domain is in its native position; 2DTG, 2HR7, 3LOH) or the 
absence/non-native position of the L2 domain (in the insulin bound IR structures; 
3W11-3W14, 4OGA). Two hydrogen bonds were observed between the insulin 
A-chain and the L2 domain formed by residues Asn407-TyrA19 and Gln410-GlnA5 
(Figure 3.31). Importantly, both TyrA19 and GlnA5 have been speculated to be part 
of binding surface 1 of insulin, the region of insulin believed to contact site 1 of the IR 
(Pullen et al, 1976). Mutagenesis studies of insulin found that mutation of TyrA19 to 
alanine greatly impacted the ligand’s ability to bind the IR, displaying an affinity of 
only 0.1% compared to native insulin (Kristensen et al, 1997). Mutation of GlnA5 to 
alanine affected the ligand by a much lesser extent, reducing the mutant insulin’s 
affinity for the IR by 50% (Marki et al, 1979). Interestingly, in the 4OGA crystal 
structure, TyrA19 and GlnA5 are observed to be hydrogen bonded to each other and 
not contact the receptor, most likely due to the absence of the other domains in the 
construct used for crystallography. This does not agree with the widely accepted 
insulin binding model where binding surface 1 of insulin (which includes TyrA19 and 
GlnA5) contacts site 1 of the IR. The IR[merge] structure on the other hand, suggests a 
mode by which TyrA19 and GlnA5 may contact the IR during insulin binding. 
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Figure 3.31: Interface between insulin and the L2 domain in the IR[merge] structure. The IR[merge] 
structure brought the L2 domain into close proximity to insulin forming a new interface between them. 
New contacts formed along this interface which involved residues Asn407 and Gln410 on the L2 
domain and TyrA19 and GlnA5 on the insulin A-chain. Domains are coloured identical to that in Figure 
3.30. 
 
Introduction of insulin to the IR[1-468, CTex] structure did not affect the salt bridge 
interaction between Arg717 and Glu438 identified in Dr Croll’s model (Figure 3.3, 
p69). Although this interaction is not seen in the 4OGA crystal structure due to the 
absence of the L2 domain, Arg717 does not interact with any other residue and thus 
the Arg717-Glu438 salt bridge cannot be ruled out. Interestingly, although the salt 
bridge interactions between Glu329-Arg270 and Lys310-Glu287 were not present in 
the starting structure of the IR[merge] model, both salt bridges were observed to form 
~25 ns and ~30 ns into the simulation respectively, indicating these inter-domain 
interactions could potentially be stabilising the conformation of the L2 domain in order 
to keep insulin bound to the receptor. This could be further tested using mutant 
receptors with mutations of these specific residues and observed for any effects they 
may have on the receptor’s affinity for insulin. 
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Approximately 50 ns into the simulation, ThrB30 on the insulin B-chain tail 
began sampling the surrounding region and eventually formed a salt bridge with Arg86 
on the L1 domain around 44 ns (Figure 3.33). This salt bridge remained in contact for 
the remaining 169 ns of the simulation suggesting the interaction between the two 
residues was stable. This interaction with Arg86 is intriguing as a previously reported 
natural mutation to proline (R86P) resulted in a receptor that was not only unable to 
bind insulin, but also displayed constitutive activation (Longo et al, 1993). This 
interaction between insulin and the receptor could potentially be a trigger event in 
response to the binding of insulin and initiate a conformational change in the receptor 
that may eventually lead to receptor activation. It is possible that the R86P mutation 
caused a change to the receptor that mimics the trigger event that occurs when ThrB30 
salt bridges to Arg86. The R86P mutation was investigated and discussed further in 
Chapter 4. 
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Figure 3.32: The previously identified interactions in the IR[1-468, CTex] simulation remained intact in the simulation of the IR[merge] structure. Addition of insulin to the 
IR[1-468, CTex] structure did not affect the interactions formed by A, Lys310–Glu287, B, Glu329–Arg270 and C, Glu438–Arg717 as they remained in contact throughout the 
simulation. These interactions could be potentially important in stabilisation of the receptor’s conformation and two of these were further investigated in Chapters 4 and 5. 
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Figure 3.33: ThrB30 on the insulin B-chain tail contacts Arg86 on the L1 domain. Simulation of the IR[merge] structure showed ThrB30 on the insulin B-chain tail to come 
into contact with Arg86 on the L1 domain, a residue previously found to cause constitutive activation of the receptor when mutated to proline (Longo et al, 1993). A, the position 
of the two residues were apart before the simulation before coming into contact during the simulation (B). This interaction was investigated further using mutant IR models in 
chapter 4. 
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3.3 CONCLUDING REMARKS 
The work presented in this chapter aimed to further understand how the CT 
peptide might interact with insulin during ligand binding and also investigate the 
potential conformational changes that may occur. Comparison and analysis of the 
IR[1-468, CT] model with available crystal structures resulted in the identification of 
potentially important interactions that may play a role in the ligand binding process. 
The residues involved in the identified interactions were located on the CR and L2 
domains and appeared to stabilise these two domains. Furthermore, a conformational 
change of the receptor was also identified in which a rotation was observed to occur 
along a hinge point between the CR and L2 domains. This rotation was also observed 
in a subsequent TMD simulation where an extra turn was induced into the CT peptide 
of the IR[1-468, CT] model in order to more closely match that observed in the 3W11 
insulin-bound IR crystal structure.  
 
The importance of the CT peptide and the role it may play during insulin binding 
was also investigated in this chapter. The rationale for this work stemmed from the 
observation of a potential hairpin-like, compact conformation of the CT peptide in the 
IR[1-468, CT] simulation that was performed prior to this project by my primary 
supervisor, Dr Tristan Croll. This compact configuration of the receptor was 
interesting as previous studies have shown the Stokes radius of the receptor decreased 
upon binding insulin, suggesting this observed conformation may be an intermediate 
or insulin-bound form of the IR (Florke et al, 2001). It is noted however, that the 
reduction was observed for the IR dimer only when in the presence of transmembrane 
domain anchors. The IR[1-468, CT] construct investigated contained only the first three 
extracellular domains of the IR in complex with the CT peptide while the remaining 
regions of the receptor were absent. While the results presented by Florke et al suggest 
the transmembrane domains are required for subdomain rearrangements, restrictions 
on these same rearrangements can also be caused by the extracellular domains 
themselves. Separation of the L1-CR-L2 domains from the remaining regions of 
extracellular domain may have removed part or all of these restrictions, allowing the 
IR[1-468, CT] structure to sample conformations it otherwise wouldn’t be able to unless 
in the presence of the transmembrane domains. 
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The closed conformation of the receptor was further investigated in this study 
using a cyclised CT peptide analogue (cyc-CT) designed to constrain the receptor into 
the compact configuration. A simulation was performed to induce the extra loop into 
the cyc-CT in order to mimic the CT peptide structure in the 3W11 insulin-bound 
crystal structure. Analysis of the simulation found the IR structure underwent a similar 
conformational change compared to that observed in the IR[1-468, CTex] simulation. The 
similarity of the conformational change between the IR cyc-CT and IR[1-468, CTex] 
simulations indicate that the hairpin structure of the CT peptide from Dr Croll’s earlier 
work is compatible with the 3W11 insulin-bound crystal structure. Thus, induction of 
the extra loop into the CT peptide results in a conformational change to a new state of 
the receptor that appears stable.  
 
BIAcore analysis was then used to further investigate the effects of the cyc-CT 
peptide on insulin binding. This was done by flowing solutions of IR[1-468] (L1, CR and 
L2 domains) with either cyc-CT or linear CT peptide and measuring its binding affinity 
to immobilised biotinylated insulin. Interestingly, the resulting binding curves showed 
the solutions containing IR+cyc-CT bound insulin with a 10-fold higher association 
rate compared to the IR+linear CT solutions, but also showed a 3.4-fold higher 
dissociation rate. This indicated that the IR+cyc-CT complex may have been in a 
conformation that favoured the binding of insulin but was unable to transition into a 
more stable binding state. Other groups have previously speculated that the IR 
undergoes more than one conformational change upon the binding of insulin (Baron 
et al, 1992; Lee et al, 1997). Thus, although use of the cyc-CT peptide may have 
allowed insulin to bind to the receptor more favourably compared to the linear CT 
peptide, it may also have prevented the receptor from transitioning into a more stable 
binding state after initial contact with the ligand. 
 
Previous studies have shown the IR undergoes a conformational change upon 
binding of insulin (Donner & Yonkers, 1983; Florke et al, 2001; Lee et al, 1997; Pilch 
& Czech, 1980; Waugh & Pilch, 1989). Furthermore, the conformational change 
observed in simulations of the IR[1-468, CT], IR[1-468, CTex] and the IR cyc-CT structures 
involved a rotation along a hinge point between the CR and L2 domains. Although 
these domains are not recognised as contributing to the insulin binding sites on the 
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receptor, the potentially important interactions and conformational changes observed 
in the work in this chapter suggest they may be important for receptor function. Indeed, 
studies using photoactive insulin analogues have shown that they are able to crosslink 
to both the CR (Yip et al, 1988) and L2 (Fabry et al, 1992) domains of the receptor, 
suggesting these domains may in fact play a larger role in the ligand binding process 
than previously thought. Despite the recent successful crystallisation of a 
insulin-bound fragments of the receptor (Menting et al, 2013; Menting et al, 2014), 
there is currently no available crystal structure that shows the complete receptor in the 
insulin-bound state and thus the conformation of the insulin-bound receptor remains 
unknown. The observed conformational change presented here in this chapter may 
potentially represent the conformational changes of the receptor following insulin 
binding.  
 
Interestingly, following the observed conformational change in the IR[1-468, CTex] 
simulation, an extensive network of salt bridges was identified that appeared to 
stabilise the receptor in this new state (Figure 3.19). This salt bridge network involved 
residues from the L1 and L2 domains and also the CT peptide suggesting multiple 
interactions between the different domains of the receptor may be necessary for the 
receptor to undergo this conformational change. Recently (September 2014), a new 
insulin-bound IR crystal structure was made available and resolved previously missing 
regions of the insulin B-chain and CT-tail (4OGA) (Menting et al, 2014). In light of 
this new information, the conformational changes observed in simulations of the 
IR[1-468, CT], IR[1-468, CTex] and the IR cyc-CT structures were assessed for their 
compatibility with the new structural data. This involved merging the IR[1-468, CTex] 
model with the coordinates of insulin from 4OGA to create a new merged model of 
the receptor (IR[merge]). Simulation of the IR[merge] structure showed that addition of 
insulin to IR[1-468, CTex] model did not significantly alter the conformation of the 
receptor as the domains of the receptor remained in relatively similar positions. 
Furthermore, merging of the IR[1-468, CTex] structure with insulin resulted in the 
formation of new interactions between the L2 domain and the insulin A-chain. These 
interactions were not observed in any of the available IR crystal structures due to either 
the absence of insulin (2DTG, 2HR7, 3LOH) or the absence/non-native position of the 
L2 domain (3W11-3W14, 4OGA).  
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Importantly, whilst the IR is known to undergo a conformational change upon 
the binding of insulin (Donner & Yonkers, 1983; Kavran et al, 2014; Lee et al, 1997), 
the structure of this change has yet to be elucidated as there is currently no available 
crystal structure of the entire insulin-bound receptor. Thus, further investigation is 
needed to gain a better understanding of how the receptor may undergo this structural 
change and potentially identify residues that may be involved in this process. 
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Chapter 4: Understanding the IR and 
identification of possible key 
residues 
4.1 INTRODUCTION 
Without a detailed crystal structure of the insulin-bound IR, researchers have had 
to use other methods to elucidate how insulin binds to its receptor. Many studies have 
contributed to describing the interactions between insulin and the IR such as 
identifying the regions on the IR that are responsible for ligand binding (Huang et al, 
2007; Huang et al, 2004; Kurose et al, 1994; Wan et al, 2004; Wan et al, 2005). 
However, the conformational changes of the IR upon insulin-binding and what 
happens during receptor activation at the structural level have yet to be determined.  
 
Alanine scanning mutagenesis studies have mapped out many residues on the IR 
that may be important for insulin binding (Mynarcik et al, 1997a; Mynarcik et al, 
1996). However, not only is this method a time intensive process, it is also not 
immediately clear for any given mutation whether the mutation directly influences the 
interaction between receptor and ligand or affects the structural conformation which 
in turn disrupts ligand binding. Molecular modelling is one way to predict the effects 
of these mutations on the structural conformation of the receptor in a virtual 
environment.  
 
There are many documented natural mutations of the IR that result in various 
diseases such as Leprechaunism (Elsas et al, 1985) and Rabson-Mendenhall syndrome 
(Rabson & Mendenhall, 1956). These diseases are associated with impaired function 
of the insulin receptor system such as insulin resistance, reduced insulin binding or 
altered activation. One particular documented mutation separates itself from the others 
and hints at other critical residues for receptor function. This rare natural mutation of 
Arg86 to proline (R86P) completely abolishes the receptor’s ability to bind insulin 
(Longo et al, 1993). More interestingly, the same mutation also results in constitutive 
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activation of the IR. Despite the nature of this mutation, little has been done to further 
understand the effect it has on the structure of the IR and its interaction with insulin. 
Therefore, the mutation and its effect on the structural conformation of the IR were 
investigated in this project which may shed light on the residues involved with insulin 
binding and receptor activation. A simultaneous simulation of the wild-type IR (wt-IR) 
was also used as a comparison in order to identify specific conformational changes 
that occurred as a result of the R86P mutation. Key residues identified to contribute to 
the conformational changes were then mutated in separate models to further 
investigate their importance. 
 
Similar to the simulation work performed in Chapter 3, the IR[1-468, CT] version of 
the IR extracellular domain was used to study the R86P mutation. Not only did this 
decrease the overall size of the simulation system from ~245,000 atoms to ~63,000 
atoms, it also reduced the computing power required and allowed multiple simulations 
to be run simultaneously.  
 
The aim of this chapter was to investigate further, with the use of molecular 
modelling and dynamics simulations, the effect of the R86P mutation on the 
conformation of the IR. Furthermore, this study also aimed to identify key residues 
through conformational changes seen in IR simulations and generate experimental 
mutations of these residues for further investigation. 
 
4.2 RESULTS AND DISCUSSION 
 ANALYSIS OF THE WT-IR SIMULATION SHOWED MINIMAL 
CONFORMATIONAL CHANGES 
The wt-IR structure was simulated for 326 ns under standard conditions. The 
structure was observed to sample a wide range of conformations where the angle 
formed by the L1 and L2 domains, measured using the same reference points defined 
in Section 3.2.1), reached between 78° and 125° (Figure 4.1). The distances between 
the centres of mass of the L1 and L2 domains for both angles were found to be 44.7 Å 
and 47.4 Å respectively. Interestingly, the CT-tail in the conformation displaying the 
smallest angle conformation closely resembled the CT peptide in the compact IR 
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structure seen in Dr Croll’s simulation work (Figure 3.5B) suggesting this 
configuration of the CT-tail may be favourable.  
 
While the structure was observed to display flexible motions during the 
simulation, full correlation analysis gave a very different result. The main correlated 
motion extracted by FCA showed small movements in the CR domain and also the 
CT-tail but relatively little change in the overall structure of the receptor (Figure 4.2A 
and B). Furthermore, projection on the first eigenvector showed the main motion was 
confined to a small range (as seen in the low magnitude of the projection) and that it 
occurred in the last 50 ns of the simulation (Figure 4.2C). These two results indicate 
that while the wt-IR had the propensity to sample a wide range of motions, it could not 
find a stable configuration and consistently returned to a similar conformation as that 
of the starting structure. 
 
 
Figure 4.1: Comparison of the smallest and largest angles of the L2 domain relative to the L1 
domain seen in the wt-IR simulation. The angle of the L2 domain covered a range between 78° (A) 
to 125° (B). The angle was measured using the C-α atoms of residues Glu120, Arg14 and Lys425 as 
reference points. The wt-IR was observed in the MD simulation to sample a wide range of motions that 
substantially moved the L2 domain relative to the L1 domain. 
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Figure 4.2: Projection and visualisation of the movement of wt-IR along the first eigenvector. A, 
the structure of wt-IR at the beginning of eigenvector 1. B, the same structure at the end of the extracted 
motion. C, projection on eigenvector 1 showing the conformational change of the receptor occurred in 
the last 50 ns of the simulation. The minimal change in the overall structure of the wt-IR suggests that 
this conformation is the most stable and that the structure only began sampling other conformations in 
the last 50 ns of the simulation. 
 
Multiple studies have demonstrated that the IR undergoes a conformational 
change upon the binding of insulin (Donner & Yonkers, 1983; Maturo, Hollenberg, & 
Aglio, 1983; Pilch & Czech, 1980). The conformational change itself, however, is 
currently unknown as the available insulin-bound crystal structures of the IR 
(3W11-3W14 and 4OGA) were resolved with a minimalised receptor involving only 
the L1 and CR domains as well as the CT peptide (Menting et al, 2013; Menting et al, 
2014). Although 3W14 does include the L2 and FnIII-1 domains, the domains were 
not crystallised in their native positions leaving their positions in the insulin-bound 
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conformation unconfirmed. Considering the wt-IR was simulated in the absence of 
insulin, the lack of any notable conformational changes in the main correlated motion 
of the wt-IR simulation was not surprising. The results from the wt-IR simulation were 
then used to compare against those observed in the IR-R86P to identify conformational 
changes and motions that may result from the mutation.  
 
 MD SIMULATION OF IR-R86P MUTANT SUGGESTS A POTENTIAL SWITCH 
COMPONENT 
The IR-R86P mutant receptor was simulated for 258 ns under the same 
conditions used in the wt-IR simulation. Similar to the wt-IR simulation, the IR-R86P 
structure was observed to undergo conformational changes where the angle formed by 
the L1 and L2 domains ranged between 72° and 117° (Figure 4.3). However, the 
centres of mass distance between the L1 and L2 domains displayed much more 
variability than that observed for wt-IR, ranging from 41.7 Å to 51.8 Å.  
 
Full correlation analysis of the IR-R86P simulation found that the main motion 
experienced by the receptor was not the conformational change mentioned above. 
Instead, the main conformational change occurred in a small region of the CR domain 
that encompassed residues Cys266 to His275 of the CR domain (green region in 
Figure 4.4A and B). This region of the CR domain was found to rotate from being 
adjacent to the L1 domain to being adjacent to the L2 domain. The CT-tail was also 
observed to shift away from the moved region of the CR domain towards the CT 
α-helix and L1 domain. The distance between the CT-tail and the CR domain, 
measured using Arg270 on the CR domain and Phe714 on the CT-tail, ranged between 
~8 Å when the two regions were in close proximity to >23 Å after the movement of 
the CR domain. The rest of the receptor remained relatively unchanged in the first 
eigenvector indicating that the motion of the CR domain contributed to the majority of 
the captured motions in the simulation. Visualisation of eigenvector 2 confirmed that 
the more prominent conformational change of the L2 domain observed in the 
simulation was the second highest correlated motion (Figure 4.4C and D). 
Interestingly, the conformational change observed for the L2 domain was found to 
have occurred in the opposite direction to what was observed in the IR[1-468, CTex] 
structure (Figure 3.18). 
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Figure 4.3: Comparison of the smallest and largest angles of the L2 domain relative to the L1 
domain seen in the IR-R86P simulation. The angle of the L2 domain covered a range between 72° 
(A) to 117° (B). The angle was measured using the C-α atoms of residues Glu120, Arg14 and Lys425 
as reference points. The IR-R86P structure sampled similar conformations compared to that observed 
in the wt-IR simulation. Analysis of these conformations however, showed the L1 and L2 domains in 
the IR R86P structure had sampled conformations that placed them over 10 Å away from each other, a 
much larger distance compared to that measured for the wt IR structure. 
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Figure 4.4: Visualisation of the movement and conformational change of IR-R86P along the first 
two eigenvectors. A, structure of IR-R86P at the beginning of eigenvector 1 (displaced region of CR 
domain is shown in green). B, structure of IR-R86P showing the position of the CR domain at the end 
of the motion in eigenvector 1. C, structure of IR-R86P at the beginning of eigenvector 2. D, structure 
of IR-R86P showing the position of the L2 domain at the end of the motion in eigenvector 2. These 
conformational changes indicate that the displacement of the CR domain seen in eigenvector 1 
contributed to more of the motions in the simulation compared to the larger, more prominent 
conformational change of the L2 domain seen in eigenvector 2. 
128 
128 Chapter 4: Understanding the IR and identification of possible key residues 
Projection on eigenvectors of the IR-R86P simulation showed that the main 
extracted motion occurred around 100 ns. A closer examination of the simulated 
trajectory found the two interactions previously identified between the CR and L2 
domains (Glu329-Arg270 and Lys310-Glu287) (Table 3.2) broke apart two 
nanoseconds prior to the main conformational change. On the other hand, the 
conformational change in the second eigenvector occurred around 10 ns into the 
simulation, potentially an early response of the receptor to the R86P mutation. From 
the simulation data, it appears that mutation of Arg86 to proline resulted in the 
conformational change of the receptor (as seen in eigenvector 2), bringing it into the 
conformation shown in Figure 4.4D. This conformation may have gradually increased 
the stress on the interactions linking the L1 and L2 domains which eventually broke 
apart, triggering another response from the receptor (in this case, the change in CR 
domain seen in eigenvector 1). 
 
 
Figure 4.5: Projection on the first three eigenvectors of the IR-R86P simulation. The projection of 
the simulation onto the first three eigenvectors show the main conformational change occurred around 
100 ns while the motion in eigenvector 2 occurred around 10 ns into the simulation. This data 
demonstrates that the IR-R86P structure experienced more conformational changes compared to that 
determined in the wt-IR and may elucidate conformational changes that may be unique to receptor 
activation. 
 
Comparison of the wt-IR and IR-R86P MD simulations found different 
inter-domain interactions between the structures. These variations formed the basis for 
predicting A-chain of events that may potentially occur during insulin binding. 
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Analysis of the two simulated trajectories (wt-IR versus IR-R86P) found Arg114 
adopted a very different position in the IR-R86P construct compared to the wt-IR 
(Figure 4.6). Further examination of the IR-R86P simulation found that this residue 
formed a small salt bridge network with Asp250 and Arg83, an interaction that existed 
for over 95% of the simulation. Conversely, this same interaction between Arg114 and 
Asp250 was only observed to form ~21 ns into the wt-IR simulation and lasted 14 ns 
before Arg114 broke away and, for the remaining 291 ns of the simulation, formed no 
additional interactions with other residues on the receptor.  
 
 
Figure 4.6: Depiction of the salt bridge network observed in the IR-R86P simulation. A salt bridge 
network was observed between Asp250, Arg114 and Arg83 during the IR-R86P simulation (B) that was 
not observed in the wt-IR simulation (A). This interaction was speculated to play a role in a potential 
switch function of the receptor that may be responsible for activation.  
 
Approximately 58 ns into the wt-IR simulation, Asp250 broke its interaction 
with Arg83 and formed a salt bridge with Arg86 (Figure 4.7). This interaction is, of 
course, disrupted by mutation of Arg86 to proline. Importantly, in the simulation of 
the IR[merge] structure, the C-terminal acid of the insulin B-chain tail was found to 
contact Arg86 on the receptor (Figure 3.33, p115). Therefore, it was hypothesised that 
Arg86 is salt bridged to Asp250 in the unbound receptor and upon the binding of 
insulin, breaks away and contacts the insulin B-chain C-terminal acid. Following this, 
Asp250 would then be available to form salt bridges with Arg114 and Arg83 which 
could then potentially trigger a much larger rearrangement of the C-terminal portion 
of the CR domain.  
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Figure 4.7: A comparison of the wt-IR and R86P structures superimposed along the L1 domain. 
Structure of the wt-IR (green) superimposed onto the IR-R86P structure (blue). The differences between 
residue interactions are shown in the expanded view where the smaller stick representation belongs to 
the wt-IR structure and the larger stick representation belongs to the IR-R86P structure. The differences 
between these two structures led to the proposal of a series of events that may be involved in receptor 
activation. 
 
This proposed chain of events and the previous simulation work with the IR[merge] 
structure provides explanations for the intriguing behaviour reported for the R86P 
mutation (Longo et al, 1993). Firstly, mutation of Arg86 to a proline residue would 
result in the permanent loss of the interaction between Arg86 and Asp250 and allow 
the latter residue to salt bridge with Arg114 and Arg83. The formation of the salt 
bridge interactions between Asp250, Arg114 and Arg83 was proposed to act as a 
switch in the receptor and cause subsequent changes in the receptor that lead to 
receptor activation. Thus, permanent loss of the interaction between Arg86 and 
Asp250 directly affected the proposed switch function, resulting in the reported 
constitutive activation of the R86P receptor (Longo et al, 1993). 
 
Secondly, mutation of Arg86 to proline would result in a loss of the interaction 
between Arg86 and the insulin B-chain C-terminal acid shown in Figure 3.33. This 
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interaction may play a role in the initial binding of insulin and mutation of Arg86 could 
have potentially affected the receptor’s affinity to bind insulin. However, a study using 
truncated insulin analogues engineered to exclude residues B26-B30 were still able to 
bind the IR with comparable affinity to native insulin (Fischer et al, 1985). This 
indicates that a loss of the interaction between the C-terminal acid and Arg86 may not 
be the underlying cause of the R86P mutation’s effect of abolishing insulin binding 
completely. Interestingly, the CT peptide was observed in this simulation to have 
increased mobility compared to the wt-IR simulation suggesting the R86P mutation 
may have affected the stability of the CT peptide. Given that Arg86 sits on the 
prominent loop on the L1 domain that contacts the CT peptide, it is possible that 
mutation of this residue affected the CT peptide’s ability to rearrange into the position 
observed in the insulin-bound IR crystal structure (Figure 3.15). This may explain 
why the R86P mutation was reported to result in complete abolishment of insulin 
binding (Longo et al, 1993). 
 
A past mutagenesis study investigated the impact of a mutation from Asp250 to 
alanine and found that it did not have a significant effect on insulin binding (Whittaker 
et al., 2002). Although this mutation did not affect low affinity binding of insulin, the 
study used the extracellular domains of the IR, previously found to only exhibit the 
low-affinity binding state (Ward & Lawrence, 2009) and therefore would not be able 
to detect high-affinity insulin binding. Importantly, Arg86 was hypothesised to interact 
with insulin and that the R86P mutation removed this interaction resulting in loss of 
insulin binding. The D250A construct investigated by Whittaker et al (2002), did not 
mutate Arg86 and therefore retained its ability to bind insulin. Based on the 
abovementioned hypothesis, mutation of Asp250 to an alanine would result in the loss 
of the interactions between Asp250, Arg114 and Arg83, removing the proposed switch 
function that may trigger other changes in the receptor leading to activation. 
 
The potentially important interactions identified in this chapter and the previous 
chapter were further investigated using mutant models to gauge their effects on 
receptor structure and its ability to bind insulin. 
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 IDENTIFICATION OF RESIDUES IMPORTANT FOR RECEPTOR FUNCTION 
Detailed analyses of the IR[1-468, CT] model, the IR-R86P model and the available 
IR crystal structures allowed the identification of specific interactions between 
residues that may play important roles in insulin binding. Mutation of the residues 
involved in the identified interactions may result in a change to the receptor’s structural 
conformation which could in turn affect its ability to bind insulin. Four select residues 
were mutated in silico before assessing their effects on receptor conformation via MD 
simulations.  
 
Mutation 1: Arginine 114 → Alanine (IR-R114A) 
A potentially important interaction between residues on the L1 and CR 
domains was observed in the IR-R86P simulation. One of the residues involved in this 
interaction was Arg114 which formed a salt bridge with Asp250 and could act as a 
switch during ligand binding. Furthermore, Arg114 was identified in a bioinformatics 
study to be highly conserved through evolution of IRs in vertebrates (Renteria et al, 
2008). A mutation from Arg114 to alanine (Figure 4.8A) would disrupt the identified 
interactions and cause a) loss of the salt bridge between Arg114, Asp250 and Arg83 
resulting in no or diminished receptor activation and b) be expected to display reduced 
insulin binding activity. 
 
Mutation 2: Glutamic Acid 329 → Alanine (IR-E329A) 
A salt bridge between Glu329 on the L2 domain and Arg270 on the CR domain 
was identified during simulations of the IR[1-468, CT] and IR cyc-CT structures (Figure 
4.8B). This interaction could potentially act as a mediator that facilitates the formation 
of the salt bridge network discussed in the Chapter 3 (Figure 3.19, p92). Furthermore, 
the residues involved in the salt bridge network were found to be highly conserved 
(Renteria et al, 2008) and thus speculated to play important roles in receptor 
functionality. Therefore, disruption of the salt bridge between Glu329 and Arg270 via 
a mutation of Glu329 to alanine could potentially result in a reduced capacity of the 
domains to form the identified salt bridge network. These interactions between the L1 
and L2 domains may facilitate the stabilisation of the insulin binding conformation 
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and a reduction in the formation of the salt bridge network could affect the receptor’s 
ability to bind insulin. 
 
Mutation 3: Alanine 351 → Aspartic Acid (IR-A351D) 
In the IR[1-468, CT] structure, Phe714 on the CT peptide was seen to be buried in 
the hydrophobic pocket of the L2 domain. This interaction appeared to help position 
and stabilise the CT peptide in relation to the rest of the receptor. Importantly, Phe714 
has previously been found in an alanine mutagenesis study to be important for insulin 
binding as mutation of this residue resulted in a 182-fold decrease in the receptor’s 
affinity for insulin (Mynarcik et al, 1997a).  
 
Conversely, the insulin-bound crystal structure (4OGA) found Phe714 to be 
buried within the interface between the CT peptide and insulin. Modelling of the 
IR[merge] structure found PheB25 on the insulin B-chain tail was ideally positioned to 
be buried within the hydrophobic pocket on the L2 domain. PheB25 has been 
demonstrated to be critical for ligand binding as mutation of this residue to alanine or 
histidine resulted in a significant reduction in the affinity towards the IR (displays 3% 
and 33% of native insulin binding activity respectively) (Glendorf et al, 2011). The 
same study also mutated PheB25 to tyrosine and found it increased insulin binding 
activity by three-fold compared to native insulin (Glendorf et al, 2011). Since tyrosine 
is another hydrophobic residue with a similar aromatic ring, it is possible that tyrosine 
is able to fit into the same hydrophobic binding pocket as PheB25 in the IR[merge] 
structure and possibly form an interaction with the receptor resulting in enhanced 
binding.  
 
To test the possibility of the interaction between the hydrophobic pocket on the 
L2 domain and either Phe714 or PheB25, one of the residues located on the edge of 
the hydrophobic pocket, Ala351, was mutated. Mutation of Ala351 to an aspartic acid 
(Figure 4.9A) would create a large steric barrier preventing entry to the pocket on the 
L2 domain. This mutation would affect the stability of the CT peptide relative to the 
rest of the receptor (in the case of Phe714) or affect the binding stability of insulin to 
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the receptor (in the case of PheB25). This should in turn cause a reduction in the 
binding affinity between receptor and ligand. 
 
Mutation 4: Glutamic Acid 438 → Alanine (IR-E438A) 
As discussed in Chapter 3, a salt bridge between Arg717 on the CT-tail and 
Glu438 on the L2 domain was identified in preliminary work performed by Dr Croll 
on the IR[1-468, CT] structure. This interaction was also seen to remain stable throughout 
subsequent simulations that stemmed from this structure. The salt bridge between these 
residues could potentially stabilise the position of the CT-tail relative to the L2 domain 
allowing the receptor to bind insulin. Therefore, a mutation of Glu438 to alanine 
(Figure 4.9B) would prevent the formation of the potential stabilising interaction 
which could in turn affect both the positioning of the CT peptide and insulin binding 
affinity. 
 
Molecular models of the IR mutations described above were generated and 
simulated to investigate their effects on the receptor. Conformational changes 
identified in these simulations were compared against those seen in the wt-IR 
simulation. Comparison between these simulations would enable identification of 
distinct conformational changes that are potentially responsible for different receptor 
functions such as ligand binding or activation.  
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Figure 4.8: IR structure showing the interactions that would be disrupted by mutations R114A and E329A. A, IR structure showing the identified interaction between 
Arg114, Asp250 and Arg83. Arg114 was selected as a potential mutation site and it was proposed that mutation of this residue to an alanine would disrupt the interaction with 
Asp250 and cause loss of receptor activation. B,IR structure showing the identified interaction between Glu329 and Arg270. This interaction was proposed to play a potential 
role in stabilisation of the CR and L2 domains as well as act as a mediator that facilitates the formation of the salt bridge network discussed in the Chapter 3 (Figure 3.19, p92). 
Disruption of this via a mutation of Glu329 to an alanine residue could potentially affect insulin binding by indirectly affecting the formation of the salt bridge network. 
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Figure 4.9: IR structure showing the interactions that would be disrupted by potential mutations A351D and E438A. A, IR structure showing the identified interaction 
between Phe714 and the hydrophobic pocket. It was proposed that by mutating a hydrophobic residue on the edge of the pocket, it would result in an unfavourable environment 
for Phe714 and prevent it forming the interaction shown. B, IR structure showing the identified interaction between Glu438 and Arg717. This interaction was observed in 
preliminary work performed by Dr Croll and was also observed to remain stable in simulations of this structure. It was proposed that mutation of Glu438 to an alanine residue 
would disrupt this interaction and potentially destabilise the CT peptide which may in turn affect insulin binding. 
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 SIMULATION AND ANALYSIS OF MUTATION 1: IR-R114A  
Raw simulation analysis 
The mutation, R114A, was designed to disrupt the formation of the salt bridge 
between Arg114 and Asp250 and could result in a receptor that cannot be activated 
but retain its ability to bind insulin. Therefore, MD simulations of this mutant IR 
construct would potentially enable the identification of distinct conformations between 
insulin binding and receptor activation  
 
The IR-R114A mutant construct was simulated for 318 ns under standard 
conditions. Similar to the wt-IR simulation, the range of motions sampled by this 
construct saw the angle formed by the L1 and L2 domains reach between 77° and 111° 
(Figure 4.10). The distances between the centres of mass of the L1 and L2 domains 
for both angles were found to be 42.2 Å and 41.1 Å respectively. This was interesting 
because unlike the wt-IR simulation, the L2 domain here moved closer to the L1 
domain despite having a larger measured angle. This may be due to the formation of 
different interactions compared to other simulated structures such as the IR[1-468, CTex] 
and IR cyc-CT models. In the IR-R114A simulation, only residues Arg331, Glu353, 
Glu355, Arg383 and Ser719 were observed to form, while Arg14, Asp12 and Arg19 
on the L1 domain no longer formed interactions with residues on the L2 domain.  
 
As seen in Figure 4.11, the two salt bridges that linked the L1 and L2 domains 
were not present in this simulation. A more detailed examination of this region found 
three different interactions that formed between the L1 and L2 domains and the CT 
peptide (Figure 4.12). The first interaction was a hydrogen bond formed by Asn348 
on the L2 domain and Asp12 on the L1 domain. Not only was this interaction the only 
link between the L1 and L2 domain, it also didn’t form until the last four nanoseconds 
of the simulation. This suggests that the structural rearrangment of the L2 domain was 
not dependent on the formation of the interactions between the L1 and L2 domains and 
other factors may have induced the structural rearrangements in the simulation. The 
formation of the hydrogen bond between Asn348 and Asp12 was most likely a result 
of the L2 domain moving closer to the L1 domain rather than being the cause of the 
rearrangment of the L2 domain. Interestingly, Asp12 has been shown in previous 
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alanine mutagenesis studies to reduce the IR’s affinity towards insulin by 
approximately 5- to 6.2-fold (Mynarcik et al, 1997b; Williams et al, 1995). This 
suggests that although Asp12 is not essential for high affinity insulin binding, the 
residue may play a smaller role in the IR such as the interaction seen in this simulation 
(forming a link between the L1 and L2 domain). However, in the latest insulin-bound 
IR crystal structure (4OGA), Asp12 was found to be positioned parallel to TyrB26 on 
the insulin B-chain tail (Menting et al, 2014). It is possible that upon insulin binding, 
TyrB26 is brought into close proximity to Asp12 and disrupts its interaction with 
Asn348, potentially triggering subsequent events in response. However, without a 
complete insulin-bound IR crystal structure, these speculations have yet to be verified.  
 
 
Figure 4.10: Comparison of the smallest and largest angles of the L2 domain relative to the L1 
domain seen in the IR-R114A simulation. The angle of the L2 domain covered a range between 77° 
(A) to 111° (B). The angle was measured using the C-α atoms of residues Glu120, Arg14 and Lys425 
as reference points. The change observed in the IR-R114A simulation was similar to that observed in 
the wt-IR simulation.  
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Figure 4.11: Residues involved in the salt bridge network in the IR[1-468, CT] simulation shown in 
their observed positions in the IR-R114A simulation.  Residues Arg331, Glu353, Glu355, Arg383 
and Ser719 formed the same interactions as those in the IR[1-468, CT] simulation. Arg14, Asp12 and Arg19 
on the L1 domain no longer formed interactions with residues on the L2 domain. Mutation of Arg115 
to an alanine residue appeared to have an adverse effect on the formation of the salt bridge network that 
was observed in the IR[1-468, CT] simulation.  
 
Both the second and third interactions involved Tyr708 on the CT peptide which 
formed interactions with Gln34 and Arg14 on the L1 domain. While Gln34 formed an 
interaction with the phenolic hydroxyl group on Tyr708, Arg14 was in contact with 
the backbone of Tyr708. Interestingly, in the latest insulin-bound crystal structure of 
the IR (4OGA), Arg14 was also found to be in contact with the CT peptide backbone. 
However, the residue in contact with Arg14 was Val713 and not Tyr708 from the 
IR-R114A simulation. This was due to the IR-R114A model being based on the earlier 
IR[1-468, CT] structure which did not have the extra loop in the CT peptide α-helix seen 
in the 3W11 crystal structure. If a similar structure of the CT peptide was to be 
introduced into the IR-R114A model, Arg14 could potentially be positioned in close 
proximity to Val713 where a similar interaction to that seen here may be formed.  
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Figure 4.12: The three interactions between the L1 and L2 domains and the CT peptide that were 
observed in the IR-R114A simulation. It was observed in the IR-R114A simulation that residues 
Asn348 and Asp12 formed a salt bridge that linked the L1 and L2 domains while Gln34, Arg14 and 
Tyr708 formed interactions that linked the L1 domain and the CT peptide. These interactions may have 
formed to replace the interactions between the L1 and L2 domains in the salt bridge network that were 
lost (Figure 4.11).  
 
Full correlation analysis (FCA) 
FCA of the IR-R114A simulation showed that the collective motions represented 
by the first 10 eigenvectors accounted for 77.5% of all the motions in the trajectory 
(Table 4.1). The percentage of total variance (PTV) for the first eigenvector was 
calculated to be over 40%, indicating that the main motion belonging to the first 
eigenvector represented almost half of all the motions in the simulation. Visualisation 
of the first eigenvector (Figure 4.13) showed that the main motion was the 
rearrangement of the L2 domain, similar to that seen in the TMD simulations of the 
IR cyc-CT and IR[1-468, CTex] structures. Although the motion depicted in Figure 4.13 
was similar to previous simulations, a much larger portion of the L2 domain 
rearrangement was determined to belong to the first eigenvector. Furthermore, the CT 
peptide was also seen to condense in size, where the CT-tail moved closer towards the 
CT α-helix, similar to the conformational change seen in preliminary work performed 
by Dr Croll (Figure 3.5).  
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Table 4.1: List of the first 10 eigenvectors of the IR-R114A and their percentage of total variance 
(PTV).  
Eigenvector Percentage 
1 40.4 
2 18.1 
3 7.8 
4 2.8 
5 2.5 
6 1.4 
7 1.4 
8 1.2 
9 1.0 
10 0.9 
Total 77.5 
 
 
Figure 4.13: Movement of IR-R114A along the first eigenvector. The conformational change of the 
IR-R114A structure along the main extracted motion represented by eigenvalue 1. A, the structure of 
IR-R114A at the beginning of the extracted motion. B, the same structure at the end of the extracted 
motion. The IR-R114A  structure after the conformational change was similar to the conformation of 
the receptor seen in preliminary work performed by Dr Croll. 
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Projection on the first eigenvector showed that a conformational change of the 
IR-R114A structure began at approximately 45 ns (Figure 4.14). The main 
conformational change was the structural rearrangement of the L2 domain indicating 
that the L2 domain began its transition towards the L1 domain early in the simulation 
before coming into close proximity with the L1 domain shortly after (as seen in Figure 
4.14 where the transition of eigenvector 1 was complete around 60 ns). This also 
supports the previous speculation that the rearrangement of the L2 domain facilitated 
the formation of the inter-domain salt bridge (Asn348 on the L2 domain and Asp12 on 
the L1 domain) as the interaction did not form until the last four nanoseconds. Around 
125 ns into the simulation, a spike was observed in the projections of both eigenvector 
1 and 2 indicating a sudden change in the receptor had occurred. Examination of the 
simulation around this time point found the L2 domain underwent a sudden change 
where it was moved away from the L1 domain. Closer analysis of the structure showed 
a previously identified salt bridge (Lys310-Glu287) formed around this time causing 
the L2 domain to be pulled upwards. This movement lasted for approximately 6 ns 
before the salt bridge broke apart and the L2 domain reverted back to its previous 
position. Although the exact reason for this occurrence is not entirely clear, this event 
shows that interactions linking the CR and L2 domains have a direct impact on the 
conformation of the receptor. 
 
Figure 4.14: Projection on the first three eigenvectors of the IR-R114A simulation. The projection 
of the simulation onto the first three eigenvectors show the main conformational change occurred 
around 45 ns. This conformational change was the structural rearrangement of the L2 domain and is 
speculated to have facilitated the formation of the interaction between the L1 and L2 domains. A spike 
around 125 ns was observed in the projections on eigenvectors 1 and 2 and indicated a change in the 
structure’s conformation had occurred. Closer examination showed the formation of a previously 
identified salt bridge between Lys310 and Glu287 caused the L2 domain to be temporarily pulled 
upwards away from the L1 domain. This event was short-lived, lasting only 6 ns, after which the L2 
domain reverted back to its previous position. This event demonstrates the effects on the receptor that 
can be caused by formation of interactions between the CR and L2 domain. 
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 SIMULATION AND ANALYSIS OF MUTATION 2: IR-E329A 
Raw simulation analysis 
The E329A mutation was designed to disrupt the formation of the salt bridge 
between Glu329 and Arg270 that was observed in previous simulations to link the L2 
and CR domains. The identified interaction was speculated to act as a potential 
mediator that aids the formation of the salt bridge network shown in Figure 3.19 as 
well as stabilise the position of the two domains. Therefore, disruption of this 
interaction would affect formation of the salt bridge network and could potentially lead 
to the destabilisation of the L2 and CR domains.  
 
The IR-E329A mutant construct was simulated for 336 ns under physiological 
conditions. It was initially thought that the interaction between Glu329 and Arg270 
facilitated the rearrangement of the L2 domain, positioning it closer towards the L1 
domain. This would in turn bring Glu353 on the L2 domain closer to Arg19 on the L1 
domain allowing the formation of the salt bridge network seen in Figure 3.19. 
Unexpectedly, as seen in Figure 4.15, despite the disruption to the interaction between 
Glu329 and Arg270, the L2 domain was still observed to undergo a substantial 
conformational change. Although the rearrangement of the L2 domain occurred in the 
same direction as those observed in previous simulations, the range of motions 
sampled by this construct was larger as the angle formed by the L1 and L2 domains 
reached up to 154°, with the smallest angle being 80°. In comparison, the next largest 
angle was observed in the A351D simulation and only reached 143°. The distances 
between the centres of mass of the L1 and L2 domains for both angles were found to 
be 43.1 Å and 39.4 Å respectively indicating the conformational change brought the 
L2 domain ~4 Å closer towards the L1 domain. 
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Figure 4.15: Comparison of the smallest and largest angles of the L2 domain relative to the L1 
domain seen in the IR-E329A simulation. The angle of the L2 domain covered a range between 80° 
(A) to 154° (B). The angle was measured using the C-α atoms of residues Glu120, Arg14 and Lys425 
as reference points. The conformational change of the L2 domain observed here was larger than that 
observed for other structures despite disrupting the interaction between Glu329 and Arg270 which was 
speculated to facilitate the rearrangement of the L2 domain. 
 
Closer examination of this structure found only residues Glu353, Arg331, Asp12 
and Arg14 formed interactions that linked the L1 and L2 domains (Figure 4.16). The 
other residues that were previously observed to form the salt bridge network in the 
IR[1-468, CTex] simulation, Ser719, Arg19, Glu355 and Arg383, were no longer 
positioned close enough to associate with each other (Figure 4.16). Unlike the 
IR[1-468, CTex] simulation, Glu353 was no longer in contact with Arg19 but instead 
formed an interaction with Arg14, possibly a result of the larger rearrangement of the 
L2 domain.  
 145 
Chapter 4: Understanding the IR and identification of possible key residues 145 
 
Figure 4.16: Residues involved in the salt bridge network in the IR[1-468, CTex] simulation shown in 
their identified positions in the IR-E329A simulation. Individual salt bridges formed between 
Arg383-Glu355, Arg14-Asp12 and Glu353-Arg331 while Ser719 and Arg19 no longer formed salt 
bridge interactions. The network of salt bridges in the IR-E329A simulation was completely different 
compared to the IR[1-468, CTex] simulation. 
 
Interestingly, while the interaction between Glu329 and Arg270 was disrupted 
in this mutant structure, another previously identified interaction (Lys310 - Glu287) 
(Figure 3.12) was seen to remain stable throughout the entire IR-E329A simulation. 
Considering the E329A mutation resulted in such a substantial conformational change 
of the receptor, it is possible that the salt bridge between Glu329 and Arg270 was in 
place to restrict the range of movement of the L2 domain and loss of this interaction 
possibly resulted in the motion shown in Figure 4.15. Furthermore, the salt bridge 
formed by Glu329 and Arg270 may have helped position residues on the L1 and L2 
domains to form the salt bridge network in the IR[1-468, CTex] simulation. It is therefore 
possible that the rearrangement of the L2 domain could potentially represent the 
receptor’s response to the binding of insulin. Although the L2 domain has not yet been 
resolved in an insulin-bound crystal structure (its position during insulin binding is 
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unknown), the simulation work performed in Section 3.2.6 indicate that the 
conformational change of the L2 domain is compatible with the structures resolved in 
the IR crystal structures (3W11, 4OGA).  
 
Intriguingly, the CT peptide was seen in the IR-E329A simulation to undergo a 
conformational change where an extra loop in the CT α-helix was partially formed 
(Figure 4.17). A similar structure of the CT peptide was observed in the insulin-bound 
IR crystal structure (3W11), indicating that the structural changes seen in this 
simulation could potentially show the receptor’s conformational change during the 
binding of insulin. On the other hand, it is also possible that the structural 
rearrangement of the L2 domain is distinctly separate to the conformational change of 
the CT peptide. To test whether the two observed motions are linked, a new model of 
the IR-E329A structure could be used where the CT peptide is replaced with the 
cyc-CT peptide (Figure 3.22). Substitution with the cyc-CT peptide would 
dramatically lower its flexibility and prevent it from undergoing the same 
conformational change shown in Figure 4.17. If the two conformations are linked, 
then the rearrangement of the L2 domain should not occur. However, if the opposite 
is true, then the L2 domain should undergo a similar rearrangement to that shown in 
Figure 4.15. 
 
Although the CT peptide in the IR-E329A simulation was observed to form an 
extra loop in its α-helix similar to that observed in the insulin-bound IR crystal 
structure (3W11), the position of the CT peptide itself was not observed to undergo 
the same change. As shown in Figure 4.18, unlike the CT peptide in the 3W11 crystal 
structure, the CT peptide in the IR-E329A simulation was not observed to shift across 
the face of the L1 domain. Instead, the position of the CT peptide remained similar to 
that seen in the 3LOH IR crystal structure (insulin is absent in this structure). This 
suggests that formation of the extra loop in the CT peptide α-helix may be independent 
to its rearrangement across the face of the L1 domain. Alternatively, considering the 
CT peptide was observed to only partially form the extra loop in the CT peptide 
α-helix, it is also possible that the CT peptide is required to shift across the face of the 
L1 domain in order for the extra loop to fully form. 
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Figure 4.17: The change in conformation of the CT peptide observed in the IR-E329A simulation. 
The CT peptide was observed to undergo a conformational change where it transitioned from the 
structure in the starting position (A) to a structure with a partially formed loop in the ending position 
(B). The conformational change involved movement of residues to begin formation of an extra loop at 
the end of the CT α-helix, a structure similar to that observed in the insulin-bound IR crystal structure 
(3W11). Residues Asn711 and Val713 are visualised in stick representation to show the change in their 
positions.  
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Figure 4.18: Comparison of the CT peptide position between the IR-E329A simulation and 3W11 
crystal structure. The CT peptide in the IR-E329A simulation was not observed to make the same shift 
in position despite partially forming an extra loop in its α-helix that was similar to that observed in 
3W11. The CT peptide in the IR-E329A simulation is coloured red while the CT peptide from the 3W11 
crystal structure is coloured green. The L1 domain is coloured blue. 
 
Full correlation analysis (FCA) 
Analysis of the IR-E329A simulated trajectory using FCA showed that the 
collective motions represented by the first ten eigenvectors accounted for 84.4% of the 
total unique motions detected for the simulation (Table 4.2). The motion described by 
the first eigenvector was determined by FCA to have a PTV of 66.5%, almost 
two-thirds of the total movement of the protein in the simulation. Not surprisingly, 
visualisation of the movement along the first eigenvector showed that the major motion 
in the IR-E329A simulation was the large rearrangement of the L2 domain (Figure 
4.19). The conformational change of the CT peptide was also determined by FCA to 
belong to the same eigenvector as the L2 domain rearrangement suggesting the two 
motions are linked. 
 
 
 
 149 
Chapter 4: Understanding the IR and identification of possible key residues 149 
Table 4.2: List of the first 10 eigenvectors of the IR-E329A and their percentage of total variance 
(PTV).  
Eigenvector Percentage 
1 66.5 
2 6.7 
3 3.6 
4 2.2 
5 1.1 
6 1.1 
7 1.0 
8 0.9 
9 0.8 
10 0.6 
Total 84.4 
 
 
Figure 4.19: Movement of IR-E329A along the first eigenvector. The conformational change of the 
IR-E329A structure along the main extracted motion represented by eigenvalue 1. A, the conformation 
of the IR-E329 structure at the beginning of the extracted motion. B, the same structure after the 
extracted motion has occurred. The large conformational change was speculated to be a result of the 
loss of the interaction between Glu329 and Arg270. This interaction may play a role in restricting the 
extent of the motion of the L2 domain. 
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Interestingly, visualisation of the motion along the second eigenvector showed 
displacement of the CR domain (Figure 4.20). This displacement of the CR domain 
involved regions in close proximity to Glu329 and Arg270 and shares similarities to 
that seen in the IR-R86P simulation (Figure 4.4A and B). Thus, similar to the R86P 
mutation, the E329A mutation could potentially lead to a constitutively activated 
receptor. Unlike the R86P mutation however, this receptor construct retains the Arg86 
residue and, based on my hypothesis, should still bind insulin.  
 
 
Figure 4.20: Movement of IR-E329A along the second eigenvector. The conformational change of 
the IR-E329A along the second eigenvector where the displaced region of the CR domain is shown in 
green. A, the conformation of the IR-E329A structure at the beginning of the extracted motion. B, the 
same structure after the extracted motion has occurred. Residues Arg270 and Ala329 are shown in stick 
representation and indicated by red arrows. This change in the CR domain was similar to that seen in 
the IR-R86P simulation and suggests the R114A mutation may also cause constitutive activation of the 
receptor. 
 
Projection on the first eigenvector showed that the major conformational change 
that represented approximately two-thirds of the IR-E329A simulation began at 
~70 ns. The change occurred gradually over the next 100 ns before settling for the 
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remainder of the simulation. The projections indicated that the conformational change 
was not an instant reaction to the mutation of E329A suggesting another component 
may have triggered the motion in the first eigenvector. Interestingly, the projection on 
the second eigenvector showed a conformational change happening at almost the same 
time (70 ns) indicating that the motion of the CR domain in Figure 4.20 led to the 
rearrangement of the L2 domain in Figure 4.19. The importance of this region was 
demonstrated in experiments performed by Kristensen et al (2002). In this study, 
truncated receptors of varying lengths were assayed for their ability to bind insulin and 
their binding affinities were measured. It was found that a truncated receptor consisting 
of the first 308 residues (L1 and CR domain) fused to the CT peptide bound insulin 
with a decreased affinity of 45 nM while a similar construct containing the first 255 
residues (missing the displaced region of the CR domain in Figure 4.20) had no 
detected insulin binding. It is therefore possible that the CR domain plays a role in 
insulin binding that has yet to be elucidated. Alternatively, it is also possible that the 
308+CT construct simply allowed the CT peptide to be oriented correctly and allowed 
it to bind insulin, albeit with a decreased affinity. The 255+CT construct on the other 
hand, may not have positioned the CT peptide in a favourable position that would 
allow it to bind insulin with a detectable affinity.  
 
 
Figure 4.21: Projection on the first three eigenvectors of the IR-E329A simulation. The projection 
of the simulation onto the first three eigenvectors show the main conformational change began around 
70 ns and gradually occurred over a 100 ns period. The motion in eigenvector 2 was found to also occur 
around 70 ns suggesting the observed conformational changes are linked. It was speculated that the 
motion in eigenvector 2 may have triggered a change in the receptor that led to the motion in eigenvector 
1. 
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 SIMULATION AND ANALYSIS OF MUTATION 3: IR-A351D 
Raw simulation analysis 
The A351D mutation was designed to disrupt the interaction between the 
hydrophobic pocket on the L2 domain and Phe714 (Figure 4.9A, p136). Later models 
of an insulin bound receptor suggested PheB25 (on insulin) could also potentially 
interact with this pocket. Mutation of the small hydrophobic alanine to a bulky, 
charged aspartic acid would create an unfavourable environment for the hydrophobic 
residues and block their binding to the binding pocket. Disruption of either of these 
interactions could potentially affect the receptor’s insulin binding capability.  
 
The IR-A351D structure was simulated for 463 ns where Phe714 was observed 
to dislodge from the hydrophobic pocket it was initially in contact with (Figure 4.22). 
The L2 domain experienced a rearrangement of 119.47° relative to the L1 domain 
(Figure 4.23), similar to the movements in simulations of previous receptor structures. 
The range of motions sampled by this construct were similar to those in the IR-E329A 
simulation and saw the angle formed by the L1 and L2 domains reach between 69° 
and 143° (Figure 4.23). The distances between the centres of mass of the L1 and L2 
domains for both angles were found to be 41.4 Å and 39.5 Å respectively, similar to 
those measured for the IR-E329A construct.  
 
The CT-tail was observed to follow the movements of the L2 domain and 
gradually formed an open conformation (Figure 4.24A and B), similar to that in the 
simulation of IR-E329A (Figure 4.17). Interestingly, at approximately 334 ns into the 
simulation, the CT-tail stopped progressing towards an open conformation and formed 
a kink in the region around Phe714 (Figure 4.24C). Following this, the CT-tail 
underwent a conformational change in the opposite direction over a period of ~100 ns 
which resulted in the CT peptide forming a hairpin-like structure (Figure 4.24D). This 
new conformation of the CT peptide closely resembled that seen in Dr Croll’s earlier 
simulation (Figure 3.5).  
 
Similar to other previous simulations, the salt bridge between Glu329 and 
Arg270 was observed to form in the IR-A351D simulation that linked the CR and L2 
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domains (Figure 4.25). The salt bridge was formed around ~83 ns and remained stable 
for the rest of the simulation. This interaction again appeared to form just before the 
rearrangement of the L2 domain suggesting that a link between the CR and L2 domains 
may be responsible for the L2 domain movement. However, the IR-E329A simulation 
also saw a similar movement of the L2 domain despite having a mutation on Glu329 
that was designed to disrupt the salt bridge with Arg270. Thus, although the identified 
salt bridge (formed by Glu329 and Arg270) may not be critical for the L2 domain 
rearrangement, some form of link between the L2 and CR domain may be necessary 
to see the conformational change (as seen in the IR-E329A simulation where a salt 
bridge between Lys310 and Glu287 compensated for the loss of the more common salt 
bridge seen in other simulations).  
 
Despite the similarity of the L2 domain movement with previous simulations, 
different salt bridge interactions were observed in the IR-A351D simulation. For 
example, residues previously identified to form the salt bridge interactions linking the 
L1 and L2 domains were positioned far from each other and only interactions within 
domains were seen (such as Glu353-Arg331, Glu355-Arg383 and Asp12-Arg14). The 
sole inter-domain interaction was a hydrogen bond formed by Arg14 and Asn349 
(Figure 4.26), a link that was not seen in any other simulation. This suggests that there 
may be multiple sites on the L1 and L2 domains that have the potential to form 
interactions to stabilise the L2 domain in the position seen in the simulations.  
 
 
 Chapter 4: Understanding the IR and identification of possible key residues 154 
 
Figure 4.22: Close-up view of Phe714 being dislodged from the potential hydrophobic binding pocket on the L1 domain. The A351D mutation was designed to disrupt a 
potential interaction between Phe714 and the hydrophobic binding pocket. A, the IR-A351D structure before starting the simulation. B, the dislodged Phe714 after beginning 
simulation of the IR-A351D structure. Residues forming the hydrophobic are shown in stick representation while Phe714 is coloured yellow.  
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Figure 4.23: Comparison of the smallest and largest angles of the L2 domain relative to the L1 domain seen in the IR-A351D simulation. The angle of the L2 domain 
covered a range between 69° (A) to 143° (B). The angle was measured using the C-α atoms of residues Glu120, Arg14 and Lys425 as reference points. The conformation 
observed in the IR-A351D simulation was similar to those observed in simulations of other structures suggesting this common conformational change may be important for 
receptor function. 
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Figure 4.24: Major structural changes of the CT 
peptide during simulation of the IR-A351D model. 
A, starting conformation of the CT peptide. B, open 
conformation of the CT-tail that closely resembled 
the structure seen in the IR-E329A simulation. C, 
structure of the CT-tail after the formation of the kink 
(Phe714 shown in yellow stick representation). D, the 
closed conformation of the CT-tail that was similar 
to the structure observed in the preliminary work 
performed by Dr Croll. 
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Figure 4.25: The interaction between Glu329 and Arg270 seen in the IR-A351D simulation. The interaction formed by these residues resulted in a link between the L2 and 
CR domains and was also observed in simulations of the other structures. It was speculated that this interaction may contribute to the conformational change of the L2 domain 
by facilitating the formation of the salt bridge network or stabilise the L2 domain in the new conformation.  
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Figure 4.26: The interaction between Arg14 and Asn349 seen in the IR-A351D simulation. The hydrogen bond between residues on the L2 and L1 domains was most likely 
formed after the rearrangement of the L2 domain brought these residues into close proximity to each other. This interaction was the only inter-domain interaction observed in 
the IR-A351D simulation, replacing the other inter-domain interactions found in the salt bridge network identified in the IR[1-468, CTex] TMD simulation (Figure 3.19, p92). 
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Full correlation analysis (FCA) 
Analysis of the IR-A351D simulation showed that the correlated motions 
represented by the first 10 eigenvectors accounted for 82% of the total motions 
detected (Table 4.3). The motion described by the first eigenvector was determined 
by FCA to have a PTV of 55.5%, over half of the total motions of the construct in the 
simulation. Both the structural movement of the L2 domain and also the 
conformational change of the CT peptide were determined by FCA to be the major 
correlated motions in the simulation (Figure 4.27). Interestingly, only the opening of 
the CT-tail was determined to belong to the first eigenvector whereas the closing 
motion was not. It is possible that the hydrogen bond between Arg717 and Glu438 
provides an anchor point for the CT-tail so that any movement of the L2 domain is 
mimicked by the CT-tail (as seen in this simulation where the CT-tail was seen to 
progress towards an open conformation at the same time as the movement of the L2 
domain).  
 
Visualisation of the first eigenvector also showed displacement of the CR 
domain similar to that seen in the second eigenvector of the IR-E329A simulation 
(Figure 4.20). Specifically, the displaced region of the CR domain involved the helical 
portion (consisting of residues 255-265) and occurred simultaneously with the 
conformational change of the L2 domain suggesting the motions may be linked. As 
discussed earlier, this portion of the CR domain has been demonstrated in previous 
experiments to potentially be important for insulin binding (Kristensen et al, 2002). 
However, without a full crystal structure of an insulin-bound IR, the conformation and 
structural arrangements of the domains remain unknown. Thus, further work is 
necessary to determine the role these residues play during insulin binding.  
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Table 4.3: List of the first 10 eigenvectors of the IR-E329A and their percentage of total variance 
(PTV).  
Eigenvector Percentage 
1 55.5 
2 11.3 
3 4.6 
4 3.5 
5 1.9 
6 1.5 
7 1.3 
8 0.9 
9 0.8 
10 0.7 
Total 82.0 
 
 
Figure 4.27: Movement of IR-A351D along the first eigenvector. The conformational change of the 
IR-A351D structure along the main extracted motion described by eigenvalue 1. A, the conformation of 
the IR-A351D structure at the beginning of the structural change. B, the same structure after the 
extracted motion has occurred. Only part of the conformational change of the CT-tail was determined 
by FCA to be part of eigenvector 1. It was speculated that the interaction between the CT-tail and the 
L2 domain (hydrogen bond between Arg717 and Glu438) may cause the CT-tail to mimic the motions 
of the L2 domain. 
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Projection on the first eigenvector showed that the main conformational change 
began around 10 ns into the simulation and took approximately 60 ns before settling 
for the remainder of the simulation (Figure 4.28). The main conformational change 
coincided with the time Phe714 was dislodged from the hydrophobic binding pocket 
(Figure 4.22) suggesting that the conformational change of the L2 domain was 
triggered by the dislodging of Phe714.  
 
Phe714 has been shown in previous mutagenesis studies to be critical for insulin 
binding as mutation of Phe714 to alanine resulted in a significant reduction in ligand 
binding (Mynarcik et al, 1997a; Mynarcik et al, 1996). The most recent crystal 
structure of the IR (4OGA) shows Phe714 buried within the junction between the 
A- and B-chain of insulin indicating the residue plays a role in the binding of insulin. 
Modelling of the IR[merge] structure (discussed in Chapter 3) found PheB25 was in a 
position where it could be buried within the same hydrophobic binding pocket. 
Simulation of the IR[merge] structure confirmed this interaction was compatible and 
indicates this interaction could form upon the binding of insulin. Although the position 
of Phe714 in the unbound state of the IR is currently unknown, it could potentially be 
buried within the hydrophobic pocket seen in our previous simulation of the IR[1-468, CT] 
structure. The binding of insulin could then pull Phe714 out of the hydrophobic pocket 
to contact insulin allowing PheB25 to take its place. The exchanging of the residues in 
the hydrophobic pocket could potentially lock insulin in place and simultaneously 
trigger the rearrangement of the L2 domain shown in Figure 4.23. 
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Figure 4.28: Projection on the first three eigenvectors of the IR-A351D simulation. The projection 
of the simulation onto the first three eigenvectors show the main conformational change (represented 
by the first eigenvector) occurred around 10 ns and continued for 60 ns before settling into a stable 
conformation for the remainder of the simulation. 
 
 SIMULATION AND ANALYSIS OF MUTATION 4: IR-E438A 
Raw simulation analysis 
The E438A mutation was designed to disrupt the salt bridge between Arg717 on 
the CT peptide and Glu438 on the L2 domain (Figure 3.3). The salt bridge could 
potentially stabilise and help position the CT peptide to bind insulin favourably. A 
mutation of Glu438 to an alanine residue would result in the loss of the salt bridge and 
potentially destabilise the position of the CT peptide which could in turn affect the 
receptor’s ability to bind insulin.  
 
The IR-E438A structure was simulated for 437 ns (Figure 4.29). Due to the loss 
of the interaction between Arg717 and the L2 domain, the CT-tail no longer remained 
stably bound to the L2. As a result, the CT-tail became highly mobile during the 
simulation. Ser719 on the C-terminal end of the CT-tail was seen in the simulation to 
form weak interactions with residues Arg383, Arg409, Lys416, His417 and Lys441. 
Each interaction appeared for a short duration (1-2 ns) before being broken by the 
highly mobile CT-tail. Due to the mobility of the CT-tail, Phe714 was also dislodged 
from the hydrophobic pocket (Figure 4.30), breaking the interaction seen in Figure 
4.9A. This resulted in the formation of a kink in the CT-tail that was almost identical 
to that seen in the IR-A351D simulation (Figure 4.24C and D). Despite the mutation 
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of a single residue on the L2 domain, two previously identified key interactions linking 
the CT peptide and the L2 domain were disrupted.  
 
Similar to that seen in the previous mutant IR simulations, the L2 domain was 
observed in the IR-E438A simulation to undergo a large rearrangement and saw the 
angle formed by the L1 and L2 domains reach between 93° and 138° (Figure 4.31). 
The distances between the centres of mass of the L1 and L2 domains for both angles 
were found to be 44.2 Å and 47.6 Å respectively. Unlike that observed in the 
IR-E329A and IR-A351D simulations, the conformational change here did not bring 
the L2 domain closer to the L1 domain, but instead moved it over 3 Å further away. 
Interestingly, the CT peptide appeared to lose most of its interactions with the L2 
domain confirming that the E438A mutation affected the stability of the CT peptide. 
Examination of the interface between the CT peptide and the L1 and L2 domains 
showed little interactions between residues unlike the salt bridge network seen in 
Figure 3.19. One interaction between the L1 and L2 domains was a hydrogen bond 
between Asn348 on the L2 domain and Arg14 on the L1 domain. This interaction was 
only seen to form after the rearrangement of the L2 domain as Asn348 was positioned 
too distant from the L1 domain in the starting conformation. Furthermore, mutation of 
Glu438 to alanine removed Arg717’s interaction with the L2 domain causing Arg717 
to arch back and interact with Glu706 and Asp707 on the α-helix of the CT peptide 
(Figure 4.32).  
 
Not surprisingly, the salt bridge formed by Glu329 and Arg270 observed in 
many of the previous simulations was also seen to form in the IR-E438A simulation 
(Figure 4.33). This interaction formed ~15 ns into the simulation and again coincided 
with the beginning of the rearrangement of the L2 domain. The salt bridge interaction 
between these two residues was very stable and remained in contact for the remainder 
of the simulation, maintaining the link between the CR and L2 domains. Therefore, 
similar to that discussed in the previous mutant simulations, a link between the CR and 
L2 domains may be required to induce a potential conformational change in response 
to the binding of insulin.  
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Figure 4.29: The hydrogen bond between Glu438 and Arg717 was disrupted by the E438A mutation. Mutation of Glu438 to Ala438 resulted in the disruption of the link 
between the CT-tail and the L2 domain. This resulted in the CT-tail becoming highly mobile during the simulation suggesting the CT peptide may also be affected. 
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Figure 4.30: Phe714 was dislodged from the potential hydrophobic binding pocket. The E438A mutation indirectly affected Phe714 by causing the CT-tail to be highly 
mobile resulting in Phe714 being dislodged from the hydrophobic pocket on the L2 domain (indicated with annotated residues). Loss of the interaction between Phe714 and the 
hydrophobic pocket could potentially effect to the IR-E438A structure in a similar manner to that observed in the IR-A351D structure. 
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Figure 4.31: Comparison of the smallest and largest angles of the L2 domain relative to the L1 domain seen in the IR-E438A simulation. The angle of the L2 domain 
covered a range between 93° (A) to 138° (B). The angle was measured using the C-α atoms of residues Glu120, Arg14 and Lys425 as reference points. The conformational 
change of the receptor observed here may be a combined result of both the loss of the interaction between Arg717 and Glu438 as well as Phe714 being dislodged from the 
hydrophobic pocket on the L2 domain. 
 167 
Chapter 4: Understanding the IR and identification of possible key residues 167 
 
Figure 4.32: Arg717 was seen to interact with other residues on the CT peptide. Mutation of Glu438 to Ala438 resulted in the loss of the hydrogen bond between Arg717 
and Glu438 causing the CT-tail to be highly mobile throughout the IR-E438A simulation. Arg717 was seen to form salt bridges with Glu706 and Asp707 on the CT peptide 
α-helix. The formation of these interactions between Arg717 and other residues on the CT peptide demonstrate that the CT-tail could not find a stable interaction after mutation 
of Glu438 to an alanine residue. 
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Figure 4.33: The interaction between Glu329 and Arg270 seen in the IR-E438A simulation. The interaction formed by these residues was also observed in previous 
simulations of IR structures (e.g. both mutant IR and the IR[1-468, CT] model). This common interaction that was observed to link the CR and L2 domain across the simulations of 
the different IR structures suggested this interaction may be important for receptor function, potentially in stabilising the conformational change observed in these simulations. 
 
 Chapter 4: Understanding the IR and identification of possible key residues 169 
Full correlation analysis (FCA) 
Analysis of the IR-E438A simulation using FCA showed the first ten 
eigenvectors accounting for 80% of the total motions detected (Table 4.4). Unlike that 
seen in previous simulations, the PTV of eigenvector 1 in the IR-E438A was much 
lower, accounting for just over a third (37.7%) of the total motions. Visualisation of 
eigenvector 1 showed little conformational changes in the overall structure with only 
the CT-tail showing substantial movement. Although the movement of the CT-tail was 
expected to be included in eigenvector 1, it was surprising that the L2 domain 
rearrangement was not determined by FCA to be the most substantial motion 
experienced by the structure. This suggested that the CT-tail in the simulation was so 
highly mobile that its motions contributed more to the total motions of the system 
compared to the rearrangement of the L2 domain.  
 
Table 4.4: List of the first 10 eigenvectors of the IR-E438A and their percentage of total variance 
(PTV).  
Eigenvector Percentage 
1 37.7 
2 13.8 
3 12.8 
4 5.7 
5 3.4 
6 2.2 
7 1.4 
8 1.3 
9 0.9 
10 0.8 
Total 80.0 
 
Interestingly, although eigenvector 2 included the L2 domain movement, some 
CT-tail motions were also determined to belong to the second eigenvector (Figure 
4.35). The CT-tail motion in this eigenvector described a motion that ranged from an 
open-like conformation (similar to that seen in the IR-A351D simulation, Figure 
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4.24B) to the folded back conformation shown in Figure 4.32. The folded back 
conformation of the CT-tail was possibly a result of dislodging Phe714 from the 
hydrophobic pocket and it is highly likely that this caused the rearrangement of the L2 
domain, inadvertently mimicking the effects seen in the IR-A351D mutation. 
Therefore, the conformational changes of the CT-tail seen in the second eigenvector 
could potentially be linked to the movement of the L2 domain (also seen in the A351D 
mutation) whereas the motions shown in Figure 4.34 may be unique to the E438A 
mutation.  
 
 
Figure 4.34: Movement of IR-E438A along the first eigenvector. The conformational change of the 
IR-E438A structure along the main extracted motion represented by eigenvalue 1. A, the structure of 
IR-E438A at the beginning of the extracted motion. B, the same structure at the end of the extracted 
motion. Eigenvector 1 shows only the motion of the CT-tail with relatively minor changes to the rest of 
the receptor indicating the highly mobile CT-tail contributed more to the total motions in the simulation 
compared to the other parts of the receptor. 
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Figure 4.35: Movement of IR-E438A along the second eigenvector. Movement of the L2 domain 
and a change in the CT-tail were determined to belong to eigenvector 2. A, the structure of IR-E438A 
at the beginning of the extracted motion. B, the same structure at the end of the extracted motion. 
Eigenvector 2 shows the conformational change of the receptor involving the L2 domain as well as 
some motions of the CT-tail. This suggested that those specific motions of the CT-tail may be linked to 
the conformational change of the L2 domain. 
 
Projection on the first eigenvector showed that a transition occurred around 50 ns 
to a different conformation where minor motions were experienced thereafter. The 
receptor then underwent a second conformational change around 350 ns where it 
assumed a conformation that was similar to the starting structure. The conformational 
change events are evidently the movements of the highly mobile CT-tail where it was 
observed to undergo large changes during the simulation. The CT-tail is known to be 
highly mobile as this region of the CT peptide has proven to be difficult to resolve in 
previous crystal structures of the IR. This region was successfully resolved in the most 
recent insulin-bound structure where it was found to be in close proximity to insulin 
(4OGA) (Menting et al, 2014). Although the position and conformation of the CT-tail 
in the 40GA crystal structure are different compared to that in our IR[1-468, CT] model, 
the 4OGA crystal did not include the L2 domain. Therefore, the position and 
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conformation of the CT-tail in the presence of the L2 domain is still currently 
unknown. Thus, the conformations of the CT-tail seen in our simulations are still 
plausible and have not yet been ruled out by the recent crystal structure.  
 
 
Figure 4.36: Projection on the first three eigenvectors of the IR-E438A simulation. The projection 
of the simulation onto the first three eigenvectors show the main conformational change occurred 
around 50 ns and settling for ~300 ns before undergoing a second conformational change. This was 
concluded to be the conformational change events experienced by the highly mobile CT-tail. 
 
 SUMMARY OF CONFORMATIONAL CHANGES 
As discussed in the previous sections, analysis of the wt-IR, IR-R86P and the 
four IR mutant simulations found the hinge point between the CR and L2 domains is 
flexible and has the propensity to undergo a conformational change. This 
conformational change was common across all the simulations conducted here and 
structures IR-E329A and IR-A351D were observed to display the largest motions 
compared to the other investigated structures. The conformational changes observed 
in each simulation were clustered into groups with RMSD of backbone atoms <3 Å 
(Gracia, 2014). A comparison of the representative structure of the most populated 
cluster for each of the models against the starting configuration is shown in Figure 
4.37. 
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Figure 4.37: Comparison of the starting conformation with those observed in the simulations of the other constructs. Conformations were clustered into groups with 
RMSD of backbone atoms <3 Å and a representative from each of the most populated clusters is shown here. A common conformational change was observed in simulations 
of the four mutant IR constructs with the IR-E329A and IR-A351D mutants undergoing a larger motion compared to the others. In contrast, relatively smaller motions were 
observed in the simulations of the wt-IR and IR-R86P structures. 
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 HOW THE CHANGES OBSERVED IN THE SIMULATIONS RELATE TO THE 
FULL SIZED IR 
It is important to note that the molecular modelling and dynamics simulation 
work was performed using the IR[1-468, CT] structure to minimise the resources required, 
a structure that is very different from the disulphide bonded homo-dimer that the IR is 
known to exist as. Therefore, any changes observed for the IR[1-468, CT] structure (as 
presented and discussed in Chapters 3 and 4) need to be assessed for their potential to 
cause other changes to the full-sized receptor. Very recently (December 2014), a 
crystal structure of the IR dimer was made available (Croll et al, 2015) and was used 
here to assess how the interactions and conformational changes observed in Chapters 
3 and 4 could potentially affect the overall structure and its other domains. This new 
crystal structure corrects errors that were found for the first and third fibronectin 
domains in the previous crystal structure (3LOH) (McKern et al, 2006). The corrected 
structure altered the position of the FnIII-1 C-C’ loop that was previously thought to 
be in close proximity to the insulin binding site, but has been shown to be shorter than 
in the earlier structure.  
 
The identified interactions listed in Table 3.2 did not appear to change in the full 
sized IR; the residues involved were observed to be located within close proximity to 
potentially form interactions, especially if the conformational change observed in the 
simulations occurs. On the other hand, residues involved in the identified salt bridge 
network shown in Figure 3.19 were found to be positioned far apart. Despite this, if 
the observed conformational change from the simulations were to occur, these residues 
could potentially be positioned within proximity for the identified salt bridge network 
to form. However, the conformational change itself may not be completely possible 
due to constraints brought about by the other receptor domains.  
 
As seen in Figure 4.38, superimposing the L2 domain from the IR[1-468, CTex] 
simulation onto the IR dimer crystal structure (only one monomer is shown for clarity 
purposes) resulted in the L1 domain and also the CT peptide positioned very far from 
their crystallised positions. Importantly, the L1 domain was observed to be located in 
a region occupied by the FnIII-2 domain from the same monomer. This may indicate 
that the observed conformational change might not be possible as transition of the 
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receptor domains shown here would result in steric clashes between the L1 and FnIII-2 
domains. Interestingly, following the larger conformational change identified in the 
IR-E329A simulation, the L1 domain was observed to move inwards towards the 
centre of the IR dimer and into the void created by the inverted ‘V’ shape of the ‘legs’ 
of the receptor. This region of the receptor would not be able to accommodate a second 
L1 domain and could potentially represent the negative cooperativity observed in 
insulin binding experiments (De Meyts, Bainco, & Roth, 1976). Problematically, 
movement of the L1 domain into this region of the IR dimer would prevent the 
dimerising of the ‘legs’ of the receptor that was demonstrated in a previous study by 
Kavran et al (2014).  
 
Figure 4.38: The IR[1-468, CTex] structure superimposed onto the new IR dimer structure via 
alignment of the L2 domain. Alignment of the IR[1-468, CTex] structure (blue and red) onto the new IR 
dimer structure (gold) resulted in the L1 domain from the first structure occupying the same region as 
the FnIII-2 domain from the latter structure. Transition of the receptor domains shown here would result 
in steric clashes between the L1 and FnIII-2 domains and the observed conformational change may not 
be possible. 
 
The discussion above was based on the assumption that the L2 domain does not 
move or change during insulin binding and remains rigid, causing the CR and L1 
domains to move along the hinge point between the CR and L2 domains. However, a 
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previous study on the IGF1R demonstrated that regions of the L2 domain changed 
upon the binding of IGF-I (Houde & Demarest, 2011) indicating the L2 domain 
undergoes some form of movement or change during ligand binding. This study used 
hydrogen/deuterium exchange experiments and found regions on the L2 domain 
became protected following ligand binding indicating a conformational change occurs 
that alters the exposed surfaces of the L2 domain (Houde & Demarest, 2011). The IR 
and IGF1R are considered to bind their ligands in a similar manner and thus the 
equivalent domains of the IR are also expected to show similar behaviours. Therefore, 
it is not entirely accurate to assume the L2 domain does not change or move during 
insulin binding. 
 
An alternative fit of the conformational change to the IR dimer crystal structure 
where the L2 domain is assumed to be more flexible, shows a very different fit 
compared to Figure 4.38. As seen in Figure 4.39, superimposing all three domains 
from the IR[1-468, CTex] simulation onto the IR dimer crystal structure (again, only one 
monomer is shown for clarity purposes) resulted in much less overall change in the 
positions of the domains. This new position of the domains does not place the L1 
domain in steric clashes with the FnIII-2 domain and also does not prevent the ‘legs’ 
of the IR dimer from coming together following insulin binding. However, the 
orientation of the L2 domain in this new fit differs widely from that in the crystal 
structure and does not share much of an interface with the FnIII-1 domain. Therefore, 
it appears that some degree of constraint on the L2 domain may be necessary to 
maintain the interface with the FnIII-1 domain, but not completely constrained that 
would cause the undesirable clashes shown in Figure 4.38.  
 
Importantly, similar arrangements of the domains were observed in simulations 
of not only wt-IR but also the four mutant receptors investigated in this chapter. It is 
noted that the simulations were performed using non-glycosylated proteins (due to the 
limitations of the software at the time of study) and that the presence of 
oligosaccharides attached to Asn111 and Asn215 may complicate the analysis. 
However, later simulations performed on a glycosylated IR dimer (Tristan Croll, 
personal communication) suggested the common conformational change observed in 
the simulations performed would not be affected by the presence of carbohydrates at 
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the aforementioned sites. Furthermore, previous experimental studies have shown that 
mutation of Asn111 and Asn215 to glutamine residues resulted in receptors that bound 
insulin with a similar affinity, suggesting glycosylation at these sites may not be 
essential for receptor function (Elleman et al, 2000). The common rotation along the 
hinge point between the CR and L2 domains identified amongst the different receptor 
constructs suggests the domains have the propensity to undergo the observed 
conformational change that may trigger other changes in the receptor leading to 
activation. However, it remains unclear from the currently available IR crystal 
structures and the conformational changes observed in the work here how the negative 
cooperativity behaviour of the IR is brought about. To further investigate the four 
mutant receptor constructs described and discussed in this chapter, recombinant IR 
mutant proteins were expressed and functionally assessed to determine the effects the 
selected mutations have on insulin binding. 
 
 
Figure 4.39: The IR[1-468, CTex] structure superimposed onto the new IR dimer structure via 
alignment of the L1, CR and L2 domains. Alignment of the IR[1-468, CTex] structure (blue and red) onto 
the new IR dimer structure (gold) resulted in a much smaller difference and would still allow the ‘legs’ 
of the IR dimer to come together following insulin binding, This suggests that the alignment of the 
domains shown here may be the more likely conformational change compared to that shown in Figure 
4.38. 
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4.3 CONCLUDING REMARKS 
Given that all four mutant IR structures were observed to undergo very similar 
structural rearrangements of the L2 domain compared to previous simulations, it 
appears that the L2 domain has the propensity to move in this direction, regardless of 
the mutation and structure of the α-helix of the CT peptide. This contradicts the 
previous idea that inducing an extra turn in the CT α-helix resulted in the 
conformational changes seen in the IR cyc-CT and the IR[1-468, CTex] simulations. From 
the data obtained here, it appears that the extra turn in the CT α-helix is not essential 
to induce the L2 domain movement that brought it into close proximity to the L1 
domain, resulting in the formation of the potential salt bridge network (as seen in 
Figure 3.19). This is based upon the fact that the L2 domain underwent a similar 
structural rearrangement despite the CT peptide displaying; a) an open conformation 
with the extra turn in the CT α-helix (the IR[1-468, CTex] simulation), b) a cyclised and 
restricted conformation with the same extra turn in the CT α-helix (IR cyc-CT 
simulation) and c) an open conformation without the extra turn in the CT α-helix (as 
seen in the IR mutant simulations). Furthermore, detailed analyses of the IR mutant 
simulations suggest that a link between the L2 and CR domain may be necessary for 
the rearrangement of the L2 domain seen in the simulations. In three of the IR mutant 
structures (IR-R114A, IR-A351D and IR-E438A), a salt bridge between Glu329 and 
Arg270 was seen to form and coincided with the L2 domain movement. Although the 
IR-E329A construct had one of the residues mutated to break the salt bridge, a different 
interaction formed by Lys310 and Glu287 appeared to compensate for the loss of the 
link between the L2 and CR domains and a similar conformational change was seen. 
Glu329 and Arg270 are highly conserved, as reported in the supplementary structural 
alignment data from a bioinformatics study (Renteria et al, 2008), suggesting these 
residues may play important roles in the receptor.  
 
Multiple experimental data indicate the IR undergoes a conformational change 
after the binding of insulin (Donner & Yonkers, 1983; Maturo et al, 1983; Pilch & 
Czech, 1980). Although the exact nature of the conformational change is currently 
unknown, a previous study found that the interface region of the IR α-subunits changed 
upon insulin binding (Waugh & Pilch, 1989). This reported conformational change 
coincides with the rearrangement of the L2 domain seen in our simulations of the 
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various IR models and could potentially represent the change to the receptor in the 
presence of insulin. Despite successfully resolving multiple insulin-bound IR 
structures (3W11-3W14, 4OGA) (Menting et al, 2013; Menting et al, 2014), the native 
position and conformation of the L2 domain has yet to be elucidated in an 
insulin-bound receptor structure.  
 
The movement of the L2 domain along the hinge point between the L2 and CR 
domains shares similarity with the conformational change of the distantly related but 
highly homologous epidermal growth factor (EGF) receptor (EGFR). This receptor 
has been successfully crystallised in both the inactive (Ferguson et al, 2003) and active 
(Ogiso et al, 2002) forms (Figure 4.40A and B). Comparison of the inactive and active 
structures shows a rotation of the L2 domain about residues 309-311 (equivalent to 
IR308-310). This rotation causes a conformational change in the receptor that places part 
of the L2 domain in contact with EGF (rotation of L2 domain is shown by the red 
arrow in Figure 4.40A). The conformational change of the L2 domain observed in all 
four mutant IR simulations share a similar movement where rotation occurred along 
the equivalent residues Cys308 to Val311. Furthermore, in two of the mutant IR 
simulations (IR-E329A and IR-A351D), a displacement of the CR domain was 
observed that coincided with the conformational change of the L2 domain. As seen in 
Figure 4.40C and D, the CR domain in the two different states of the EGFR also 
undergoes a movement when the receptor is in its active state. Thus, the binding of 
ligand to its receptor could potentially trigger a change in the CR domain that induces 
a conformational change in the L2 domain leading to receptor activation.  
 
More recently, a study of the IGF1R also presented a model of ligand binding 
that proposed a rotation of the L1 and CR domains along the same hinge point (Kavran 
et al, 2014). Although the simulations performed in the work presented in this chapter 
show a conformational change along the same hinge point as that observed in the work 
performed by Kavran et al (2014), the motion occurred in the opposite direction. 
Kavran et al (2014) posited an outward rotation of the L1 and CR domains following 
the binding of IGF-I (Kavran et al, 2014). An outward motion of the L1 and CR 
domains would result in an increase in size of the receptor, contradicting previous 
reports that the receptor experiences a decrease in Stokes radius upon insulin binding 
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(Florke et al, 2001). The work presented here on the other hand agrees with the 
previously reported results as movement along the conformational change would bring 
the L1 and CR domains inwards towards the rest of the receptor and in turn resulting 
in a more compact structure.  
 
Kavran et al (2014) also presented evidence for auto-inhibition function of the 
extracellular region of the receptor, where the domains are arranged in a way that 
prevents activation of IGF1R. Their results indicated that binding of ligand caused a 
rearrangement that released the restriction and allowed phosphorylation of the kinase 
domain. Considering the high homology between the IR and IGF1R, the authors 
speculated the same mechanism also occurs in the IR. Therefore, the conformational 
change of the receptor that was observed in the simulations could potentially be a 
rearrangement that releases the restriction on the receptor and lead to phosphorylation 
of the kinase domain. 
 
Importantly however, the proposed rotation of the L1 and CR domains has yet 
to be shown in a ligand bound crystal structure and further work is needed to validate 
these ideas. Currently, there is no available experimental data to pinpoint the position 
and orientation of the L2 domain upon insulin binding nor is there any evidence that 
contradicts the conformational changes seen in our simulations. The MD simulations 
provided valuable information towards predicting potential conformational changes of 
the receptor and the identification of key residues. The resulting predictions from the 
IR mutant simulations were expressed as recombinant IR proteins and the effects of 
these mutations on insulin binding were experimentally validated.  
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Figure 4.40: Comparison of the changes in the EGFR in the ligand bound and unbound structures. 
A, EGFR in the inactive structure. The red arrow indicates motion of the L2 domain during activation. 
B, Structure of the EGFR bound to its ligand, EGF (EGF shown as orange representation). Equivalent 
regions of the inactive and active structures are shown in red and yellow to show the movement of the 
L2 domain. C, D, EGFR in the inactive and active structure. The CR domain that has a different 
conformation between the two states of the EGFR is shown in green. The conformational changes 
observed for in simulations of the different IR structures showed a similar rotation of the L2 domain 
suggesting this conformational change may be a part of receptor activation. 
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Chapter 5: Recombinant mutant IR protein 
expression and functional 
assessment 
5.1 INTRODUCTION 
The binding of insulin to the insulin receptor (IR) involves complex interactions 
and conformational changes that result in the activation of the receptor. Prior to the 
successful crystallisation of the IR extracellular domain in 2006 (McKern et al, 2006), 
researchers attempted to identify regions and residues on the IR that were important 
for ligand binding using different approaches such as alanine scanning mutagenesis, 
receptor chimeras and truncated receptor constructs (Andersen et al, 1992; Brandt et 
al, 2001; Gauguin et al, 2008; Kristensen et al, 1998; Lou et al, 2006; Mynarcik et al, 
1996; Schumacher et al, 1991; Slaaby et al, 2006; Surinya et al, 2002; Williams et al, 
1995).  
 
Studies generating truncated receptors produced different IR constructs 
containing varying lengths and domains of the protein. These experiments were able 
to identify specific regions essential for receptor functions such as ligand binding and 
negative cooperativity (Brandt et al, 2001; Kristensen et al, 1998; Lou et al, 2006; 
Surinya et al, 2002). Other studies using alanine scanning mutagenesis experiments 
found that residues on the L1 domain and CT peptide affected the receptor’s affinity 
for insulin and speculated that these regions were responsible for ligand binding 
(Mynarcik et al, 1997a; Williams et al, 1995). The successful crystallisation of the IR 
extracellular domain in complex with the CT peptide (PDB ID 3LOH) revealed that 
many of the residues on the L1 domain previously thought to interact with insulin were 
in fact in contact with the CT peptide (Smith et al, 2010). More recently, the 
insulin-bound IR structure was successfully resolved (PDB ID 4OGA) and showed 
insulin primarily bound to the CT peptide, making very little contact with the other IR 
domains (Menting et al, 2014). This suggested that many of the previously identified 
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residues may play a role in stabilising the CT peptide along the L1 domain rather than 
directly contacting insulin.  
 
Although these previously identified residues were not found to be in direct 
contact with insulin, the receptor’s affinity towards insulin was still affected after 
mutation of these residues, suggesting they may affect the receptor in other ways. One 
possibility is that mutation of the residues disrupted interactions within the receptor 
that may have resulted in structural changes affecting insulin binding indirectly, 
preventing transmission of the binding event to realise the biological effect (receptor 
activation). Therefore, without fully understanding the conformational changes 
experienced by the receptor during ligand binding and its subsequent activation, it is 
difficult to identify the exact roles of these residues. For example, are they directly 
responsible for binding insulin? Do they stabilise the receptor during ligand binding? 
Or are they simply important for maintaining the integrity of receptor conformation? 
Do they act as relays of binding events through the receptor? 
 
The computational work described in Chapters 3 and 4 attempted to address 
these issues by investigating the IR and several mutant forms, and the conformations 
that were identified during molecular modelling and simulations of the constructs. 
Detailed analysis resulted in the identification of potential mutations on the IR, most 
not in direct contact with insulin, that may affect ligand binding through 
conformational changes in the overall structure. Recombinant of the mutant IR 
proteins incorporating these changes would allow in vitro assessment of their insulin 
binding capabilities and provide some validation of the predictions that were derived 
from the in silico modelling and simulations. The aim of the work in this chapter was 
to express recombinant wt-IR and mutant IR proteins and assess their effects on insulin 
binding. This was achieved by first genetically engineering vectors to incorporate the 
desired changes into the IR coding sequences, expressing the protein in host cells and 
purifying sufficient expressed protein for validation studies. Binding kinetics and 
equilibrium experiments were then performed and analysed using surface plasmon 
resonance to determine the binding affinities of each receptor protein to insulin. 
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Native IR consists of extracellular, transmembrane and intracellular domains 
where the transmembrane domain is embedded in the cell lipid bilayer, exposing the 
extracellular domains to external factors. Although full validation studies of mutated 
receptors should eventually include cell-based assays to examine the downstream 
effects of insulin binding, this is outside the scope this project. As evidenced by 
previous studies, truncated IR constructs lacking the transmembrane domain did not 
always display the same characteristics as the wild-type receptors (Florke et al, 2001). 
On the other hand, other studies have demonstrated high affinity binding to the 
extracellular domain of the IR by use of analogues where the extracellular domain is 
fused to a dimerising structure such as an immunoglobulin Fc domain (Bass et al, 
1996) or leucine zipper (Hoyne et al, 2000). With this in mind, the constructs for this 
project were designed following the principles of the IR fusion proteins described by 
Hoyne et al (2000). The IR fusion proteins described in their work consisted of the IR 
extracellular domains fused to a leucine zipper that has been shown to facilitate dimer 
formation (O'Shea, Klemm, Kim, & Alber, 1991). Furthermore, in order to maximise 
efficiency during purification and to allow facile immobilisation, a Strep-tag II was 
appended to the C-terminal end of the leucine zipper. 
 
The Strep-tag II was improved from the original Strep-tag which bound 
streptavidin with high affinity (Schmidt & Skerra, 2007). This second generation tag 
reduced the restrictions on attachment sites and also allowed increased binding to a 
variant of streptavidin, termed Strep-Tactin (Korndorfer & Skerra, 2002). Proteins 
tagged with the Strep-tag II can then be easily purified using Strep-Tactin following 
the procedures described by Schmidt et al (2007). Following the leucine zipper, the 
constructs were fused to a C-terminal Strep-tag II via a (Gly6)-Ser-Ala flexible linker 
to enable quick and efficient purification of the expressed protein, and to minimise 
potential interference with dimerising activities of the leucine zipper. Schmidt and 
Skerra recommended the addition of Ser-Ala N-terminal to the Strep-tag II for high 
affinity recognition by the anti-Strep antibody, StrepMAB-Immo (Schmidt & Skerra, 
2007). The Gly6 linker sequence was recommended to allow increased flexibility 
between the leucine zipper and Strep-tag II and to avoid any complications that may 
arise due to the two structures being directly next to each other. 
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Various methods have been used in past studies to measure binding of insulin to 
different IR constructs. Common approaches included competition assays with 
radio-labelled insulin analogues (Kristensen et al, 2002) and isothermal titration 
calorimetry (Menting et al, 2009). These approaches, however, required either 
significant amounts of receptor protein or access to radio-labelled materials and thus 
were not preferred approaches for this project. Advances in techniques for label-free 
binding studies allowed consideration of such for the current studies (Hoa et al, 2007; 
Rich & Myszka, 2004). An example of a label-free approach is surface plasmon 
resonance (SPR). An embodiment of this technology is in BIAcore (GE Healthcare, 
NSW, Australia) instrumentation, where the required volumes and amounts of protein 
are much lower compared to other approaches (Rich & Myszka, 2004) and no internal 
labelling of receptor or ligand is required. An additional advantage of using SPR 
techniques is the ability to monitor the formation and separation of protein-protein 
complexes in real-time (Rich & Myszka, 2004), and the concomitant analysis of 
on-rates and off-rates with corresponding affinity/dissociation equilibrium constants.  
 
5.2 RESULTS AND DISCUSSION 
 VECTOR DESIGN 
The IR protein and mutant variants were generated for in vitro experiments to 
validate the predictions formed from the modelling and simulation work presented in 
Chapters 3 and 4. The strategy was to compare insulin binding affinities of wild-type 
IR to IR mutant constructs to assess the effects those mutations have on ligand binding. 
Receptor constructs were linked to a leucine zipper to avoid potentially complicating 
factors in purification and manipulation that might arise from the presence of the 
transmembrane domain and also to recapitulate high affinity binding (Hoyne et al, 
2000). 
 
Following the leucine zipper, a Strep-tag II was engineered into the C-terminal 
end of the protein for purification, Western blots and binding assays. The Strep-tag II 
is an eight residue sequence (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) that specifically 
binds to streptavidin (Schmidt, Koepke, Frank, & Skerra, 1996) and has been 
successfully expressed in multiple studies as Strep-tag II fusion proteins for 
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purification purposes (Junttila et al, 2005; Witte et al, 2004). Finally, two stop codons 
were engineered behind the Strep-tag II to ensure complete termination of translation, 
preventing the addition of the V5 epitope and His tag (included in the pIB-V5/His 
vector) to the end of the expressed protein. A schematic diagram of the 
wild-type/mutant IR and protein constructs is shown in Figure 5.1 and the expected 
amino acid sequences are shown in Figure 5.2. 
 
Figure 5.1: Schematic of the structure of wt-IR and mutant IR constructs. All receptor constructs 
contained the entire extracellular domain of the IR (1-906) followed by a leucine zipper sequence 
described by Hoyne et al (2000). A linker sequence containing six glycine residues separated the leucine 
zipper from the Strep-tag II sequence described by Schmidt et al (1996). Finally, two stop codons were 
included 3’ to the Strep-tag II to ensure complete termination of translation. Mutations and their 
approximate locations are indicated.  
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Figure 5.2: The expected sequence of the expressed protein and comparison of the native IR 
domain structure to the expressed IR constructs. (Top) The amino acid sequence expected for the 
expressed IR constructs are shown above. All constructs generated contained a signal peptide (black), 
the IR sequence (blue), leucine zipper (orange), Gly6-Ser-Ala linker and Strep-tag II (purple) followed 
by a double stop codon (cyan). The four selected mutation sites (R114A, E329A, A351D, E438A; note 
that this numbering relates to the extracellular domain only, beginning at the residue immediately after 
the signal peptide (histidine)) are represented as red letters. The α/β cleavage site is coloured green and 
the residues are not present in the mature IR protein. (Bottom) The transmembrane (red) and tyrosine 
kinase (green) domains of native IR (Left) were replaced with a leucine zipper (orange) and Strep-tag 
II (purple) in the recombinantly produced IR (Right). The extracellular domains of both the native and 
recombinant receptors are coloured blue. 
MATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELEN
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1040 
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 GENERATION OF VECTOR CONSTRUCTS 
The initial approach to generation of IR vector constructs was to amplify the 
sequence from a plasmid obtained through Addgene and clone into a suitable vector. 
Due to the plasmid containing the gene sequence for the IR-B isoform, site-directed 
mutagenesis was attempted to remove the extra amino acids that are not present in 
IR-A. Repeated failed cloning experiments to produce the desired products led me to 
suspect an issue with the plasmid template and this was investigated further. As shown 
in Figure 5.3, the template plasmid as well as restriction enzyme digestion with 
HindIII and SalI showed the plasmid was larger than the 7600 bp reported by the 
contributing authors of the plasmid (Jacob et al, 2002). Although no sequencing was 
performed to confirm a cause, it is highly likely that this explained why the cloning 
experiments were repeatedly yielding negative results and thus a new plasmid 
containing the sequence encoding for IR-A was ordered from a different supplier. It is 
important to note here that the entire sequence of the plasmid was unavailable from 
Addgene as the contributing authors of this plasmid only supplied partial sequencing 
data. While the partial sequences matched portions of the IR sequence, they do not 
explain the size of this plasmid. 
 
Figure 5.3: DNA agarose gel of the Addgene plasmid. Analysis of the products after restriction 
enzyme digest by HindIII and SalI indicated the plasmid was larger than the expected 7600 bp (plasmid 
and IR-B gene). The template only lane also showed bands that were larger than the expected size. Thus, 
it was concluded that the Addgene plasmid was unsuitable for further cloning experiments and a new 
plasmid was obtained. 
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The new plasmid, a Gateway pDONR 221 vector supplied by GeneCopoeia, was 
checked for appropriate size and used to produce the designed expression vectors via 
multiple cloning steps. Firstly, sequence coding for the extracellular domains of the IR 
was amplified from the vector and inserted into the pIB/V5-His insect vector using 
restriction enzyme cloning. Secondly, a DNA fragment containing sequence encoding 
the leucine zipper, 6x Gly linker, Strep-tag II and the double stop codon, synthetically 
produced by Sigma Aldrich, was inserted into the newly generated IR-pIB/V5-His 
vector using restriction enzyme cloning. The new vector containing all the desired 
components was then used as the template to generate IR mutant constructs via a 
modified inverse PCR method. Throughout each step of the construct generation 
process, the vector sequences were verified via DNA sequencing performed by the 
Queensland University of Technology’s Molecular Genetics Research Facility (QUT 
MGRF) sequencing service. Progression of each step was only performed after 
verification of the desired sequence was obtained. The results from the DNA 
sequencing analysis confirming the presence of the desired mutations are provided in 
Appendix G. 
 
 TRANSFECTION OF SF9 INSECT CELLS WITH GENERATED VECTORS 
Insect cells are commonly used to express recombinant proteins as they are able 
to properly perform many of the post-translational modifications of proteins in similar 
ways to mammalian cells (Harrison & Jarvis, 2006). They are also reported to be 
capable of high productivity relative to their ease of use as an expression system. 
However, studies have shown different glycosylation patterns between insect and 
mammalian cells such as truncated oligosaccharides or the lack of sialylation of 
N-glycans (Altmann, Staudacher, Wilson, & Marz, 1999) which could potentially 
impact post-translational processing of the expressed protein. 
 
The IR is a heavily glycosylated protein containing 19 sites where N-linked 
glycosylation occurs (Sparrow et al, 2008). A study that expressed IR in the presence 
of tunicamycin, an inhibitor of N-linked oligosaccharide formation, found N-linked 
glycosylation to be essential for correct protein folding and structural formation (Olson 
et al, 1988). Mutagenesis studies have identified specific glycans on the IR that are 
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important for receptor function. For example, mutation of residues Asn893 and 
Asn906 resulted in a receptor that displayed normal insulin binding but impaired 
receptor kinase activity and autophosphorylation (Leconte, Carpentier, & Clauser, 
1994). Another study showed that individually, mutation of Asn397 and Asn418 did 
not adversely affect the IR while mutation of both residues severely affected receptor 
processing resulting in no receptors on the cell surface (Bastian et al, 1993). Finally, a 
study investigated 15 glycosylation sites with individual and combinations of residue 
mutations and found that mutation of many of these glycosylation sites did not result 
in adverse effects, indicating the protein has some level of tolerance for variations in 
glycosylation states (Elleman et al, 2000).  
 
Despite the differences between insect and mammalian cell expression systems, 
the IR extracellular (Sissom & Ellis, 1989) and protein-tyrosine kinase domain (Ellis 
et al, 1988) have been successfully expressed in insect cells and were shown to 
demonstrate similar activity to those expressed from mammalian cells. Therefore, the 
use of insect cells to express IR constructs was a viable option for the work in this 
project and the produced protein was expected to bind insulin with an affinity 
comparable to those expressed in mammalian cells.  
 
 PURIFICATION AND VERIFICATION OF EXPRESSED PROTEIN  
Collected conditioned media from the Sf9 cultures was separated using 
SDS-page gels and visualised via silver staining to determine the successful expression 
of the desired proteins. As shown in Figure 5.4, bands at ~150 kDa, ~110 kDa and 
~40 kDa were seen in the lanes (as highlighted by the red boxes) and were consistent 
with expected migration of the uncleaved IR protein, IR α-chain and IR β-chain 
fragment (containing the extracellular domains of the IR β-chain as well as the leucine 
zipper, 6x Gly linker and the Strep-tag II) respectively. Although the apparent relevant 
intensities of the boxed regions in Figure 5.4 suggested the uncleaved receptor was 
more abundant in the conditioned media than the correctly processed IR, the intensity 
of the band around the IR β-chain was promising and protein expression Sf9 cells were 
continued.  
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Figure 5.4: Silver stain analysis of collected non-purified conditioned media. Three bands were 
identified in each lane at ~150kDa, ~110kDa and ~40kDa that corresponded to the uncleaved IR protein, 
IR α-chain and IR β-chain fragment respectively. The intensity of the band corresponding to the IR 
β-chain was promising and expression of the designed protein was continued. 
 
Expressed protein constructs were purified using the Strep-tag II system. The 
expressed protein from conditioned media was precipitated and resuspended in 
purification wash buffer before following the purification procedures outlined by 
Schmidt et al (2007). The expressed protein was eluted into three fractions after 
addition of elution buffer and, as shown in Figure 5.5A, subsequent silver stain 
analysis on reducing SDS-PAGE gels showed the samples were of high purity (≥90%), 
indicating the purification process was able to successfully isolate the tagged protein 
from the conditioned media. One protein band was clearly visible in the silver stain of 
purified materials (Figure 5.5A), where the molecular weight corresponded to the 
α-chain (~110 kDa). Faint bands were also observed in some of the lanes (mutants 1 
and 3) that corresponded to the size of the β-chain fragment.  
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The purified proteins were then verified for the intended constructs via Western 
blot analysis using HRP-conjugated Strep-Tactin and a polyclonal anti-IR antibody, 
which bound specifically to the Strep-tag II and multiple regions of the IR respectively. 
HRP-Strep-Tactin bound to a band corresponding to the molecular weight of the 
β-chain (Figure 5.5B). A second band corresponding to the entire uncleaved protein 
(150 kDa) was also detected, albeit at much lower intensities.  
 
As seen in Figure 5.5C, Western blot analysis using the IR polyclonal antibody 
showed multiple bands corresponding to the molecular weights of the same three 
fragments identified in Figure 5.4. The IR polyclonal antibody binds to multiple 
regions of the receptor and is stated by the manufacturer as highly specific to IR (with 
20% cross-reactivity with mouse IR and 5% cross-reactivity with human insulin 
receptor-related receptor). Therefore, the multiple bands visible in the Western blot 
are indicative of the presence of IR.  
 
The eluted protein samples of each purified construct were then quantified using 
a Bradford quantification assay (BSA protein standard was used). Table 5.1 lists the 
total amount of protein for each construct and indicates a yield of approximately 10 to 
600 µg of purified protein was obtained. The protein yields were used to determine 
loading protocols in the silver stain and Western blot analyses as well as the functional 
experiments.  
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Figure 5.5: Silver stain and Western blot analysis of purified IR protein constructs. A, Each lane 
contained ~300 ng of protein, using the amounts determined from protein quantification. Distinct bands 
in each lane at ~110 kDa were clearly visible that corresponded to the IR α-chain. Faint bands were also 
visible that corresponded to the size of the IR β-chain fragment. B, The HRP-Strep-Tactin probe 
visualised thick bands corresponding to the IR β-chain indicating the IR protein constructs contained 
the Strep-tag II C-terminal of the receptor. Fainter bands corresponding to uncleaved IR protein were 
also visible but at much lower intensities. C, The IR polyclonal antibody confirmed the presence of the 
uncleaved IR protein, IR α-chain and IR β-chain fragment in all the IR protein constructs. The thick 
bands in the two Western blots are possibly due to different glycosylation patterns of the IR β-chain 
resulting in slight variations in the size of the band, causing multiple bands in close proximity to appear 
as one thick band. 
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Table 5.1: Protein amounts of purified recombinant IR constructs.  
IR construct Total eluted protein (µg) 
wt-IR 508 
IR-R114A 11 
IR-E329A 662 
IR-A351D 319 
IR-E438A 149 
 
As seen in Figure 5.5A, while only one protein band corresponding to the IR 
α-chain was clearly visible under silver stain, faint bands corresponding to the IR 
β-chain fragment were observed in the lanes containing mutants 1 and 3. Interestingly, 
thick bands corresponding to the expected size of the IR β-chain fragment were 
observed in subsequent Western blot analyses (Figure 5.5B and C). Colour 
development in silver stains is primarily controlled by the formation of complexes 
between silver and charged amino acids (Nielsen & Brown, 1984). Examination of the 
sequences of both IR α-chain and β-chain fragment showed significantly fewer 
charged residues in the β-chain fragment. Thus, it is possible that due to its smaller 
size and amino acid composition, the β-chain fragment was relatively weakly stained 
compared to the IR α-chain, resulting in the faint bands observed. Furthermore, the IR 
is known to be heavily glycosylated and has been demonstrated to show different 
glycosylation patterns (Sparrow et al, 2008). It is expected that both the IR α-chain 
and β-chain fragment would each have different glycosylation patterns resulting in 
different sizes. These differences would be more apparent at the lower molecular 
weights (IR β-chain fragment) compared to the higher molecular weights (IR α-chain). 
Therefore, the region around the expected molecular weight of the IR β-chain fragment 
may contain multiple bands that are in very close proximity to each other. This would 
also explain the presence of thick bands in the western blot analysis, where multiple 
bands in close proximity could appear as one thick band 
 
Although a third band corresponding to the uncleaved IR was observed in Figure 
5.4 and not in the post-purification silver stain results, faint bands at the same size were 
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observed in the subsequent Western blot analyses (Figure 5.5B and C, upper bands) 
and indicated that uncleaved IR was present in the samples, but in much lower 
quantities. This suggests that the band corresponding to the expected size of the 
uncleaved IR in the silver stain results may have contained other proteins of similar 
size that were removed during the purification process. 
 
Unexpectedly, the Western blot analyses showed a band corresponding to the 
β-chain fragment for the IR-A351D mutant that was much fainter compared to the 
other IR constructs (Figure 5.5B and C). The band corresponding to the IR α-chain on 
the other hand, was also fainter but not to the same extent as that for the β-chain 
fragment. Although these bands indicated the presence of the receptor in the eluted 
sample, this was particularly concerning as similar amounts of protein were loaded 
into each of the lanes (~300 ng) and lanes were therefore expected to have similar 
intensity bands. One possibility is that an issue with the binding of the probes to the 
IR-A351D β-chain fragment resulted in the observed faint band. However, considering 
the same probes bound to the β-chain fragments of the other IR constructs and that the 
IR-A351D β-chain fragment had no change in its β-chain fragment (mutation is located 
in the α-chain), it is not clear what factor may have affected the binding of the probes. 
It may also be possible that there was less protein than the 300 ng that was thought to 
be loaded into the lane. This could have come about due to either inaccurate protein 
quantification or inefficient transfer of material from the SDS-PAGE gel onto the 
nitrocellulose membrane. Either of these possibilities could have affected the amount 
of protein in the lane and potentially cause the observed faint band. Alternatively, the 
A351D mutation could potentially have caused increased degradation of the expressed 
receptor protein compared to the other mutations resulting in the fainter bands in the 
Western blots. It is common for misfolded or damaged proteins to be degraded by cell 
systems, acting as a quality control mechanism (Goldberg, 2003). Although not all 
mutations undergo proteolysis, the A351D may have caused changes in the overall 
receptor structure that either flagged the protein for degradation or allowed increased 
accessibility to proteolytic sites. Despite this, functional assays were still performed 
using this mutant protein to assess the effects of the A351D mutation on the receptor’s 
ability to bind insulin.  
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 BIACORE ANALYSIS OF WT-IR DEMONSTRATES HIGH AFFINITY BINDING TO 
INSULIN 
An initial approach to these studies followed a published method for the 
Strep-tag II, which would have allowed repeated use of the same biosensor chip via 
‘stripping’ of one receptor protein and replacement with another (Schmidt & Skerra, 
2007). In this approach a BIAcore chip with covalently bound anti-mouse 
immunoglobulin was used to capture the StrepMAB-Immo™ for subsequent binding 
of the receptor proteins; insulin was then flowed over this stacked arrangement. The 
resulting very low RU responses, seen as insulin was flowed over the surface, were 
difficult to distinguish from the normal drift of the baseline (data not shown). A 
different approach, described in the methods section 2.5.1 and 2.5.2, using direct 
immobilisation of StrepMAB-Immo™ onto the sensor chip surface yielded better 
results, and was the method used for the studies described here. 
 
Figure 5.6 shows the binding curves of various concentrations of insulin to the 
immobilised wt-IR and is representative of triplicate experiments. The binding 
interaction between insulin and the immobilised wt-IR had apparent elements of fast 
association and dissociation rates. Furthermore, the response level of each association 
curve was observed to increase towards a new plateau as the concentration of insulin 
was increased from 1 nM to 25 nM, suggesting the immobilised receptor was gradually 
becoming saturated with bound ligand, but was not fully saturated under the conditions 
used. The BIAevaluation software was used to fit the binding curves to a two-state 
reaction model where a KD value of 3.4±1.7 nM was determined (Figure 5.9A). The 
residual plot is also provided in Figure 5.6 and shows the experimental data fit well to 
the binding model used in the analysis with maximum deviations from the model of 
less than 2 response units.  
198 
198 Chapter 5: Recombinant mutant IR protein expression and functional assessment 
 
Figure 5.6: BIAcore analysis of insulin binding to immobilised wt-IR. Upper, a range of 
concentrations of insulin (1, 2.5, 5, 10 and 25 nM) flowed over the immobilised receptor. Association 
of insulin was followed for 270 s and dissociation after the final concentration was measured for 900 s. 
The binding curve is representative of triplicate experiments. In this and all following BIAcore traces, 
the transient artefacts introduced by buffer changes were removed from the data prior to analysis and 
presentation. Lower, plot of the residuals show the binding curves fit well to the two-state reaction 
model used in the analysis. The response level of the binding curves were observed to remain above 
baseline levels suggesting insulin had not yet completely dissociated from the immobilised receptor. 
 
A recent study also investigated insulin binding to the receptor using an SPR 
approach (Subramanian et al, 2013). Multiple differences were identified between the 
data presented here and that reported by Subramanian et al (2013). Firstly, the   value 
determined for the wt-IR presented here (3.37 nM) represents approximately 10-fold 
stronger binding compared to the 38.1 nM reported by Subramanian et al (2013). 
Although both the work in this project and that performed by Subramanian et al (2013) 
used a construct containing the IR extracellular domain, the wt-IR construct used here 
was fused to the leucine zipper, a structure lacking in the Subramanian et al (2013) 
study. As demonstrated in previous studies, fusion of the IR extracellular domains to 
a dimer inducing structure such as a leucine zipper (Hoyne et al, 2000) or Fc domain 
(Bass et al, 1996) is required to restore high affinity binding of insulin to the receptor 
ectodomain fragment. Therefore, the binding affinity measured by Subramanian et al 
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(2013) represented low affinity binding of the receptor whereas the binding data 
presented here was able to capture the high affinity binding state.  
 
Secondly, Subramanian et al (2013) immobilised their receptor onto the surface 
of the biosensor chip via an anti-IR antibody, recognising residues 223-228 on the CR 
domain. Whilst the CR domain is not believed to bind insulin directly, capturing the 
receptor via a domain that has been demonstrated previously to display changes during 
insulin binding (Houde & Demarest, 2011) could affect how the receptor responds to 
insulin binding. This concern was avoided in the work here as the BIAcore 
experiments were designed to immobilise the receptor protein via the binding to 
StrepMAB-Immo™ antibody through a sequence peptide inserted at the C-terminal 
end of the protein. This design intended to position the receptor in an upright 
orientation (mimicking a membrane-bound receptor) and present the binding site to 
insulin. Furthermore, higher concentrations of insulin were required (168 to 5381 nM) 
in the Subramanian et al study (Subramanian et al, 2013) compared to those used here 
(1 to 25 nM), suggesting access to the receptor binding site may have also been 
affected.  
 
Whilst the binding curves showed a fast dissociation of insulin from the 
immobilised wt-IR, it was observed that the response levels of the binding curve did 
not return to baseline levels (Figure 5.6). This was interpreted as evidence that a 
subpopulation of the immobilised receptors bound insulin with very slow dissociation 
rates, resulting in a small portion of the ligand that had not yet completely dissociated 
from the IR within the time-frame of observation. This observation was in line with 
the previously proposed two-state binding model of the IR (Equation 1.1, p11) where 
insulin initially binds to the IR in a low affinity binding state before subsequently 
transitioning into a high affinity binding conformation. Previous studies have 
demonstrated that insulin displays two different dissociation rates; while the receptor 
initially binds insulin rapidly, displaying rapid association and dissociation rates, a 
subpopulation of receptors subsequently bind insulin with a stronger affinity resulting 
in the ligand dissociating from the IR at a slower, time-dependent rate (Corin & 
Donner, 1982; Donner & Corin, 1980). The initial association rate ka1 observed here, 
1.26 x106 M-1s-1, is in keeping with that observed by Corin and Donner (1982) for 
200 
200 Chapter 5: Recombinant mutant IR protein expression and functional assessment 
full-length membrane bound receptor (1.8 x106 M-1s-1). It was also observed that the 
response level of the binding curves did not return to baseline and this was interpreted 
to represent the slower, time-dependent dissociation rate that was reported for insulin. 
This could be clarified in future investigations by modifying the method used here to 
allow longer dissociation and association times, such as those used by Corin and 
Donner (up to 3 hrs) (Corin & Donner, 1982). Longer time-frames would allow the 
dissociation reaction to run to completion and could potentially see the traces in these 
experiments return to baseline. Most importantly, the data observed here provides 
evidence that the recombinant wt-IR expressed in this work appears to behave in a 
similar manner to that reported for the full-length IR. 
 
 BIACORE ANALYSIS OF MUTANT IR SHOWED A REDUCTION TO INSULIN 
BINDING 
The binding curves for the four IR mutants are shown in Figure 5.7 and Figure 
5.8. The key difference between the binding responses here compared to that observed 
for the wt-IR was that the response levels of the IR-R114A and IR-E438A mutant 
constructs returned to baseline levels while that of the IR-E329A and IR-A351D 
mutant receptors did not. The residual plot for each mutant is also provided below their 
respective binding curves and shows small deviations (±2 response units) of the 
experimental data from the two-state reaction model used in the analyses indicating a 
good fit.  
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Figure 5.7: BIAcore analysis of insulin binding to immobilised IR-R114A and IR-E329A. A range 
of concentrations of insulin (1, 2.5, 5, 10 and 25 nM) flowed over the immobilised receptor. Association 
of insulin was followed for 270 s and dissociation after the final concentration was measured for 900 s. 
The binding curve is representative of triplicate experiments. Beneath each binding curve is a plot of 
the residuals show the binding curves fit well to the two-state reaction model used in the analysis. The 
binding curves of the IR-R114A mutant were observed to return to baseline levels compared to wt-IR 
whereas those in the IR-E329A mutant remained similar, suggesting the IR-R114A mutant may have 
lost its high affinity binding state. 
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Figure 5.8: BIAcore analysis of insulin binding to immobilised IR-A351D and IR-E438A A range 
of concentrations of insulin (1, 2.5, 5, 10 and 25 nM) flowed over the immobilised receptor. Association 
of insulin was followed for 270 s and dissociation after the final concentration was measured for 900 s. 
The binding curve is representative of triplicate experiments. Beneath each binding curve is a plot of 
the residuals show the binding curves fit well to the two-state reaction model used in the analysis. The 
binding curves of the IR-A351D mutant were observed to remain above baseline levels, similar to that 
observed in the wt-IR, whereas that in the IR-E438A mutant was seen to return close to baseline levels, 
suggesting a partial loss of the high affinity binding state in the latter mutant. 
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The table in Figure 5.9A lists the binding parameters and the standard error of 
the mean from triplicate measurements for the wt-IR and the four mutant IR proteins. 
The functional data for the four mutant IR proteins were fit to the same two-state 
binding model as that used for the wt-IR (Equation 1.1, p11). All the mutants 
displayed binding affinities that were four-fold to 10-fold lower than that measured for 
wt-IR with the IR-R114A mutation resulting in the greatest reduction in affinity. The 
remaining three mutant receptors were found to have similar binding affinities to each 
other. The wt-IR, IR-E329A and IR-E438A constructs had similar initial association 
rates (ka1), but the IR-E329A and IR-E438A mutant constructs displayed more than 
5-fold increased dissociation rates compared to wt-IR. Interestingly, mutants 
IR-R114A and IR-A351D showed faster association rates, having ka1 values over 
double that of the wt-IR. Despite this however, they also showed much higher 
dissociation rates, having kd1 values eight to 19-fold higher than the wt-IR. 
 
Analysis of the ka1 values of the four mutant constructs compared to the wt-IR 
is shown in Figure 5.9B. The IR-R114A and IR-A351D mutants showed significantly 
faster association compared to wt-IR (p<0.05). The analysis of the kd1 values of the 
four mutant constructs compared to the wt-IR is shown in Figure 5.9C. All four mutant 
IR proteins showed a statistically significant reduction in dissociation rate compared 
to the wt-IR (p<0.05). The analysis of the KD values of the four mutants compared to 
the wt-IR is shown in Figure 5.9D. Similar to the kd1 values, all four mutants showed 
a statistically significant reduction in the equilibrium constant relative to wt-IR 
(p<0.001).  
 
The ka2 and kd2 values are defined in the BIAcore user manual as the forward 
and reverse rate constants for the conformational change of the receptor (GE 
Healthcare, 2007a). Importantly, the user manual also specifically states that 
conformational changes do not result in a response in BIAcore and that further 
experiments using other methods should be used to investigate the conformational 
properties (such as the rate constants for the conformational change) (GE Healthcare, 
2007a). 
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Figure 5.9: Comparison of insulin 
binding to wt-IR and the four IR 
mutants. A, table of the kinetic 
constants for the five IR proteins. The 
95% confidence interval for the KD, 
ka1 and kd1 constants are provided in 
brackets below each value. Kinetic 
constants that were significantly 
different compared to wt-IR are 
highlighted in pink. B, comparison of 
the ka1 values for the five IR proteins. 
Only the R114A and A351D IR 
proteins were found to be statistically 
significant compared to wt-IR. 
C, comparison of the kd1values for the 
five IR proteins. All the IR mutant 
proteins were determined to be 
statistically significant compared to 
the wt-IR. D, comparison of the KD 
values for the five IR proteins. All the 
IR mutant proteins were determined to 
be statistically significant compared to 
wt-IR. All experiments were 
performed in triplicate. Significance 
was expressed above the columns as 
stars (*=p<0.05, **=p<0.01, 
***=p<0.001, ****=p<0.0001). 
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Each of the four mutations of the IR caused intriguing effects on the binding 
interaction between insulin and its receptor. Interestingly, despite the R114A and 
A351D mutations causing weaker binding (higher KD values) to insulin, the 
association rates for each were more than twice that measured for wt-IR. Even more 
intriguing is the fact that the same mutations had dissociation rates that were eight to 
19-fold higher than wt-IR. This suggests that these two mutations not only increased 
accessibility to the primary binding site, but lowered overall affinity of the receptor. 
Previous studies have demonstrated that insulin initially binds to binding site 1 on the 
IR before crosslinking to site 2 and resulting in the subsequent transition to the high 
affinity state of the receptor (De Meyts et al, 1976; Ward & Lawrence, 2009). The 
observations for the IR-R114A and IR-A351D constructs suggest these mutations may 
have resulted in the receptor taking on a conformation that causes binding site 1 to be 
more accessible but affected part or all of the subsequent events such as crosslinking 
of insulin to site 2 or the transition of the receptor to the high affinity state. As 
demonstrated by different studies, the IR undergoes a conformational change upon 
ligand binding (Donner & Yonkers, 1983; Maturo et al, 1983; Pilch & Czech, 1980), 
transitioning into a structural state that binds insulin more strongly. Therefore, these 
two mutations of the IR may have potentially caused conformational changes in the 
receptor that favoured ligand binding but also prevented the transition into the high 
affinity state, thus resulting in faster dissociation of insulin.  
 
The other mutant receptors, IR-E329A and IR-E438A, displayed association 
rates that closely matched that of the wt-IR and suggested that the mutations did not 
affect how the receptor initially interacted with insulin. However, their measured 
dissociation rates were over twice the wt-IR rate. This suggests that the two mutations 
likely did not affect the resting state of the receptor but caused defects in the 
subsequent responses of the receptor such as the transition into the high affinity 
conformation.  
 
Interestingly, two of the mutant constructs, IR-E329A and IR-A351D, displayed 
response levels that did not return to baseline levels similar to that observed for the 
wt-IR. This observed behaviour was interpreted as a slow dissociation of insulin from 
the immobilised receptor constructs. As discussed in Section 5.2.5, previous studies 
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have observed a slow, time-dependent dissociation of insulin representing the high 
affinity state of the receptor (Corin & Donner, 1982) and this may have been captured 
in the experimental data here. However, these mutant constructs also displayed higher 
dissociation rates compared to the wt-IR suggesting the mutations only affected the 
receptors initial rapid binding of insulin. On the other hand, the response levels of the 
remaining two mutant IR constructs, IR-R114A and IR-E438A, were observed to 
return to baseline levels. This observation was interpreted as a loss of the high affinity 
binding reported by Corin and Donner (1982), where insulin was observed to 
dissociate from the IR at a slow, time-dependent rate.  
 
While previous mutagenesis studies have identified mutations on the IR that 
affect the binding affinity for insulin, the majority have focussed on residues in the 
vicinity of the primary or secondary binding site in the crystal structure. Few studies 
have looked at residues that are more distant but may play a role in conformational 
change. This study instead focussed on mutations chosen to shed light on potential 
conformational changes induced by insulin binding. Interestingly, the mutations in 
past studies that were found to cause the highest reduction in affinity for insulin 
involved residues that were either located on the CT peptide (demonstrated to be 
critical for insulin binding (Kristensen et al, 2002; Kristensen et al, 1998; Molina et 
al, 2000)) or have been shown in the insulin-bound crystal structures to be in close 
proximity to insulin (Menting et al, 2013; Menting et al, 2014). In contrast, mutations 
in past studies that were found to cause similar reductions in binding affinity to those 
investigated here were mostly located in the interface between the L1 domain and the 
CT peptide and thus did not appear to directly contact insulin. These mutations most 
likely affected insulin binding indirectly, via disruption of the interactions between the 
L1 domain and the CT peptide. Likewise, the IR mutations investigated in the work 
presented here primarily focussed on residues which potentially affected IR 
conformation rather than directly contacting insulin.  
 
The R114A mutation was found to result in the largest impact on insulin binding 
compared to wt-IR, having a KD value almost 10-fold higher and a dissociation rate 
almost 19-fold faster. This is in direct contrast to previous experimental data that 
showed the R114A mutation caused a three-fold reduction in the dissociation constant 
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compared to truncated wild-type IR (Williams et al, 1995). This discrepancy between 
my results and the published data could potentially be a result of using different IR 
proteins as well as the nature of the binding experiments that were undertaken. Unlike 
the IR proteins described in the work here, Williams et al (1995) used a truncated 
version of the receptor containing only the extracellular domains of the IR (a structure 
that displays only low affinity binding) whereas the experiments here investigated 
binding to receptors fused to dimerising structures to capture the high affinity binding 
state. Furthermore, the binding experiments performed here measured short term 
binding interactions (270 s association and 900 s dissociation time) whereas Williams 
et al (1995) conducted long-term equilibrium experiments (overnight incubation with 
insulin). As described in Section 4.2.3, this mutation was chosen based on the 
observations from the simulation data analysis and was proposed to result in a receptor 
that would maintain its ability to bind insulin but cannot be activated. Both the data 
here and that reported by Williams et al (1995) support the idea that this mutation 
could still bind insulin despite the two different sets of data showing the mutant IR 
binds insulin with different affinities (Williams et al, 1995). The experimental results 
presented here also support the idea that this particular mutation may lead to a loss of 
receptor activation as it was observed that the response levels of the binding curves 
returned to baseline levels, unlike that observed for wt-IR, and was interpreted as a 
loss of the high affinity binding state of the receptor, potentially a result of loss of the 
proposed switch function. Interestingly, despite having a weaker equilibrium constant 
as well as a faster dissociation rate compared to the wt-IR, the IR-R114A mutant also 
displayed a faster association rate. This suggests that apart from preventing the 
transition of the receptor into the high affinity binding state, the mutation may have 
also increased accessibility of insulin to the receptor binding sites. From the 
simulations performed in Chapter 4, Arg114 was observed to form a stable interaction 
with Asp250 which resulted in the formation of a link between the L1 and CR domains. 
Therefore, it is possible that Arg114 not only plays a role in the switch function 
proposed in Chapter 4, but also facilitates the stabilisation of the L1 and CR domains. 
Destabilisation of this link could have potentially caused the L1 domain to become 
more flexible and mobile, increasing accessibility to the receptor binding site and 
resulting in the fast association of insulin. Based on these conclusions, it appears that 
the experimental data here agrees with the simulation data and analyses performed in 
Chapter 4. 
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The E329A mutation was designed to break the link between the CR and L2 
domains by disrupting the interaction identified between Glu329 and Arg270. As seen 
from the experimental data, this mutation did not affect insulin binding to the same 
extent as the other mutations as it displayed a similar association rate compared to 
wt-IR and had the least impact on dissociation rate. Furthermore, the response levels 
of the IR-E329A binding curves was observed to remain above baseline levels, similar 
to that observed for the wt-IR, suggesting this mutant construct was able to transition 
into the high affinity binding state. While insulin binding affinity and the dissociation 
rate were not impacted to the same extent as the other mutations, the differences 
compared to the wt-IR were still determined to be statistically significant. From the 
IR-E329A simulation, analysed and discussed in Section 4.2.5, the receptor was 
observed to display the largest flexibility between the CR and L2 domains compared 
to simulations of the other mutations. This flexibility appears to be a result of loss of 
the interaction between Glu329 and Arg270 which in turn destabilised the CR and L2 
domains. Importantly, in the distantly related but structurally homologous EGFR, 
ligand binding involves a conformational change along a hinge point between the CR 
and L2 domains (Figure 4.40, p181). A similar movement along this region of the 
IGF1R was proposed by Kavran et al (2014) to lead to high affinity binding to IGF-I 
and this same hinge point in the IR could also be important for high affinity insulin 
binding. The interaction identified between the CR and L2 domains could therefore 
play a potential role in stabilising the high affinity conformation of the receptor and 
disruption of this may have affected its stability. Thus, while the experimental data 
indicates that the IR-E329A mutant was able to transition into the high affinity binding 
state, the faster dissociation rate and the increased flexibility between the CR and L2 
domains in the simulation suggests the receptor may have lost the ability to stabilise 
the high affinity binding conformation and may have quickly reverted back to the low 
affinity binding state. Furthermore, another link between the two domains (Lys310 and 
Glu287) was observed during the IR-E329A simulation and was speculated to 
compensate for the loss of the interaction between Glu329 and Arg270. Thus, while 
disruption of the link between the CR and L2 domains possibly caused the effects 
observed for the IR-E329A mutant, the potential compensating interaction provided 
by Lys310 and Glu287 may have helped retain receptor function. Disruption of both 
these interactions could potentially destabilise the CR and L2 domains to a greater 
extent than the single mutation investigated here. 
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The A351D mutation was selected to affect the hydrophobic pocket on the L2 
domain and make it an unfavourable environment for Phe714. Later models of an 
insulin-bound receptor, generated in Section 3.2.6 by merging the coordinates of 
insulin to the receptor model investigated here, suggested PheB25 (on insulin) could 
also potentially interact with this pocket. The experimental data presented here show 
the mutation resulted in a significant impact on the receptor’s affinity for insulin and 
the dissociation rate. Interestingly, the mutation also increased the association rate of 
insulin, similar to that observed in the IR-R114A mutant, suggesting an increased 
accessibility to the receptor binding site. Considering Ala351 is located over 25 Å 
away from Arg114, the A351D mutation is not believed to cause the same change in 
the receptor as the R114A mutation despite both mutations resulting in better 
accessibility to the binding site. The interaction between the hydrophobic pocket on 
the L2 domain and either Phe714 or PheB25 was proposed to be responsible for high 
affinity insulin binding (Section 4.2.3). In the IR-A351D simulation performed in 
Section 4.2.6, formation of this interaction was prevented causing Phe714 to gain 
increased mobility resulting in destabilisation of the CT peptide. This may have been 
reflected in the binding data where the receptor protein was observed to display an 
increased dissociation rate compared to wt-IR. Furthermore, the experimental data 
suggests that the receptor was able to transition to the high affinity binding state 
(response levels of the binding curves were observed to remain above baseline levels) 
but could not stably bind insulin in that conformation. Therefore, the stability of the 
high affinity binding conformation may have been affected in this IR mutant. From the 
analysis of the IR-A351D simulation in Section 4.2.6, it was observed that the salt 
bridge network identified in IR[1-468, CTex] (Figure 3.19) was not present and that only 
one inter-domain interaction was observed. This salt bridge network was proposed to 
stabilise the receptor in the insulin-bound conformation and thus loss of this network 
may have caused the receptor to be unstable during the high affinity binding state. As 
a result of this, the receptor may revert back to the low affinity conformation or release 
insulin prematurely resulting in the faster dissociation rate and the decrease in affinity 
for insulin that were observed in the experimental work. 
 
The E438A mutation was designed to disrupt the interaction between Glu438 
and Arg717 that was proposed to stabilise the CT peptide. The experimental data show 
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this mutation affected the overall affinity of the receptor for insulin and the 
dissociation rate but did not greatly impact the association rate. Additionally, the 
response levels of the binding curves were observed to return to baseline levels 
suggesting loss of the high affinity state of the receptor. These effects of the mutation 
may have come about due to destabilisation of the CT peptide. As seen in the 
IR-E438A simulation, the CT-tail was observed to become highly mobile while also 
causing the L2 domain to move further away from the L1 domain. While the mutant 
receptor was able to initially bind insulin, as reflected in the similar association rate 
compared to wt-IR, the increased mobility of the CT peptide may have affected how 
stably insulin bound to the receptor resulting in the faster dissociation rate as well as 
affecting the binding affinity. Interestingly, it was identified in the analysis of the 
IR-E438A simulation that Phe714 was observed to dislodge from the hydrophobic 
pocket on the L2 domain (Figure 4.30, p165), an effect similar to that induced by the 
A351D mutation. Both the A351D and E438A mutations resulted in similar effects on 
receptor binding and it is possible that these effects were brought about by the indirect 
disruption to the interaction between Phe714 and the hydrophobic pocket on the L2 
domain. The main difference between these two mutations was that IR-E438A 
displayed binding curves that had response levels return to baseline levels suggesting 
a loss of the high affinity binding state which may have come about due to the 
destabilisation of the CT peptide. Therefore, based on the simulation and experimental 
data, Glu438 may potentially play a role in high affinity binding of insulin via 
stabilisation of the CT peptide. 
 
5.3 CONCLUDING REMARKS 
Past mutagenesis studies have found residues on the IR that may play potentially 
important roles in ligand binding (Mynarcik et al, 1997a; Whittaker et al, 2002; 
Williams et al, 1995). Studies have also contributed to finding important insulin 
binding regions of the receptor via methods such as truncated receptor analysis (Brandt 
et al, 2001; Kristensen et al, 1998; Lou et al, 2006; Surinya et al, 2002) and chimeric 
receptor experiments (Andersen et al, 1992; Gauguin et al, 2008; Schumacher et al, 
1991; Slaaby et al, 2006). These studies however, were primarily focussed on residues 
surrounding the speculated binding interface between the receptor and insulin (sites 1 
and 2 on IR and binding surface 1 and 2 on insulin). More recent crystal structures of 
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the IR have shown that a subset of these residues were in fact, in contact with the CT 
peptide and thus did not directly bind insulin (Menting et al, 2013; Menting et al, 2014; 
Smith et al, 2010). The work presented here on the other hand, took a different 
approach that first identified conformations and interactions that may be potentially 
important determinants of the conformational change triggered by insulin binding. Key 
residues involved in these conformations or interactions were then mutated using in 
silico methods and MD simulations performed. These residues are not located in the 
speculated binding sites of the IR and thus have had little research focus to date. 
 
Studies have shown that IR truncated prior to the membrane lacks high 
insulin-binding affinity and that replacement of this with domains that have the 
propensity to dimerise (Fc domain, leucine zipper) reconstitutes wild-type-like 
behaviour (Bass et al, 1996; Hoyne et al, 2000). In the work presented here, I chose to 
replicate the Hoyne et al leucine zipper construct (Hoyne et al, 2000). The overall 
structure of the construct is shown in Figure 5.1. Furthermore, the Strep-tag II was 
included 3’ to the leucine zipper construct for protein purification and for use in the 
planned functional experiments. The Strep-tag II is necessary for the planned BIAcore 
experiments as it allows the correct positioning of the tagged receptor on the sensor 
chip surface. The orientation of the receptor is important as previous studies that 
directly immobilised the target protein onto the biosensor chip surfaces reported 
weaker affinities compared to native binding (Forbes et al, 1998; Subramanian et al, 
2013). Forbes et al speculated that the discrepancy in binding was potentially a result 
of incorrectly positioned receptors on the sensor chip surface that led to the reported 
impaired binding (Forbes et al, 2002). Thus, the Strep-tag II was added to avoid this 
potential problem and yield affinities that appear similar to native IR binding. 
Silver stain and Western blot analysis showed the successful expression and 
purification of the five designed IR protein constructs. Importantly, one of the mutant 
IR constructs, IR-A351D, was observed in the Western blots to have fainter bands 
compared to the other IR constructs. Degradation of the protein was identified as one 
of the potential causes for this faint band and raised concerns about the subsequent 
binding assays that were to be performed. If the sample included substantial amounts 
of degraded fragments containing the Strep-tag II, they would still be captured onto 
the surface of the biosensor chip via the anti-Strep antibody, resulting in an incorrect 
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estimate of the amount of immobilised functional receptor and interfering with the 
binding data. However, as seen in the BIAcore experiments, the IR-A351D construct 
was observed to bind insulin with a similar response and behaved similarly compared 
to the other mutants as well as the wt-IR, indicating the purified IR-A351D sample 
consisted of mostly functional receptor proteins.  
 
Previous experiments investigating insulin binding have reported insulin binding 
affinities and rate constants that differ from those determined from the work presented 
here. However, it is important to note that many of these studies were performed using 
equilibrium experiments that incubate insulin with the receptor for long periods of time 
(Bass et al, 1996; Hoyne et al, 2000; Schaffer, 1994). As demonstrated in a previous 
study, insulin displays two different dissociation rates from the IR; a rapid dissociation 
rate after initial ligand binding and a slow, time-dependent dissociation rate (Corin & 
Donner, 1982; Donner & Corin, 1980). In these studies, the slower dissociation rate 
was observed in a subpopulation and this population increased after longer incubation 
periods (Corin & Donner, 1982). Therefore, after long incubation periods, the 
receptors investigated in the equilibrium studies would be saturated with insulin bound 
to the high affinity state. The BIAcore experiments used here on the other hand, only 
measured the binding interactions between ligand and receptor for short periods of 
time (270 s association and 900 s dissociation time). Furthermore, different 
experimental conditions such as the low temperatures (0-15°C) in the equilibrium 
studies compared to the 25°C in the experiments performed here could also affect the 
binding parameters. Therefore, it is difficult to directly compare the results presented 
here to those obtained from long-term equilibrium experiments. As an example, the 
binding affinity obtained in the work here was approximately 10-fold weaker 
compared to that measured for the soluble IR ectodomain (Schaffer, 1994). A similar 
difference between immobilised receptor in BIAcore experiments and experimental 
data using soluble IGF1R was also reported by Forbes et al (2002) despite the receptor 
construct used in the BIAcore study also having a dimer inducing structure (Fc 
domain). Importantly, while the binding affinities obtained here cannot be compared 
to those obtained from equilibrium experiments, they can be compared against each 
other as they were all designed to have the same structural arrangements (IR 
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extracellular domain fused to a leucine zipper) and performed under the same 
conditions. 
 
In summary, five recombinant IR-leucine zipper fusion constructs were 
successfully generated and confirmed. The results showed the high purity of the 
protein elution samples and near complete conversion to correctly cleaved mature IR 
constructs. These recombinant proteins were then assessed via BIAcore analysis to 
determine their binding affinity towards insulin. The resulting data revealed the control 
wt-IR displayed a binding affinity comparable to a similar investigation using a surface 
plasmon resonance approach (Forbes et al, 2002) but was 10-fold weaker compared to 
studies using soluble IR (Schumacher et al, 1991). The mutations were all found to 
have a negative effect on the binding affinity of the receptor to insulin but displayed 
intriguing behaviours in regards to their association and dissociation rates, suggesting 
the residues involved may play different roles during the insulin binding process. 
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The IR plays a critical role in metabolism, mediated by the binding of its native 
ligand, insulin (Lee & Pilch, 1994). Abnormalities in the IR have been shown to lead 
to various illnesses and diseases such as diabetes (Olefsky, 1976), cancer (Frasca et al, 
1999), Leprechaunism (Elsas et al, 1985) and Rabson-Mendenhall syndrome (Rabson 
& Mendenhall, 1956). In the last few decades, extensive studies have contributed to 
the further understanding of the mechanism by which insulin engages and activates its 
receptor. These studies detected regions of the receptor that were speculated to directly 
contact insulin during the binding process, demonstrated the essential role of the 
C-terminal peptide in insulin binding and identified potentially important residues and 
regions via mutagenesis and chimera investigations.  
 
In the last decade, crystal structures of the extracellular portion of the IR (2DTG, 
2HR7, 3LOH) and also a set of insulin-bound IR fragments (3W11-3W14, 4OGA) 
were successfully resolved and allowed visualisation of the overall structure and 
positions of the different receptor domains. Very recently (December 2014), a new 
crystal structure of the IR dimer was made available (Croll et al, 2015) and provided 
greater resolution of the domain structures compared to the previous structure of the 
full extracellular domain (3LOH). In particular, the revised structure corrects folding 
errors in the FnIII-1 and FnIII-3 domains while a tentative model of the region 
connecting the CT peptide to the FnIII-2 domain was also made available. Importantly, 
the newer version of the FnIII-1 domain resulted in some changes to the interface 
between the L2 and FnIII-1 domains that are highly relevant to some of the work 
presented here. 
 
Despite this wealth of information made available by these studies however, the 
exact sequence of events by which insulin binds to and activates its receptor remains 
elusive. The conformational changes of the receptor that occur during and after the 
binding of insulin have yet to be elucidated. With a lack of availability of a crystal 
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structure of a complete insulin-bound IR, further work was needed to understand the 
insulin binding process.  
 
Early simulation and modelling work identified a potential binding site on the 
L2 domain for the CT-tail (Dr Tristan Croll, personal communication). Further work 
by Dr Croll resulted in generation of a new truncated IR model, IR [1-468, CT], that 
remained stable in subsequent MD simulations. Interestingly, the CT peptide in this 
IR [1-468, CT] structure was observed in the simulation to form a hairpin-like structure 
and caused the L1 and L2 domains to come into close proximity, forming a more 
compact structure (Figure 3.5). This was congruent with previous experimental work 
that showed a decrease in the Stokes radius of the receptor upon insulin binding (Florke 
et al, 2001) and the observed hairpin-like structure was speculated to reflect the 
conformational state of an intermediate or insulin-bound receptor.  
 
Using the IR [1-468, CT] structure as the starting point and in light of the currently 
available information, it was hypothesised that long term simulation and molecular 
dynamics analyses of receptor structures can be used to identify significant residues 
that are key to receptor-ligand interactions. This was investigated by first aiming to 
further understand the insulin binding process by comparing the available crystal 
structure data to simulation data of the IR and identify residues that may play important 
roles in ligand binding. Following this, the importance of these identified residues was 
investigated by performing MD simulations on mutant IR models before expression of 
the same mutations as IR protein constructs. Experimental investigations of the 
expressed IR proteins were then undertaken and complemented the predictions drawn 
from the analysis of the computational work. 
 
As reported in Chapter 3, an in-depth analysis of the currently available IR 
crystal structures was conducted and compared against molecular dynamics 
simulations of the IR [1-468, CT] structure. This resulted in the identification of two 
potentially important salt bridge interactions between the CR and L2 domains that have 
not been reported previously (Table 3.2). Despite these two regions not being 
commonly recognised as forming one of the two binding sites for insulin, studies have 
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shown that photoactive insulin analogues crosslinked to the CR domain of the receptor 
(Yip et al, 1988), suggesting formation of these interactions could potentially be 
important in the IR. Other studies have also suggested that these domains may 
contribute to insulin binding in different ways. A region of the L2 domain in the closely 
related insulin-like growth factor 1 receptor (IGF1R) was shown in a study to become 
protected from hydrogen exchange following ligand binding indicating a 
conformational change occurred involving the L2 domain (Houde & Demarest, 2011). 
The CR domain, on the other hand, was shown in another study to play a potential role 
in ligand specificity as substitution of this region with its equivalent from IGF1R 
resulted in a receptor that bound both insulin and IGF-I with high affinity (Schumacher 
et al, 1991). These studies demonstrated the potential importance of the CR and L2 
domains and warrant further investigation to understand their impacts on insulin 
binding.  
 
In the simulations of wild-type and mutant IR[1-468, CT] constructs performed here, 
a common conformational change of the receptor was observed. This change involved 
the CR and L2 domains which, as discussed above, have been shown in other studies 
to contribute indirectly to receptor binding. Based on the fact that the IR has been 
shown to undergo a conformational change upon the binding of insulin (Donner & 
Yonkers, 1983; Florke et al, 2001; Lee et al, 1997; Pilch & Czech, 1980; Waugh & 
Pilch, 1989), the observed conformational change was proposed to potentially reflect 
the structural change experienced by the receptor upon ligand binding. Importantly, 
the conformational change appeared to involve a rotation along a hinge point located 
between the CR and L2 domain and was associated with a compaction of receptor 
shape. A recent study of the IGF1R extracellular domains speculated the existence of 
the same hinge point between the CR and L2 domain and suggested that rotation along 
this point would result in activation of the receptor (Kavran et al, 2014). 
Problematically, Kavran et al (2014) speculated that rotation along the hinge point 
results in the L1 and CR domains moving away from the adjacent FnIII domains, a 
conformational change proposed to be in response to the binding of IGF-I. Such a 
movement of the domains would result in a spatially wider receptor which directly 
contrasts with previous reports that the insulin receptor experiences a decrease in 
Stokes radius upon insulin binding (Florke et al, 2001). However, this proposal by 
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Kavran et al (2014) was based on the identification of an insulin-bound IR dimer that 
displayed a different conformation compared to the crystal structure of the 
extracellular domains of the IR (crystal structure 3LOH (McKern et al, 2006)). This 
different structural configuration was interpreted by the authors as the conformation 
of the receptor in the insulin-bound state and was used as the basis of their 
investigations (Kavran et al, 2014). Problematically, this structure of the receptor is 
not representative of the native IR structure as the CT peptide was fused directly to the 
FnIII-1 and FnIII-2 domains and was dominated by multiple non-specific crystal 
contacts. Therefore, the conformational change of the IR in response to insulin binding 
that was proposed by Kavran et al (2014) may not be entirely accurate. 
 
The conformational change observed in the work presented here, also showed 
the L1 and CR domain rotating along the identified hinge point, but in a different 
direction to that proposed by Kavran et al. The conformational change, when 
superimposed onto the IR dimer, moves the L1 domain inwards at varying distances 
(depending on the IR construct) towards the centre of the dimer (Figure 4.38) rather 
than outwards as described by Kavran et al. Such a drastic change in the conformation 
of the receptor would likely result in subsequent domain rearrangements that may lead 
to receptor activation. However, upon dimerisation of the two ‘legs’ of the IR dimer 
as demonstrated by Kavran et al (Kavran et al, 2014), this centre region of the receptor 
would not be able to accommodate the L1 domain if the conformational changes seen 
in the simulations performed here were to occur. Thus, it is important to note here that 
this conformational change may not be observed in the IR dimer due to the presence 
of the other IR domains. In fact, the conformational changes may have come about due 
to an increased flexibility of the domains in the IR[1-468, CT] construct. Use of the 
IR[1-468, CT] construct in the molecular modelling and dynamics simulation work was 
chosen to limit the computing capacity required but still represented a structure that 
has been shown to bind insulin. If resources permit, a model of the full-sized IR dimer 
could be explored in the future and could potentially provide information on the 
behaviour of the other domains that were not investigated here.  
 
Nevertheless, the conformational change observed in the simulation of the 
IR[1-468, CT]  construct revealed a potential range of motions which may be involved in 
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receptor functions. The range of motions and the observed conformational change 
were investigated further by taking the coordinates of the L1, CR and L2 domains from 
the IR[1-468, CTex] model and merging them with the coordinates of insulin from the most 
recent insulin-bound crystal structure (4OGA) (Menting et al, 2014). Molecular 
modelling and dynamics simulations of this merged IR structure (IR[merge]) found the 
observed conformation of the L1, CR and L2 domains in the IR[1-468, CTex] model was 
able to accommodate the addition of insulin without causing any major changes in the 
overall structure. Furthermore, the position of insulin in IR[merge] was compatible with 
the results from previous crosslinking studies that attempted to map the IR binding 
sites for insulin (Fabry et al, 1992; Kurose et al, 1994; Shoelson et al, 1993; Waugh, 
DiBella, & Pilch, 1989; Wedekind et al, 1989; Yip et al, 1988).  
 
Importantly, Yip et al reported that an insulin analogue, with a photoactive 
molecule linked to LysB29, crosslinked to an IR fragment containing residues 205–
316, mapping to the CR domain (Yip et al, 1988). Although LysB29 is not located 
close to the CR domain in the IR[merge] structure, the probe used in the Yip et al study, 
N-[4-(p-azido-m-[125I]iodophenylazo)benzoyl]-3-aminopropyl-N', is quite bulky and 
is long enough to reach the CR domain and allow crosslinking to occur. Figure 6.1 
shows the possible regions of the receptor that the photoactive molecule can potentially 
reach based on the position of LysB29 in the IR[merge] structure. These potential regions 
of the receptor all fall within the IR fragment that the photoactive molecule was found 
to be crosslinked, suggesting the position of LysB29 in the IR[merge] structure agrees 
with the experimental data from the Yip et al study. Another study using a biotinylated, 
photoreactive derivative of insulin found residue PheB1 on the insulin B-chain 
crosslinked to an IR fragment containing parts of the L2 and FnIII-1 domain (Fabry et 
al, 1992). Interestingly, during simulation of the IR[merge] structure, PheB1 was 
observed to briefly migrate upwards towards the C-terminal end of the L2 domain. 
Such a migration would place PheB1 in close proximity to the junction between the 
L2 and FnIII-1 domains, with potential to crosslink to this receptor region. This 
interaction has not been observed in any of the available insulin-bound crystal 
structures of the IR due to the absence or non-native position of the L2 domain 
(3W11-3W14, 4OGA). Thus, the IR[merge] structure may highlight other interactions 
between insulin and receptor that have yet to be found through other means. Closer 
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examination of the IR[merge] structure found new potential interactions between insulin 
and the receptor, particularly between the insulin A-chain and the receptor’s L2 
domain. This potential binding interface between insulin and the IR has not been 
previously reported, nor has this region of the receptor received much research focus. 
Future work could focus on investigating this potential binding interface using mutant 
receptor constructs or insulin analogues to investigate these interactions further.  
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Figure 6.1: Regions on the IR[merge] structure that the insulin analogue used by Yip et al could 
potentially crosslink. The photoactive molecule used by Yip et al was added to the IR[merge] structure 
at the reported linking residue (LysB29) (Yip et al, 1988) and shows the regions of the receptor it can 
potentially crosslink. A, crosslinking of the photoactive molecule to the hinge point between the CR and 
L2 domains; B, crosslinking of the photoactive molecule to the N-terminal end of the CR domain; C, 
crosslinking of the photoactive molecule to the C-terminal end of the CR domain. These structures 
demonstrate that the IR[merge] structure agrees with the results reported by Yip et al (1988). The IR[merge] 
structure is shown in secondary structure representation and the photoactive molecule is shown in van 
der Waals representation. The domains in the IR[merge] structure are coloured as follows: L1-CR-L2, 
blue; CT peptide, red; insulin A-chain, grey; insulin B-chain, orange. The photoactive molecule is 
coloured purple and green, where the purple region is cleaved while the green region is 
photo-crosslinked to the receptor. 
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Considering the CT peptide has been demonstrated to play an essential role in 
ligand binding, it was very interesting when the CT-tail in the IR [1-468, CT] structure 
was observed in its simulation to form a hairpin-like structure which coincided with 
the L1 and L2 domains coming into close proximity. As discussed in Chapter 3, this 
was important because previous experimental work showed a decrease in the Stokes 
radius of the receptor upon insulin binding (Florke et al, 2001) and suggested that the 
observed change could potentially reflect the conformational state of an intermediate 
or insulin-bound receptor. Thus, this conformation of the CT-tail was explored further 
by investigating the effects of a cyclised CT peptide analogue (cyc-CT) on the 
receptor. It is important to note here that prior to this investigation, the structural data 
highlighting the primary insulin binding site and the interactions between receptor and 
ligand were unavailable (crystal structures 3W11-3W14 and 4OGA). Analysis of 
IR cyc-CT simulation saw the construct undergoing a conformational change that was 
similar to that seen in the IR[1-468, CT] simulation but involved a larger motion. 
Following this, real-time binding experiments were conducted using the truncated IR[1-
468] construct in the presence of either cyc-CT or linear CT peptide to further 
understand how cyclisation of the CT peptide affected ligand binding. 
 
Results from these binding experiments showed the truncated IR[1-468] construct 
bound to immobilised insulin with a 10-fold higher association rate in the presence of 
the cyc-CT peptide compared to linear CT. However, cyc-CT also induced a 3.4-fold 
faster dissociation of the receptor from insulin. It wasn’t until the availability of the 
first insulin-bound crystal structures (3W11-3W14) that it became clearer how 
cyclisation of the CT peptide may have caused these observed differences in ligand 
binding. Simulations of the IR[1-468, CTex] and IR cyc-CT structures that induced the 
extra turn in the α-helix of the CT peptide mimicking that observed in the 
insulin-bound crystal structures found a similar conformational change despite 
different interactions identified between the domains. These differences were possibly 
reflected in the real-time binding experiments. For example, the higher association rate 
measured for the IR+cyc CT complex suggested that the cyc-CT may be restricting the 
receptor into a conformation that binds insulin favourably, perhaps the same 
conformation that was observed in simulations of the IR[1-468, CTex] and IR cyc-CT 
structures. However, cyclisation of the CT peptide may have resulted in restrictions 
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that prevent it from matching the bound state of the linear form of the CT peptide, 
resulting in the higher dissociation rate measured for IR+cyc CT compared to IR with 
the linear CT. 
 
The idea that the receptor may undergo more than one conformational change 
has previously been proposed by other groups (Baron et al, 1992; Lee et al, 1997). 
Baron et al (1992) proposed that their experimental data provided direct evidence 
towards distinct conformational changes of the receptor; the first change upon the 
initial binding of insulin, a pre-activated conformation of the receptor that is able to 
bind ATP before autophosphorylation results in complete activation of the receptor 
and its subsequent signal cascade (Baron et al, 1992). Lee et al (1997) also found 
evidence for different conformations of the receptor, detected via fluorescence 
spectroscopy (Lee et al, 1997). Lee et al proposed a similar model for receptor 
activation where insulin binds to the receptor triggering an initial conformational 
change (Lee et al, 1997). Following this, a second conformational change was 
proposed to occur which is transmitted through the receptor before 
autophosphorylation results in receptor activation (Lee et al, 1997). The binding 
results for the IR+cyc-CT presented here may be interpreted as evidence for different 
conformations of the receptor during the insulin binding process. The higher 
association rate of the IR+cyc-CT complex could potentially reflect the receptor in the 
post insulin-bound state whereas the higher dissociation rate could indicate the 
receptor’s inability to follow through and transition into the intermediate, pre-activated 
conformation suggested by Baron et al (1992).  
 
A potentially unique structure to probe binding-activation steps in ligand binding 
is one incorporating a documented natural mutation of the IR, R86P, that was reported 
to lack insulin binding activity but was constitutively activated (Longo et al, 1993). 
When this mutation was studied in the present work, a distinctly different structural 
change was observed when comparing simulations of IR-R86P and wt-IR. Analysis of 
the IR-R86P simulation found displacement of a region of the CR domain (green 
region in Figure 4.4A and B) that was not observed in simulation of the wt-IR 
structure. This motion involved residues Cys266 to His275 moving from their starting 
position and towards the L2 domain. Interestingly, the starting position of the CR 
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domain was in close proximity to a region of the L1 domain that was identified in the 
4OGA crystal structure to be in contact with the insulin B-chain tail (Menting et al, 
2014). This movement of the CR domain could potentially act as an indicator of insulin 
binding and cause subsequent changes that may lead to receptor activation. As 
discussed earlier in this chapter, previous studies have reported that LysB29 on insulin 
crosslinks to a region of the receptor that contains residues 205–316 on the CR and L2 
domain (Yip et al, 1988). The simulation data of the IR-R86P construct has 
demonstrated residues 266-275 have a range of motions that include the potential to 
move into close proximity to where LysB29 on insulin is located in the 4OGA crystal 
structure (Menting et al, 2014). Therefore, upon engagement of insulin, LysB29 could 
potentially move into the position shown in the 4OGA crystal structure and induce a 
response from the receptor that involves the displacement of residues 266-275 on the 
CR domain. This motion was not observed in the wt-IR simulation. In both 
simulations, insulin was not present but the IR-R86P simulation can be interpreted to 
reveal motion, the displacement of CR domain, that may represent motion associated 
with a constitutively activated receptor, a state for which this mutated receptor is 
known. This motion could potentially be a subsequent change of the receptor triggered 
by the proposed switch function for Arg86 described in Section 4.3.2, where the 
presence of insulin results in breaking of the salt bridge interaction with Asp250 and 
result in the displacement of the CR domain.  
 
Based on the computational work performed in Chapter 3 and the first two 
sections of Chapter 4, four key residues were predicted to form interactions that may 
potentially be important in insulin binding and receptor conformation. The four key 
residues identified were Arg114, Glu329, Ala351 and Glu438. The interactions 
involving these key residues were then disrupted by mutation of the residue in question 
and further investigated using mutant IR models and molecular dynamics simulations. 
The selected mutations for the identified residues were R114A, E329A, A351D and 
E438A. Analysis of the four mutant IR simulations found a common conformational 
change amongst them and it appeared to be very similar to that observed for the 
IR[1-468, CTex] and IR cyc-CT structures. The conformational change observed in the 
mutant IR constructs showed the hinge point between the CR and L2 domains allowed 
for a large degree of rotation, with the largest rotation observed in the IR-E329A 
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simulation. As discussed in detail in Section 4.2.9, the receptor domains involved (L1, 
CR and L2) have the propensity to undergo the observed conformational change and, 
when superimposed with the new crystal structure of the IR dimer (Croll et al, 2015), 
appeared to be able to accommodate the conformational change without requiring 
substantial rearrangements. However, it still remained unclear how the negative 
cooperativity nature of the receptor comes about. As mentioned previously, future 
work could explore the use of IR dimer models to study the effects of single point 
mutations to the entire IR structure and may shed light on how insulin binding affects 
the conformational changes of the receptor, including how negative cooperativity is 
induced. 
 
The choice of insect cells for expression of the IR constructs in Chapter 5 raised 
some concerns as the protein products may differ due to the intrinsic differences in 
how these host cells process and perform post-translational modifications (Jarvis, 
2003; Tomiya, Narang, Lee, & Betenbaugh, 2004). However, further research into the 
literature showed this concern has been addressed by previous studies investigating 
expressed IR fragments from insect cell expression systems (Ellis et al, 1988; Sissom 
& Ellis, 1989). These studies demonstrated that despite different glycosylation 
patterns, the expressed IR proteins from insect cells displayed both insulin binding 
ability as well as in vivo phosphorylation comparable to those expressed in mammalian 
host cells (Ellis et al, 1988; Sissom & Ellis, 1989). Furthermore, whilst the proteins 
expressed in this project were not assessed for correct folding, subsequent binding 
experiments showed that the expressed wt-IR bound insulin with a comparable affinity 
to that reported for IGF1R examined under similar conditions (Forbes et al, 2002), and 
all mutants bound insulin with affinities in the nanomolar range. 
 
Following successful expression, purification and validation of the wt-IR and the 
four IR mutants, the protein constructs were assessed for their ability to bind insulin 
using BIAcore experiments. The resulting binding data showed each mutation in the 
IR resulted in a detrimental effect on the receptor’s binding affinity for insulin. 
Surprisingly, the IR-R114A and IR-A351D mutants were measured to have higher 
association rates compared to the wt-IR control indicating they bound insulin much 
faster. The same mutants also displayed a faster dissociation rate suggesting those IR 
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constructs were not able to maintain high affinity binding to insulin. The IR-E329A 
and IR-E438A mutant receptors on the other hand, were found to maintain similar 
association rates compared to wt-IR but also displayed faster dissociation rates, albeit 
not to the same extent as the other two mutants. Aside from the possible explanations 
for the decrease in binding affinity discussed in Chapter 5, other possibilities have 
risen in light of the new crystal structure of the IR (Croll et al, 2015).  
 
The R114A mutation was selected based on the identification of a salt bridge 
network formed between Arg114, Asp250 and Arg83 in the IR-R86P simulation. This 
interaction was proposed to act like a switch mechanism in which binding of insulin 
would disrupt this salt bridge network in the wt-IR and trigger subsequent receptor 
changes. However, in the latest IR crystal structure (Croll et al, 2015), this proposal 
has to be questioned, as Arg114 is observed to be hydrogen bonded to Ser719 of the 
CT-tail. Based on this interaction and the fact that the CT peptide is essential for ligand 
binding, it is possible Arg114 is still part of a switch mechanism and that mutation of 
Arg114 to alanine disrupted this interaction with Ser719 and caused an as yet unknown 
effect on the receptor’s ability to bind insulin. Loss of this interaction would allow 
Ser719 to interact with other residues which could in turn potentially affect how 
interactions associated with those residues behave during insulin binding. It is 
important to note however, that the new IR structure (Croll et al, 2015) is of the 
receptor in the “open” conformation rather than the “closed” conformation that was 
shown by Kavran et al to occur after ligand binding (Kavran et al, 2014). Therefore, 
the position of Arg114 may be different in the “closed” conformation and may still be 
able to participate in the proposed switch mechanism. As has been highlighted 
throughout the history of proposed structures and their refinements, the currently 
proposed interactions from the most recent structures may be further modified as 
detailed information comes to hand. 
 
The E329A was chosen due to the identification of a potentially important 
interaction between Glu329 and Arg270. Interestingly, this interaction was observed 
to form during the conformational change observed in almost all the simulations of the 
IR (including the IR mutants and excluding the E329A mutation). This interaction 
appeared to maintain the structure of the receptor after the observed conformational 
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change rather than initiate it suggesting it may play a role in stabilisation of the receptor 
after insulin binding. In the new crystal structure of the IR, the two residues involved 
in this interaction are not observed to be in close proximity to each other (Croll et al, 
2015). However, if the CR and L1 domain undergo a similar conformational change 
via rotation along the hinge point discussed earlier, it is not impossible for these 
residues to come into closer proximity to form the interaction identified in the 
simulations. Based on this new crystal structure data and the BIAcore data presented 
here, it may be that Glu329 does not directly partake in insulin binding which explains 
why the IR-E329A mutant was able to bind insulin with a comparable association rate 
as wt-IR. Following insulin binding, the receptor could potentially undergo the 
observed conformational change and bring Glu329 into close proximity to Arg270 
where the identified salt bridge is allowed to form, stabilising the receptor in this new 
conformation. The E329A mutation most likely affected this part of the insulin binding 
process as the receptor may still have been able to undergo a structural transition to 
bind insulin with high affinity but could not maintain this conformation due to the loss 
of the salt bridge between Glu329 and Arg270. This would also explain why this 
mutant IR had a faster dissociation rate compared to wt-IR but not to the same extent 
as the IR-R114A and IR-A351D mutants.  
 
The A351D mutation was originally selected to test the possibility of the 
interaction between the hydrophobic pocket on the L2 domain and Phe714 on the CT 
peptide. Later models of an insulin bound receptor, generated by merging the 
coordinates of insulin with the IR[1-468, CT] model (generated in Section 3.2.6), 
suggested PheB25 (on insulin) could also potentially interact with this pocket. 
However, in the new IR crystal structure, the hydrophobic pocket of the L2 domain is 
shown to be directly facing a region of the FnIII-1 domain and may instead be able to 
accommodate a different residue, Phe518 (Croll et al, 2015). Therefore, this new 
crystal structure presents a different hypothesis; that the hydrophobic pocket on the L2 
domain contacts Phe518 following insulin binding. Furthermore, while the 
hydrophobic pocket and Phe518 are not shown in this crystal structure to be in direct 
contact with each other, the structure itself is in the “open” conformation of the 
receptor. As demonstrated in a previous study, the “legs” of the receptor dimerise upon 
ligand binding (Kavran et al, 2014) forming the “closed” configuration of the receptor 
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which could potentially bring Phe518 into direct contact with the hydrophobic pocket. 
In a recent hydrogen/deuterium-exchange study, the IGF1R equivalent of the region 
surrounding Ala351 in IR was shown to be part of a tryptic fragment where some of 
its residues gained protection upon ligand binding (Houde & Demarest, 2011). In light 
of the new crystal structure, it seems likely that upon ligand binding, the facing regions 
of the L2 domain and FnIII-1 come into close proximity bringing Phe518 into contact 
with the hydrophobic binding pocket. Therefore, the A351D mutation most likely 
affected the receptor via this potential interaction with Phe518 rather than the 
interaction with Phe714 or PheB25 as previously thought. Such a change would make 
it unfavourable for the faces of the L2 and FnIII-1 domains to come into contact with 
each other and could potentially prevent the receptor from transitioning into a 
conformation that binds insulin with a higher affinity.  
 
Alternatively, the A351D mutation may have caused changes to the receptor that 
resulted in migration of the L1 domain away from the FnIII-2 domain. The same effect 
on the receptor may have occurred in a previous cryo-electron microscopy study of the 
insulin receptor where the receptor was visualised to resemble a “Y” shape (Woldin et 
al, 1999) rather than the “T” and inverted “V” shapes found in other electron 
microscopy studies (Christiansen et al, 1991; McKern et al, 2006). The “Y” shaped 
receptor suggests unfolding of the receptor where the L1 domain may have dissociated 
away resulting in the differently shaped receptor. Therefore, it is possible that the 
A351D mutation caused a similar dissociation of the L1 domain. Such a change in the 
receptor would result in a more accessible binding site on the receptor, increasing the 
association rate of insulin. This same dissociation of the L1 domain however, would 
also result in fast dissociation of insulin as the bound ligand would not be able to 
crosslink to the second binding site on the receptor. This also explains the loss of high 
affinity binding of the IR-A351D mutant receptor. However, these are speculations 
only and further work will be needed to elucidate how the receptor was affected by the 
A351D mutation. 
 
The E438A mutation was selected based on the interaction formed between 
Glu438 and Arg717 observed in the IR[1-468, CT] model. Similar to Ala351, Glu438 is 
also observed in the latest crystal structure to be located in close proximity to the 
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interface between the L2 and FnIII-1 domains. As such, the interaction between 
Glu438 and Arg717 observed in the IR[1-468, CT] model appears less likely to occur. 
Similar to what was discussed for the A351D mutation, Glu438 appears to face the 
FnIII-1 domain and that the E438A mutation likely affected the interface between the 
L2 and FnIII-1 domains rather than the salt bridge interaction between Glu438 and 
Arg717 observed in the IR[1-468, CT] model. However, despite the possibility that both 
the E438A and A351D mutations disrupted the interface between the L2 and FnIII-1 
domains, the E438A mutation had much less impact on the receptor’s affinity for 
insulin compared to the A351D mutation. This is possibly due to the fact that Glu438 
is shown in the crystal structure to be located close to the edge of the L2-FnIII-1 
interface compared to Ala351 which is situated at the centre. Thus, based on the new 
crystal structure data and the BIAcore results, it would appear that Glu438 may play 
less of a role in ligand binding compared to Ala351 or rather, the hydrophobic pocket 
in which Ala351 resides. 
 
The experimental work presented in Chapter 5 was able to determine the binding 
affinity of the mutant IRs towards insulin and provide new insights into the roles their 
respective residues may play in ligand binding. However, the effects of these mutations 
on the subsequent activation of the receptor following insulin binding still remain 
unknown. Future work should involve the expression of these mutant receptors on cell 
surfaces and measurement of autophosphorylation to assess how the mutations may 
have affected receptor activation. Furthermore, structural analyses of not only the 
mutant IR constructs but also the wt-IR protein construct generated in this project may 
provide new information into the binding mechanisms of the IR, and our laboratory is 
currently exploring collaborative work to undertake cryo-electron microscopy and 
crystallography of these constructs.  
 
The work presented here describes the study and analysis of different IR 
molecular models that resulted in the identification of potentially key residues that may 
be important during insulin binding. This led to the investigation of three novel (to the 
best of our knowledge) and one previously studied mutation in the IR that were 
demonstrated through binding experiments to affect the receptor’s ability to bind 
insulin. The use of a combination of computational and experimental work contributed 
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to the further understanding of the steps involved in insulin binding and initial 
responses to that binding. Increased knowledge of how the IR binding mechanism 
works will aid future research into how illnesses and diseases involving the IR may 
come about and could potentially lead to the development of new therapeutic avenues 
to combat these health-related issues. 
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APPENDIX A: SUMMARY OF AVAILABLE CRYSTAL STRUCTURES OF 
IR AND IGF1R EXTRACELLULAR DOMAINS AND THEIR USES IN THIS 
STUDY 
PDB ID Receptor Residues 
involved 
Reference Computational model 
generated from structure 
2HR7 IR 31-495 (Lou et al, 2006) IR[1-468, CT] structure 
generated in Section 3.1 
2DTG IR 31-682, 
782-936 
(McKern et al, 2006) IR[1-468, CT] structure 
generated in Section 3.1 
3LOH IR 31-682, 
720-737, 
782-936 
(Smith et al, 2010) IR[1-468, CT] structure 
generated in Section 3.1 
3W11 IR 32-186, 
195-292, 
303-337, 
732-742 
(Menting et al, 2013) IR[1-468, CTex] structure 
generated in Section 3.2.2 
3W12 IR 32-186, 
195-292, 
303-337, 
732-742 
(Menting et al, 2013) Unused 
3W13 IR 32-186, 
195-292, 
303-337, 
732-742 
(Menting et al, 2013) Unused 
3W14 IR 32-538, 
561-622, 
732-742 
(Menting et al, 2013) Unused 
4OGA IR 32-186, 
195-292, 
303-337, 
732-746 
(Menting et al, 2014) IR[merge] structure generated 
in Section 3.2.6 
1IGR IGF1R 31-490, 
498-508 
(Garrett et al, 1998) Unused 
 
  
256 
256 Appendices 
APPENDIX B: PATCH USED IN MODELLING OF IR CYC-CT 
 
PRES THIM               0.00 ! Patch to create a thioether bond between a  
                             ! methionine and acetylated 
GROUP                        ! N-terminus, methionine must be first residue  
                             !chosen in patch statement 
 
ATOM 1CB  CT2     -0.18 
ATOM 1HG1 HA       0.09 
ATOM 1HG2 HA       0.09 
ATOM 1CG  CT2     -0.14 ! 
ATOM 1HG1 HA       0.09 !      1HG1        2HY1  2OY  2HN 
ATOM 1HG2 HA       0.09 !       |           |     ||   | 
ATOM 2CAY CT2     -0.14 !   ---1CG---1SD---2CAY--2CY--2N--- 
ATOM 2HY1 HA       0.09 !       |           | 
ATOM 2HY3 HA       0.09 !      1HG2        2HY3 
ATOM 1SD  S       -0.08 ! 
GROUP                   !       
ATOM 2CY  C        0.51 !       
ATOM 2OY  O       -0.51 !       
 
DELETE ATOM 1CE 
DELETE ATOM 1HE1 
DELETE ATOM 1HE2 
DELETE ATOM 1HE3 
DELETE ATOM 2HY2 
 
BOND 1SD 2CAY 
 
ANGLE 1CG 1SD 2CAY  1SD 2CAY 2HY1  1SD 2CAY 2HY3  1SD 2CAY 2CY 
 
DIHE 1HG1 1CG  1SD  2CAY    1HG2 1CG  1SD  2CAY 
DIHE 1CG  1SD  2CAY 2HY1    1CG  1SD  2CAY 2HY3    1CG  1SD  2CAY 2CY 
DIHE 1SD  2CAY 2CY  2OY     1SD  2CAY 2CY  2N 
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APPENDIX C: IR-A AMINO ACID SEQUENCE 
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APPENDIX D: IR-A DNA SEQUENCE 
        1 gagaaggacg cgcggccccc agcgcctctt gggtggccgc ctcggagcat gacccccgcg 
       61 ggccagcgcc gcgcgctctg atccgaggag accccgcgct cccgcagcca tggccaccgg 
      121 gggccggcgg ggggcggcgg ccgcgccgct gctggtggcg gtggccgcgc tgctactggg 
      181 cgccgcgggc cacctgtacc ccggagaggt gtgtcccggc atggatatcc ggaacaacct 
      241 cactaggttg catgagctgg agaattgctc tgtcatcgaa ggacacttgc agatactctt 
      301 gatgttcaaa acgaggcccg aagatttccg agacctcagt ttccccaaac tcatcatgat 
      361 cactgattac ttgctgctct tccgggtcta tgggctcgag agcctgaagg acctgttccc 
      421 caacctcacg gtcatccggg gatcacgact gttctttaac tacgcgctgg tcatcttcga 
      481 gatggttcac ctcaaggaac tcggcctcta caacctgatg aacatcaccc ggggttctgt 
      541 ccgcatcgag aagaacaatg agctctgtta cttggccact atcgactggt cccgtatcct 
      601 ggattccgtg gaggataatt acatcgtgtt gaacaaagat gacaacgagg agtgtggaga 
      661 catctgtccg ggtaccgcga agggcaagac caactgcccc gccaccgtca tcaacgggca 
      721 gtttgtcgaa cgatgttgga ctcatagtca ctgccagaaa gtttgcccga ccatctgtaa 
      781 gtcacacggc tgcaccgccg aaggcctctg ttgccacagc gagtgcctgg gcaactgttc 
      841 tcagcccgac gaccccacca agtgcgtggc ctgccgcaac ttctacctgg acggcaggtg 
      901 tgtggagacc tgcccgcccc cgtactacca cttccaggac tggcgctgtg tgaacttcag 
      961 cttctgccag gacctgcacc acaaatgcaa gaactcgcgg aggcagggct gccaccagta 
     1021 cgtcattcac aacaacaagt gcatccctga gtgtccctcc gggtacacga tgaattccag 
     1081 caacttgctg tgcaccccat gcctgggtcc ctgtcccaag gtgtgccacc tcctagaagg 
     1141 cgagaagacc atcgactcgg tgacgtctgc ccaggagctc cgaggatgca ccgtcatcaa 
     1201 cgggagtctg atcatcaaca ttcgaggagg caacaatctg gcagctgagc tagaagccaa 
     1261 cctcggcctc attgaagaaa tttcagggta tctaaaaatc cgccgatcct acgctctggt 
     1321 gtcactttcc ttcttccgga agttacgtct gattcgagga gagaccttgg aaattgggaa 
     1381 ctactccttc tatgccttgg acaaccagaa cctaaggcag ctctgggact ggagcaaaca 
     1441 caacctcacc atcactcagg ggaaactctt cttccactat aaccccaaac tctgcttgtc 
     1501 agaaatccac aagatggaag aagtttcagg aaccaagggg cgccaggaga gaaacgacat 
     1561 tgccctgaag accaatgggg accaggcatc ctgtgaaaat gagttactta aattttctta 
     1621 cattcggaca tcttttgaca agatcttgct gagatgggag ccgtactggc cccccgactt 
     1681 ccgagacctc ttggggttca tgctgttcta caaagaggcc ccttatcaga atgtgacgga 
     1741 gttcgacggg caggatgcgt gtggttccaa cagttggacg gtggtagaca ttgacccacc 
     1801 cctgaggtcc aacgacccca aatcacagaa ccacccaggg tggctgatgc ggggtctcaa 
     1861 gccctggacc cagtatgcca tctttgtgaa gaccctggtc accttttcgg atgaacgccg 
     1921 gacctatggg gccaagagtg acatcattta tgtccagaca gatgccacca acccctctgt 
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     1981 gcccctggat ccaatctcag tgtctaactc atcatcccag attattctga agtggaaacc 
     2041 accctccgac cccaatggca acatcaccca ctacctggtt ttctgggaga ggcaggcgga 
     2101 agacagtgag ctgttcgagc tggattattg cctcaaaggg ctgaagctgc cctcgaggac 
     2161 ctggtctcca ccattcgagt ctgaagattc tcagaagcac aaccagagtg agtatgagga 
     2221 ttcggccggc gaatgctgct cctgtccaaa gacagactct cagatcctga aggagctgga 
     2281 ggagtcctcg tttaggaaga cgtttgagga ttacctgcac aacgtggttt tcgtccccag 
     2341 gccatctcgg aaacgcaggt cccttggcga tgttgggaat gtgacggtgg ccgtgcccac 
     2401 ggtggcagct ttccccaaca cttcctcgac cagcgtgccc acgagtccgg aggagcacag 
     2461 gccttttgag aaggtggtga acaaggagtc gctggtcatc tccggcttgc gacacttcac 
     2521 gggctatcgc atcgagctgc aggcttgcaa ccaggacacc cctgaggaac ggtgcagtgt 
     2581 ggcagcctac gtcagtgcga ggaccatgcc tgaagccaag gctgatgaca ttgttggccc 
     2641 tgtgacgcat gaaatctttg agaacaacgt cgtccacttg atgtggcagg agccgaagga 
     2701 gcccaatggt ctgatcgtgc tgtatgaagt gagttatcgg cgatatggtg atgaggagct 
     2761 gcatctctgc gtctcccgca agcacttcgc tctggaacgg ggctgcaggc tgcgtgggct 
     2821 gtcaccgggg aactacagcg tgcgaatccg ggccacctcc cttgcgggca acggctcttg 
     2881 gacggaaccc acctatttct acgtgacaga ctatttagac gtcccgtcaa atattgcaaa 
     2941 aattatcatc ggccccctca tctttgtctt tctcttcagt gttgtgattg gaagtattta 
     3001 tctattcctg agaaagaggc agccagatgg gccgctggga ccgctttacg cttcttcaaa 
     3061 ccctgagtat ctcagtgcca gtgatgtgtt tccatgctct gtgtacgtgc cggacgagtg 
     3121 ggaggtgtct cgagagaaga tcaccctcct tcgagagctg gggcagggct ccttcggcat 
     3181 ggtgtatgag ggcaatgcca gggacatcat caagggtgag gcagagaccc gcgtggcggt 
     3241 gaagacggtc aacgagtcag ccagtctccg agagcggatt gagttcctca atgaggcctc 
     3301 ggtcatgaag ggcttcacct gccatcacgt ggtgcgcctc ctgggagtgg tgtccaaggg 
     3361 ccagcccacg ctggtggtga tggagctgat ggctcacgga gacctgaaga gctacctccg 
     3421 ttctctgcgg ccagaggctg agaataatcc tggccgccct ccccctaccc ttcaagagat 
     3481 gattcagatg gcggcagaga ttgctgacgg gatggcctac ctgaacgcca agaagtttgt 
     3541 gcatcgggac ctggcagcga gaaactgcat ggtcgcccat gattttactg tcaaaattgg 
     3601 agactttgga atgaccagag acatctatga aacggattac taccggaaag ggggcaaggg 
     3661 tctgctccct gtacggtgga tggcaccgga gtccctgaag gatggggtct tcaccacttc 
     3721 ttctgacatg tggtcctttg gcgtggtcct ttgggaaatc accagcttgg cagaacagcc 
     3781 ttaccaaggc ctgtctaatg aacaggtgtt gaaatttgtc atggatggag ggtatctgga 
     3841 tcaacccgac aactgtccag agagagtcac tgacctcatg cgcatgtgct ggcaattcaa 
     3901 ccccaagatg aggccaacct tcctggagat tgtcaacctg ctcaaggacg acctgcaccc 
     3961 cagctttcca gaggtgtcgt tcttccacag cgaggagaac aaggctcccg agagtgagga 
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     4021 gctggagatg gagtttgagg acatggagaa tgtgcccctg gaccgttcct cgcactgtca 
     4081 gagggaggag gcggggggcc gggatggagg gtcctcgctg ggtttcaagc ggagctacga 
     4141 ggaacacatc ccttacacac acatgaacgg aggcaagaaa aacgggcgga ttctgacctt 
     4201 gcctcggtcc aatccttcct aacagtgcct accgtggcgg gggcgggcag gggttcccat 
     4261 tttcgctttc ctctggtttg aaagcctctg gaaaactcag gattctcacg actctaccat 
     4321 gtccaatgga gttcagagat cgttcctata catttctgtt catcttaagg tggactcgtt 
     4381 tggttaccaa tttaactagt cctgcagagg atttaactgt gaacctggag ggcaaggggt 
     4441 ttccacagtt gctgctcctt tggggcaacg acggtttcaa accaggattt tgtgtttttt 
     4501 cgttcccccc acccgccccc agcagatgga aagaaagcac ctgtttttac aaattctttt 
     4561 tttttttttt tttttttgct ggtgtctgag cttcagtata aaagacaaaa cttcctgttt 
     4621 gtggaacaaa agttcgaaag aaaaaacaaa acaaaaacac ccagccctgt tccaggagaa 
     4681 tttcaagttt tacaggttga gcttcaagat ggtttttttg gttttttttt tttctctcat 
     4741 ccaggctgaa ggattttttt tttctttaca aaatgagttc ctcaaattga ccaatagctg 
     4801 ctgctttcat attttggata agggtctgtg gtcccggcgt gtgctcacgt gtgtatgcac 
     4861 gtgtgtgtgt ccattagaca cggctgatgt gtgtgcaaag tatccatgcg gagttgatgc 
     4921 tttgggaatt ggctcatgaa ggttcttctc aagggtgcga gctcatcccc ctctctcctt 
     4981 ccttcttatt gactgggaga ctgtgctctc gacagattct tcttgtgtca gaagtctagc 
     5041 ctcaggtttc taccctccct tcacattggt ggccaaggga ggagcatttc atttggagtg 
     5101 attatgaatc ttttcaagac caaaccaagc taggacatta aaaaaaaaaa aagaaaaaga 
     5161 aagaaaaaac aaaatggaaa aaggaaaaaa aaaaagaact gagatgacag agttttgaga 
     5221 atatatttgt accatattta atttttaaag tctctggtat tagcctcata agttattgac 
     5281 tattccccgg ggttggcggg gagtggggac atgagttggt ctgcctgttg tggggccggg 
     5341 aaggggaggg agtcaggcac aagtggcctc tttgtttggt cttaaaggca tccatttctg 
     5401 ggaatgaagc catgttcgct gctaacactt ttggatgttg tgaggccacg tggagtgtgt 
     5461 gagagactag gttttatgga tggtctggtt caggtaccag gtctgctgga aggttcctgt 
     5521 tcggataagc tggtagctac ctagctctga gcctgccttc aagaacacct gtgttcatcc 
     5581 tctgattctc tgtgtgtacc tcttgtggcg tttcctctcc cgggtgtgaa catcctaacc 
     5641 gttattgtgc aaacccaaga acgtcagatc ccaaagcaca acaacctgga tggactttgg 
     5701 gaacatctaa gcaatgtaag agagaggtgc actgagagta cgtcttggtc ccctccaccc 
     5761 tgagagcatc tgacggtcct cagtactgaa ctcccggaag ctgctctgag cccggtgacc 
     5821 tcatctgggc caggtgtggt gcctgagctg aatgctcagg tgcttacagt gttgcaatcc 
     5881 ctaagagagt agagtctgga ggagaaaccg tgaaaaagac cttacacacc accaagaact 
     5941 tccgaatggg cgtgaatcca ccgtttcttc tctttgcaaa aagaaccacc acagctgctc 
     6001 aaagaacaca gtgaactcat cactttggtt catcaaaaaa tcatcgccca tgcgttattc 
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     6061 ctgagtgcat tttcttacaa ctttttgact gcttcctttt cttcttctct taagagttgt 
     6121 gggcttaaga atgggataga gtcataatgg caacctccaa gccctctcaa ttcttgatta 
     6181 agaacacagg tagacatgaa tcccaattgt ctattgctat cttatttata tgattcggga 
     6241 aaatacagca tgtaaaaata ttgctgagga gcctcagtga ttgggtacaa gaagcaagag 
     6301 tacagaaatt atttttgcca aatttatttt gtaaatatga gggtctgtac ctaaatttaa 
     6361 aaaaaaaaca cgtagaacta ggtattttgt tctcttctta gtaaatttgt agtggttgta 
     6421 tactacacta gctgcaattt tcacattttt ctaattcaga aaggtttttc ttatattagg 
     6481 ggaaaaagta tttattttaa tatataaaat cactctgaaa atcactctca taaaaaatgg 
     6541 agcgcatgta aatttttatc aaagaaaaat aaacaggtga atgggggata gtgattttct 
     6601 tttttcagca cagtctacct cagtgtattg ttaagatgtg attcaatcat ggacatcttt 
     6661 gagatttcag aattctacct ggaaccggtc tgaatcaggg aacgtgtgta tcagctgatt 
     6721 cgaatgccag ggaccagtaa gaattttgag ggagggagtt gggatggaga aggtatggcc 
     6781 tttatgcgag catagatcct tttcttcctg gctggtaata ttcttctctg aatttaatct 
     6841 tcctttaaaa aaaaatcctc catctattgt cactatgttc cccaaacata aactaagttc 
     6901 caggctgtca tgatgtatct gatatatggg gtaacccagc aaggtgtacc ttcctttggt 
     6961 gagagatggc tgccggggca aagacgggct ttgattcaga gcaagcattc ccacctgttc 
     7021 catggaatcc ccctgaagtg agcacaaagg tgccctgggc tccctgatgg tttatgccca 
     7081 ctcctttcag gctggtgatg caccttacac acaaacacct aatgcaatgt ctttttaaat 
     7141 tctccaagtg ggatgggagc atgtgaggga aattccaatc caaaacccat taatgtgctg 
     7201 aacgcttttt tttttttttt tttttttttt gcaacaacac cttggacctc tgtgttgggg 
     7261 tttgactgac ctcaagctga tattattgga ccttgtgcag ctttgataac ccatgtgaga 
     7321 gtctaggcag gaccagtggg gcccaaatct tgctgctctt gtacttttag gcactgccct 
     7381 tgcagactca cctttctcca cctgccctgg agaaaggtag ggtgtgctgg gcctgcccct 
     7441 tgcaaatggg attcaccagt ttcatttatt tgactctact gccacagtga aaagagcaaa 
     7501 cagctattgg gttgcaaacc tcctttgaca ttaggaaatg ttgactttgt aacaataaaa 
     7561 ctttggtcct agaaagacac ggttgtcctg ggagtttgta gtgttaagtt gcaacaacaa 
     7621 caacaaaaag caacaaaacc agcttaggat aacacttttt gttgcttgtt cttaaagatg 
     7681 tctcactatg attaaaaccc ttttcattaa tgtagtgaaa gccacacagg agttccttct 
     7741 tccaggagga gaataccaag cacatcactt tctctctgca tcagtgatgt caaatacgca 
     7801 tcagaaaatg ttcaggtttt aggagctgtc ctaggtgctg tttcatcatt ggaagcagtg 
     7861 agaaagagaa gcactgctgc ttgtctggat ataggctgag gatgattgag agaagctgtg 
     7921 ggaactgaca caagggtctg cataggtcat cctgtgaccc tggggactat gttaccaact 
     7981 gacagacaga tctttcactg tatcctagca gggcaggtag tccaccaaga aatgtgctta 
     8041 ttggattggg aggtgtttat ttgtagtctg ctgtaacacg tgtgaaagag caggagcgtc 
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     8101 atcagcatat gacttgcgct ggtcatccgg taaatggatg tgctgtagtc ccagtgctaa 
     8161 tcatttctct ccttcacagt gggtggaagt ttagggttaa atgtcctttg aatgtcacct 
     8221 ggtgagtcct tgacacctta ggctcttcag aaacaatggt tttgttgagg atggggaaca 
     8281 gggaatgccg attttatata catggtacac agagaggggt gtcacttcag aaaatcttcc 
     8341 agcatgttct tcagaatatt aatttatatg cgaggtgagg ttgggaatga aaagaacagg 
     8401 tcagcacttt tttttttcct agaacataca aaagaacatg gtggactttc agggagtgca 
     8461 atggaaggtg aatatttcct taagggtccc cgagaaatgg gagtgagggg aggggacaca 
     8521 atggcttttt gagcttactt ttaccttctg atactagtca aggtccagaa ccagccacca 
     8581 gccaaatttc tatctgggtg cgggccactg aaaatccttg ttaaaaacca gatcacaaat 
     8641 ctggggctct tggtcccatt ggagaaggaa ggaagagcct caaaataagt gtgcacccat 
     8701 gcacatattc aggaacagct tgtttagtct ttacactttg cctgaaagtt gcttctcctc 
     8761 gtccctttgt gtgcctgggt ggcctcggcc ctgtgcgttg gcaacgcagg atcaaatgtg 
     8821 ctgcagcttt tgcagaaaac aactcagaaa cacaaaaccc cccaacagct caattattat 
     8881 tttttcaatg ttttcctaca agagccaagt agcaccatgt acagaagacg cctttttttt 
     8941 tggaatattg aaatcgttct gcatgtaaaa tatgggataa tgacctgttt atattaaaat 
     9001 tctgattaaa ttatctgaga ata 
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APPENDIX E: PRIMER SEQUENCES FOR ADDGENE VECTOR 
Intended modification Sense Primer Anti-sense primer 
Amplification of IR-B 
extracellular domains 
5’-TTAGGAAGGATTGG 
ACCGA-3’ 
5’-CACTGCTTACTGGC 
TTATCG-3’ 
Site-directed mutagenesis 
to remove the extra 
sequence in IR-B 
5’-CCATCTCGGAAACG 
CAGGTC-3’ 
5’-TCTGGGGACGAAA 
ACCACG-3’ 
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APPENDIX F: LEUCINE ZIPPER FRAGMENT SEQUENCE 
 
CGG GCT CTA GAG GGT GGT AGG ATG AAG CAA CTA GAA GAT AAA GTT 
GAG GAA CTC CTG AGT AAA AAC TAT CAT TTA GAA AAT GAG GTA GCA 
CGA TTG AAA AAG CTT GTG GGA GAG AGA GGT GGT GGT GGT GGT GGT 
TCG GCG TGG TCC CAT CCG CAA TTC GAG AAG TGA TGA ACC GGT CCG 
GGC 
 
Sequence of the leucine zipper fragment ordered from Sigma Aldrich. The regions are 
coloured as follows: leucine zipper, red; Gly6 linker, cyan; Strep-tag II and double stop 
codon, green; 5’ XbaI and 3’ AgeI restriction enzyme site, blue. 
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APPENDIX G: MUTAGENESIS SEQUENCING DATA 
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Sequencing data for each of the selected mutations. The mutation in each construct is 
indicated in the brackets and the mutation site is underlined red. 
